Search Result
Results for "
patent
" in MedChemExpress (MCE) Product Catalog:
10
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-126395
-
|
Fluorescent Dye
|
Others
|
Patent Blue V has been widely used in sentinel lymph node mapping. Patent Blue V is also a food coloring agent and an alternative dye for trypan blue (TB) in descemet membrane endothelial keratoplasty (DMEK) .
|
-
-
- HY-W110929
-
Acid blue 1
|
Fluorescent Dye
|
Cancer
|
Patent Blue V (Acid blue 1) is a novel biological dye that can be used as an intraocular dye for retinectomy. Retinectomy refers to the removal of the translucent inner limiting membrane (ILM). The application of appropriate dyes in vitreoretinal surgery can achieve the purpose of complete removal. Patent Blue V can be used to stain retinal premembranous structures. Spectral analysis shows that Patent Blue V has strong absorption below 450 nm and above 600 nm, showing a blue-green color. Patent Blue V is also used as a marker in lymphangiography for resection of neoplastic lymph nodes .
|
-
-
- HY-131453A
-
|
Mitochondrial Metabolism
|
Metabolic Disease
|
Mitochondrial respiration-IN-1 hydrobromide (compound 49) is a potent mitochondrial inhibitor (IC50=8.8 mg/mL) extracted from patent US20110301180A1, compound 49. Mitochondrial respiration-IN-1 hydrobromide significantly reduces mitochondrial respiration in platelets .
|
-
-
- HY-79369
-
|
ADC Linker
|
Cancer
|
Succinic anhydride is a cyclic anhydride and a nonclaevable ADC linker extracted from patent WO2009064913A1. Succinic anhydride can react with compound 4 of the patent to link the proagent to an amine or hydroxy 1 group of a targeting polypeptide .
|
-
-
- HY-W110929R
-
|
Fluorescent Dye
|
Cancer
|
Patent Blue V (Standard) is the analytical standard of Patent Blue V. This product is intended for research and analytical applications. Patent Blue V (Acid blue 1) is a novel biological dye that can be used as an intraocular dye for retinectomy. Retinectomy refers to the removal of the translucent inner limiting membrane (ILM). The application of appropriate dyes in vitreoretinal surgery can achieve the purpose of complete removal. Patent Blue V can be used to stain retinal premembranous structures. Spectral analysis shows that Patent Blue V has strong absorption below 450 nm and above 600 nm, showing a blue-green color. Patent Blue V is also used as a marker in lymphangiography for resection of neoplastic lymph nodes .
|
-
-
- HY-126395R
-
|
Fluorescent Dye
|
Others
|
Patent Blue V (calcium salt) (Standard) is the analytical standard of Patent Blue V (calcium salt). This product is intended for research and analytical applications. Patent Blue V has been widely used in sentinel lymph node mapping. Patent Blue V is also a food coloring agent and an alternative dye for trypan blue (TB) in descemet membrane endothelial keratoplasty (DMEK) .
|
-
-
- HY-U00054
-
-
-
- HY-U00243
-
-
-
- HY-145589
-
-
-
- HY-U00233
-
-
-
- HY-100119
-
-
-
- HY-19497
-
AVE-5530; BART-1741
|
Others
|
Metabolic Disease
|
Canosimibe is a cholesterol absorption inhibitor extracted from patent WO2004087655A1.
|
-
-
- HY-U00320
-
-
-
- HY-100124
-
-
-
- HY-100154
-
-
-
- HY-U00312
-
|
MEK
|
Cancer
|
MEK-IN-1 is a MEK inhibitor extracted from patent WO2008076415A1.
|
-
-
- HY-W005637
-
-
-
- HY-145497
-
|
Others
|
Others
|
Dipentamethylenethiuram Tetrasulfide is a material for constructing rubber (extracted from patent CN112876756A) .
|
-
-
- HY-101819
-
|
Bacterial
|
Infection
|
Antibacterial compound 1 is a oxazolidinone extracted from patent WO1999037630A1 with antibacterial activities.
|
-
-
- HY-108324
-
-
-
- HY-14802C
-
|
RAR/RXR
Autophagy
|
Cancer
|
(+)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.
|
-
-
- HY-14802D
-
|
RAR/RXR
Autophagy
|
Cancer
|
(-)-Talarozole is a potent inhibitor of retinoic acid metabolism extracted from patent WO 1997049704 A1.
|
-
-
- HY-P1445
-
-
-
- HY-109073
-
-
-
- HY-B1179
-
-
-
- HY-103649
-
-
-
- HY-100172
-
|
Proteasome
|
Cancer
|
Proteasome-IN-1 is a proteasome inhibitor extracted from patent WO 2013142376 A1.
|
-
-
- HY-135596
-
Diacyl-raloxifene hydrochloride; Raloxifene diacyl analog
|
Others
|
Others
|
Raloxifene dimethyl ester hydrochloride is an analog of Raloxifene, extracted from patent US5464845A, compound 28 .
|
-
-
- HY-132819
-
LY-3411067
|
JAK
|
Others
|
Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1) .
|
-
-
- HY-153185
-
-
-
- HY-79369S
-
|
Isotope-Labeled Compounds
ADC Linker
|
Cancer
|
Succinic anhydride-d4 is the deuterium labeled Succinic anhydride. Succinic anhydride is a cyclic anhydride and a nonclaevable ADC linker extracted from patent WO2009064913A1. Succinic anhydride can react with compound 4 of the patent to link the proagent to an amine or hydroxy 1 group of a targeting polypeptide[1].
|
-
-
- HY-16564
-
-
-
- HY-104028A
-
-
-
- HY-U00348
-
4-(2,2-Difluoroethenyl)-α-ethyl-2-oxo-1-pyrrolidineacetamide
|
Others
|
Neurological Disease
|
Anticonvulsant agent 1 is an anticonvulsant agent extracted from patent WO2001062726A2, Compound 156.
|
-
-
- HY-119864
-
-
-
- HY-160705
-
|
Liposome
|
Cancer
|
PNI 132, an ionizable lipid derived from the patent WO2020252589A, is useful in the formulation of lipid nanoparticles.
|
-
-
- HY-20588
-
|
CRAC Channel
|
Others
|
CRAC intermediate 2 is a intermediate compound for CRAC inhibitor synthesis, extracted from patent WO 2013059666A1.
|
-
-
- HY-101750
-
|
Others
|
Cardiovascular Disease
|
Arrhythmias-Targeting Compound 1 is used in the research of arrhythmias, extracted from patent WO 2001028992 A2.
|
-
-
- HY-U00412
-
-
-
- HY-U00378
-
-
-
- HY-101730
-
|
Bacterial
|
Infection
|
Antibacterial compound 2 is a useful antibacterial agent extracted from patent US5652238, compound example 9.
|
-
-
- HY-U00392
-
-
-
- HY-104038
-
-
-
- HY-100177
-
|
Others
|
Others
|
L-Threonine derivative-1 is a acetylsalicylic-L-threonine ester extracted from patent US 20060287244 A1.
|
-
-
- HY-100120
-
-
-
- HY-111471
-
-
-
- HY-139758
-
-
-
- HY-139766
-
|
Bacterial
|
Infection
|
Antibacterial agent 49 (example 12) is a antibacterial agent (extracted from patent WO2013030735A1) .
|
-
-
- HY-139769
-
-
-
- HY-139770
-
-
- HY-139771
-
-
- HY-139772
-
-
- HY-139773
-
-
- HY-139774
-
-
- HY-139776
-
-
- HY-139778
-
-
- HY-12973
-
-
- HY-139757
-
-
- HY-141889
-
-
- HY-156051
-
|
HCV
|
Infection
|
Tetrazolast is a HCV inhibitor with the inhibitory activity ranging from 5% to 20%, extracted from patent WO2005030774.
|
-
- HY-79369S1
-
|
ADC Linker
|
Cancer
|
Succinic anhydride- 13C2 is the 13C labeled Succinic anhydride[1]. Succinic anhydride is a cyclic anhydride and a nonclaevable ADC linker extracted from patent WO2009064913A1. Succinic anhydride can react with compound 4 of the patent to link the proagent to an amine or hydroxy 1 group of a targeting polypeptide[2].
|
-
- HY-147571
-
-
- HY-13873
-
-
- HY-22166
-
|
Others
|
Metabolic Disease
|
Glycolic acid oxidase inhibitor 1 is a glycolate oxidase inhibitor, extracted from patent EP0021228A1, in Table IV.
|
-
- HY-100257
-
-
- HY-125381
-
-
- HY-128722
-
|
HIV
|
Infection
|
HIV-1 inhibitor-3 is a HIV infection inhibitor extracted from patent US2018360927 .
|
-
- HY-128940
-
|
ADC Linker
|
Cancer
|
EC089 is a cleavable linker used in conjugates of tubulysins and folates, and extracted from patent WO2011069116A1 .
|
-
- HY-U00377
-
-
- HY-U00314
-
|
Others
|
Neurological Disease
|
Anti-neurodegeneration agent 1 a neurodegeneration-targeting compound extracted from patent WO2008039514A1, Compound I.
|
-
- HY-111471A
-
|
JAK
|
Inflammation/Immunology
|
JAK-IN-5 hydrochloride is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283 .
|
-
- HY-131268
-
-
- HY-116349
-
-
- HY-N9372
-
-
- HY-143581
-
-
- HY-154799
-
|
Others
|
Cancer
|
Anticancer agent 112 is a potent anti-cancer agent for cancer research, extracted from patent WO2020198567 .
|
-
- HY-160670
-
-
- HY-160671
-
-
- HY-158167
-
-
- HY-U00273
-
-
- HY-U00300
-
|
Others
|
Cancer
|
Cancer-Targeting Compound 1 is used in the research of hormone-?related cancer, extracted from patent WO 2008021331 A2.
|
-
- HY-13788C
-
-
- HY-110390
-
|
Others
|
Cardiovascular Disease
|
GR148672X is a triacyglycerol hydrolase (TGH) inhibitor with an IC50 of 4 nM extracted from patent WO 2001016358 A2.
|
-
- HY-111353
-
-
- HY-136556
-
-
- HY-117771A
-
|
DAGL
|
Metabolic Disease
|
DO34 analog is a triazole DAGL(α) inhibitor extracted from patent WO2017096315 A1, compound 100.
|
-
- HY-114423
-
-
- HY-111777
-
-
- HY-126216
-
|
TAM Receptor
|
Cancer
|
TAM-IN-2 is a TAM inhibitor extracted from patent US 20170275290 A1, pyrrolotriazine compound 0904 .
|
-
- HY-D1061
-
|
Fluorescent Dye
|
Others
|
2,4,5,6-Tetraaminopyrimidine is a coloring agent extracted from patent US20170258692A1, compound A .
|
-
- HY-U00436
-
-
- HY-135889
-
|
Bacterial
|
Infection
|
CPFX2090 is a cephalosporin antibacterial compound extracted from patent WO2013052568A1, Compound Example 16g .
|
-
- HY-138945
-
-
- HY-139401
-
|
FAP
|
Cancer
|
FAPI-34 is a fibroblast-activating protein (FAP) inhibitor with favorable pharmacokinetic and biochemical properties. (patent WO2019154886A1).
|
-
- HY-139616
-
|
Others
|
Others
|
Sec61-IN-2 (A347) is a protein secretion inhibitor (extracted from patent WO2020176863) .
|
-
- HY-139617
-
|
Others
|
Others
|
Sec61-IN-2 (A3) is a protein secretion inhibitor (extracted from patent WO2020176863) .
|
-
- HY-145590
-
|
ROR
|
Cancer
|
Retezorogant is a retinoid-related orphan receptor γ (RORγ) antagonist, extracted from patent WO2016093342 A1.
|
-
- HY-112267
-
-
- HY-143729
-
-
- HY-10247
-
|
Raf
|
Cancer
|
BRAF inhibitor is a B-Raf inhibitor extracted from patent WO/2011103196 A1, Compound P-0850.
|
-
- HY-U00362
-
|
Proteasome
|
Neurological Disease
|
Neurodegenerative Disorder-Targeting Compound 1 is a calpain inhibitor extracted from patent WO2010128102A1, compound example 63 .
|
-
- HY-17477
-
|
Others
|
Inflammation/Immunology
|
Guacetisal is obtained from the esterification of acetylsalicylic acid with guaiacol which has the potential for chronic bronchitis treatment extracted from patent CN 106866420 A.
|
-
- HY-U00429
-
|
Others
|
Neurological Disease
|
NOT Receptor Modulator 1 is a nuclear receptor NOT modulator extracted from patent WO 2008034974 A1, Example 39 in table1.
|
-
- HY-115122
-
-
- HY-B2208
-
|
Others
|
Others
|
Glycol salicylate is a derivative of salicylic acid and can be used to improve the aesthetic appearance of the skin, extracted from patent US 20150148320 A1.
|
-
- HY-B2121
-
Naproxen impurity O
|
iGluR
|
Neurological Disease
|
6-Methoxy-2-naphthoic acid is an NMDA receptor modulator extracted from patent WO 2012019106 A2.
|
-
- HY-135781
-
|
Others
|
Cancer
|
H-Arg(Pbf)-OMe hydrochloride is an arginine analogue extracted from patent US20150197500A1, Compound Arg-06 .
|
-
- HY-U00310
-
|
Others
|
Neurological Disease
|
Neuromuscular-targeting compound 1, extracted from patent WO2009099594 A1, Paragraph 0100, is useful in treatment of neuromuscular diseases.
|
-
- HY-10216
-
BAY 869766 R enantiomer; RDEA119 R enantiomer
|
MEK
|
Cancer
|
Refametinib R enantiomer is a MEK inhibitor extracted from patent WO2007014011A2, compound 1022, has an EC50 of 2.0-15 nM.
|
-
- HY-U00395
-
-
- HY-18625
-
|
VEGFR
|
Cancer
|
VEGFR-2-IN-5 is a VEGFR2 inhibitor extracted from patent WO2013055780A1, Page 69 .
|
-
- HY-18625A
-
|
VEGFR
|
Cancer
|
VEGFR-2-IN-5 hydrochloride is a VEGFR2 inhibitor extracted from patent WO2013055780A1, Page 69 .
|
-
- HY-137093
-
-
- HY-109173
-
BAY 1902607
|
P2X Receptor
|
Neurological Disease
|
Filapixant is a purinoreceptor antagonist extracted from patent WO2016091776A1, example 348. Filapixant is the active reference substance of Eliapixant .
|
-
- HY-137452
-
-
- HY-139615
-
|
Others
|
Cancer
|
Sec61-IN-1 is a potent sec61 inhibitor (Patent WO2020176863A1, compound A317) .
|
-
- HY-145551
-
|
Others
|
Inflammation/Immunology
|
Atinvicitinib is a kind of pyrazole compound. Atinvicitinib has the potential for the research of atopic dermatitis (extracted from patent WO2021123094A1) .
|
-
- HY-24463
-
|
Others
|
Others
|
3,4-Di-O-acetyl-L-fucal is the reactant for synthesis antibiotics (extracted from patent WO1999026956A1) .
|
-
- HY-U00362A
-
|
Others
|
Neurological Disease
|
(Rac)-Neurodegenerative Disorder-Targeting Compound 1 is a calpain inhibitor (extracted from patent WO2010128102A1, compound 63) .
|
-
- HY-143728
-
-
- HY-145826
-
|
Bcl-2 Family
|
Cancer
|
Mcl-1 inhibitor 8 is a MCL-1 inhibitor, example 228, extracted from patent WO2019222112 .
|
-
- HY-150617
-
M4076; ATM Inhibitor-5
|
ATM/ATR
|
Cancer
|
Lartesertib (M4076) is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1) .
|
-
- HY-153186
-
|
Liposome
|
Others
|
LNP Lipid-3 is an ionizable lipid extracted from patent WO2021113777A, and can be used for the generation of Lipid nanoparticles (LNPs).
|
-
- HY-156603
-
|
c-Met/HGFR
|
Cancer
|
Canlitinib is a tyrosine kinase inhibitor, extracted from patent WO2018072614 (IV-2). Canlitinib has the potential for cancer study.
|
-
- HY-12039
-
Bafetinib analog
|
Bcr-Abl
|
Cancer
|
Lyn-IN-1 (Bafetinib analog) is a potent and selective dual Bcr-Abl/Lyn inhibitor, extracted from patent WO2014169128A1.
|
-
- HY-13464
-
-
- HY-19772
-
ESM-HDAC391; CHR-5154; HDAC-IN-3
|
HDAC
|
Cancer
|
GSK3117391 (ESM-HDAC391) is a histone deacetylase (HDAC) inhibitor, extracted from patent WO/2008040934 A1.
|
-
- HY-N0348
-
|
Others
|
Inflammation/Immunology
|
Dexamethasone 9,11-epoxide, a compound extracted from patent CN 106520896 A and RU 2532902 C1, is an intermediate in the preparation of dexamethasone.
|
-
- HY-103036
-
-
- HY-U00420
-
-
- HY-100084
-
|
ROR
|
Inflammation/Immunology
|
Methyl-3β-hydroxycholenate is a ROR gamma modulator extracted from patent US20110263046 A1, in figure 2.
|
-
- HY-112275
-
-
- HY-135864
-
|
Ras
|
Cancer
|
KRAS inhibitor-6 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound A .
|
-
- HY-100171
-
-
- HY-130261
-
|
Bcl-2 Family
|
Cancer
|
Mcl-1 antagonist 1 is a Mcl-1 protein antagonist extracted from patent WO2019173181, compound 200 .
|
-
- HY-136604
-
|
RAD51
|
Cancer
|
RAD51-IN-3 is a Rad51 inhibitor extracted from patent WO2019051465A1, compound Example 66A .
|
-
- HY-111463
-
-
- HY-135053
-
-
- HY-136339
-
-
- HY-138698
-
|
Deubiquitinase
|
Others
|
FT206 is an inhibitor of carboxamides as ubiquitin-specific protrase extracted from patent WO 2020033707 A1, example 11-1 .
|
-
- HY-145567
-
PH94B
|
Others
|
Neurological Disease
|
Fasedienol is a neurochemical stimulator of the vomeronasal organ (VON). Fasedienol alleviates the symptoms of PMS and anxiety (extracted from patent WO1998014194A1) .
|
-
- HY-145825
-
|
Bcl-2 Family
|
Cancer
|
Mcl-1 inhibitor 7 is a potent Mcl-1 inhibitor, example 35, extracted from patent WO2020097577A .
|
-
- HY-148878
-
|
Ras
|
Cancer
|
Ras modulator-1 is a modulator of Ras. Ras modulator-1 is an active compound extracted from patent US20120302581 .
|
-
- HY-156604
-
|
Btk
|
Cancer
|
Cinsebrutinib is a Bruton's tyrosine kinase inhibitor, extracted from patent WO2021207549 (compound 5-6). Cinsebrutinib has the potential for cancer study.
|
-
- HY-101832
-
|
PCSK9
|
Metabolic Disease
|
SBC-110736 is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor extracted from patent WO2014150395A1 .
|
-
- HY-U00059
-
|
Others
|
Metabolic Disease
|
Pyrrole-derivative1 is extracted from patent WO/2002/085851A1, example 2, developed for the treatment of diabetic disease.
|
-
- HY-101766
-
BGB-3111 analog
|
Btk
|
Inflammation/Immunology
|
Btk inhibitor 2 (BGB-3111 analog) is a Bruton's tyrosine kinase (BTK) inhibitor extracted from patent US 20170224688 A1.
|
-
- HY-W016622
-
7-Methyl-2H-1,5-benzodioxepin-3(4H)-one
|
Others
|
Others
|
Watermelon ketone is fragrance chemical compound with special odorant which has been widely used in the fragrance industry, extracted from patent CN 103058984 A.
|
-
- HY-128523
-
-
- HY-111887
-
CYT-0851; RAD51-IN-2
|
RAD51
|
Cancer
|
Emzadirib (RAD51-IN-2) is a RAD51 inhibitor extracted from patent WO2019/051465A1 .
|
-
- HY-135866
-
|
Ras
|
Cancer
|
KRAS inhibitor-8 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound C .
|
-
- HY-112494
-
|
Ras
|
Cancer
|
KRas G12C inhibitor 1 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
|
-
- HY-112491
-
|
Ras
|
Cancer
|
KRas G12C inhibitor 1 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
|
-
- HY-14898
-
-
- HY-112493
-
|
Ras
|
Cancer
|
KRas G12C inhibitor 3 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
|
-
- HY-112492
-
|
Ras
|
Cancer
|
KRas G12C inhibitor 2 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
|
-
- HY-135865
-
|
Ras
|
Cancer
|
KRAS inhibitor-7 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound B .
|
-
- HY-135884
-
AG-946; PKR activator 2
|
Pyruvate Kinase
|
Cardiovascular Disease
|
Tebapivat (PKR activator 2) is a potent pyruvate kinase-R (PKR) activator extracted from patent WO2019035863A1, compound 385 .
|
-
- HY-128523A
-
|
Others
|
Inflammation/Immunology
|
Kgp-IN-1 hydrochloride is an arginine-specific gingipain (Rgp) inhibitor extracted from patent WO2017201322A1, compound 13-R .
|
-
- HY-136266
-
|
HCV
|
Cancer
|
HCV-IN-29 is a hepatitis C virus (HCV) inhibitor exacted from patent US8329159B2, compound 1e .
|
-
- HY-111948
-
-
- HY-131706A
-
|
Trk Receptor
|
Cancer
|
GNF-8625 monopyridin-N-piperazine hydrochloride (TRKi-2), a TRK inhibitor, which is from the patent WO 2020038415 A1 .
|
-
- HY-138202
-
|
Src
|
Inflammation/Immunology
|
Lck-IN-1 is a potent lymphocyte protein tyrosine kinase (Lck) inhibitor extracted from patent WO2007013673A1, example 48 .
|
-
- HY-138695
-
-
- HY-139396
-
-
- HY-132847
-
SCD-044
|
LPL Receptor
|
Others
|
Vibozilimod (SCD-044, example 33) is a S1p1 receptor agonist (extracted from patent WO2012140020A1) .
|
-
- HY-132806
-
RG-7816; RO-7017773
|
GABA Receptor
|
Neurological Disease
|
Alogabat (example 8) is a GABAA α5 receptor positive allosteric modulators (PAMs) (extracted from patent WO2018104419A1) .
|
-
- HY-145017
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 20 is a KRAS G12C inhibitor extracted from patent CN112694475A, example 1 .
|
-
- HY-145055
-
|
HBV
|
Infection
|
HBV-IN-11 is a potent HBsAg secretion inhibitor with an EC50 of 0.46 µM (From patent WO2018085619A1, example 28) .
|
-
- HY-D1107
-
|
PARP
|
Others
|
NCT-TFP is PARP probe used to identifying Poly(ADP-ribose) polymerases (PARP) inhibitors (extracted from patent US20190331688A1) .
|
-
- HY-46760
-
|
Liposome
|
Others
|
CCD Lipid01 is a cationic lipid useful in the delivery of biologically active agents to cells and tissues (extracted from patent WO2015095340 A1) .
|
-
- HY-U00301
-
|
Others
|
Cardiovascular Disease
|
Anti-hypertensive sulfonanilide 1 is a potent antihypertensive agent extracted from patent EP0338793A2, compound XVIIIa,b*, example No.1.
|
-
- HY-U00415
-
|
Dopamine Receptor
mAChR
|
Neurological Disease
|
Benzamide Derivative 1 is a benzamide derivative from patent EP0213775A1, compound 18. Benzamide Derivative 1 may be useful in treatment of gastrointestinal disorders.
|
-
- HY-B2187
-
Diacetotoluide
|
Others
|
Metabolic Disease
|
Diacetazotol inhibits dioxin-induced ethoxyresorufin-O-deethylase (EROD) activity with IC50 of 75±4 nM. Diacetazotol extracts from patent US20070032458, compound 3.
|
-
- HY-126292
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 13 is a KRAS G12C inhibitor extracted from patent WO2018143315A1, compound 30 .
|
-
- HY-111465
-
|
CDK
|
Cancer
|
CDK8-IN-4 is an inhibitor of CDK8 extracted from patent WO2014090692A1, compound example 16, with an IC50 of 0.2 nM.
|
-
- HY-129181
-
|
FGFR
|
Cancer
|
FGFR4-IN-4 (compound 693) is a FGFR4 inhibitor with anti-tumor activity, extracted from patent WO2018113584A1 .
|
-
- HY-128934
-
-
- HY-131658
-
|
VEGFR
|
Others
|
VEGFR-2-IN-6 (example 64) is a VEGFR2 inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110 .
|
-
- HY-103035
-
|
Phosphodiesterase (PDE)
|
Cancer
|
BIO-32546 (example 12b, S-isomer) is an autotaxin (ATX) modulator (IC50: 1 nM), extracted from the patent US20170158687A1 .
|
-
- HY-139298
-
Di((Z)-Non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate
|
Liposome
|
Inflammation/Immunology
|
L319 is an ionizable cationic lipidoid and can be used for synthetic liposomes, from the patent WO-2011153493-A2, compound 1 .
|
-
- HY-139326
-
-
- HY-139911
-
|
Ras
|
Cancer
|
KRAS G12D inhibitor 7 is a potent inhibitor of KRAS G12D (extracted from patent WO2021108683, compound 114) .
|
-
- HY-145584
-
JPI-547/OCN-201
|
PARP
|
Cardiovascular Disease
Neurological Disease
|
Nesuparib is a potent inhibitor of PARP. Nesuparib is useful for the research of neuropathic pain, neurodegenerative disease, and cardiovascular disease (extracted from patent WO2016200101A2) .
|
-
- HY-145596
-
ZTS-00007928
|
Bacterial
|
Infection
|
Sirpefenicol (ZTS-00007928) is a phenicol antibacterial agent. Sirpefenicol can be used in bacterial infections in animals (extracted from patent WO2020068607A1) .
|
-
- HY-145060
-
|
HBV
|
Infection
|
HBV-IN-12 is a potent hepatitis B surface antigen (HBsAg) inhibitor. From patent WO2021204252A1, compound 1_B .
|
-
- HY-145018
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 21 is a KRAS G12C inhibitor extracted from patent WO2021219090A1, example 7 .
|
-
- HY-145019
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 22 is a KRAS G12C inhibitor extracted from patent WO2021219072A1, example 120 .
|
-
- HY-143568
-
-
- HY-143733
-
|
EGFR
|
Cancer
|
HER2-IN-5 is a potent and orally active HER-2 inhibitor, example 10, extracted from patent WO2021164697 .
|
-
- HY-148493
-
|
Bacterial
|
Infection
|
MK-3402 is a metallo-beta-lactamase inhibitor (Example 303 in reference patent). MK-3402can be used in the research of bacteria .
|
-
- HY-13277
-
|
IRAK
|
Inflammation/Immunology
|
IRAK inhibitor 3 is an interleukin-1 (IL-I) receptor-associated kinase (IRAK) kinase modulator extracted from patent WO2008030579 A2.
|
-
- HY-12647
-
-
- HY-79511
-
O-Desmorpholinopropyl Gefitinib
|
FAAH
Autophagy
|
Others
|
FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is a potent FAAH(fatty acid amide hydrolase) inhibitor extracted from Patent WO/2008/100977A2.
|
-
- HY-19762
-
SCD inhibitor 1
|
Stearoyl-CoA Desaturase (SCD)
|
Cancer
|
GSK1940029 (SCD inhibitor 1) is a stearoyl-coa desaturase (SCD) inhibitor extracted from patent WO/2009060053 A1, compound example 16.
|
-
- HY-101430
-
-
- HY-P1350
-
|
Bacterial
|
Infection
|
H-Lys-Trp-Lys-OH is a small molecule peptide which displays antibacterial and antiviral activities extracted from patent CN 104072579 A, Compound AMP12.
|
-
- HY-U00416
-
|
Ras
|
Cancer
|
ARS-1323, the racemate of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.
|
-
- HY-111483
-
AZD0364
|
ERK
|
Cancer
|
Tizaterkib (AZD0364) is a potent and selective ERK2 inhibitor extracted from patent WO2017080979A1, compound example 18, has an IC50 of 0.6 nM.
|
-
- HY-112165
-
-
- HY-129171
-
-
- HY-114168
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 5 is a KRas G12C inhibitor extracted from patent WO2017201161A1, Compound example 147 .
|
-
- HY-100325
-
-
- HY-126296
-
-
- HY-101159
-
|
ADC Linker
|
Cancer
|
Mal-amido-PEG8-C2-acid (example 142) is a nonclaevable ADC linker, extracted from patent US2018339985 .
|
-
- HY-129490
-
|
Phosphodiesterase (PDE)
|
Cancer
|
Enpp-1-IN-1 is a Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitor extracted from patent WO2019046778, Example 55 .
|
-
- HY-135883
-
-
- HY-U00390
-
|
JAK
|
Cancer
|
JAK3-IN-7 is a potent and selective JAK3 inhibitor extracted from patent WO2011013785A1, has an IC50 of <0.01 μM.
|
-
- HY-U00068
-
|
PPAR
|
Metabolic Disease
|
PPARα-MO-1 is a potent PPARα modulator extracted from patent WO/2004/110982A1, formula I.
|
-
- HY-U00288
-
4-(3-Cyano-5,6-difluoroindol-1-yl)-2-hydroxybenzoic acid
|
Xanthine Oxidase
|
Metabolic Disease
|
Xanthine oxidase-IN-1 is a xanthine oxidase inhibitor extracted from patent WO2008126898A1, page 68, compound example 3, with an IC50 of 6.5 nM.
|
-
- HY-N7421
-
|
Others
|
Neurological Disease
|
Smilagenin acetate is a sapogenin derivative extracted from patent US20030004147A1. Smilagenin acetate increases the expression of acetylcholine m2 receptors and can be used for the research of dementia .
|
-
- HY-112301A
-
trans-BLU-667
|
RET
|
Cancer
|
trans-Pralsetinib (trans-BLU-667) is a rearranged during transfection (RET) inhibitor extracted from patent US20170121312A1, Compound Example 129 .
|
-
- HY-136773
-
-
- HY-131974
-
-
- HY-136073
-
|
Wnt
|
Cancer
|
Wnt pathway activator 2 is a potent Wnt activator extracted from patent WO2012024404A1, compound 2, has an EC50s of 13 nM .
|
-
- HY-136306
-
|
Beta-lactamase
Bacterial
|
Infection
|
Metallo-beta-lactamase ligand 1 is a class B β-lactamase inhibitor with antibacterial activity extracted from patent WO2019221122A1, compound A .
|
-
- HY-130797
-
-
- HY-114017
-
-
- HY-132247B
-
|
Others
|
Cancer
|
(S)-ErSO is the dextrorotatory enantiomer of ErSO. (S)-ErSO is inactive in MCF-7 cells (from patent WO2020009958A1, compound (s)-105) .
|
-
- HY-139910
-
|
Ras
|
Cancer
|
KRAS G12D inhibitor 6 is a potent inhibitor of KRAS G12D (extracted from patent WO2021108683A1, compound 112) .
|
-
- HY-145106
-
-
- HY-145109
-
-
- HY-19990
-
-
- HY-145402
-
|
CDK
|
Cancer
|
CDK7-IN-7 is a potent and selective CDK7 kinase inhibitor with an IC50 of <50 nM (Patent CN112661745A, compound T-01) .
|
-
- HY-B1179R
-
|
Others
|
Inflammation/Immunology
|
Dipyrocetyl (Standard) is the analytical standard of Dipyrocetyl. This product is intended for research and analytical applications. Dipyrocetyl is an anti-inflammatory and analgesic agent extracted from patent WO 2011132171 A1.
|
-
- HY-16355
-
|
PI3K
|
Cancer
|
NVP-QAV-572 is a PI3K inhibitor extracted from patent US7998990B2, Compound Example 8, has an IC50 of 10 nM.
|
-
- HY-20587
-
|
CRAC Channel
|
Inflammation/Immunology
|
CRAC intermediate 1 is a key intermediate in the chemical synthesis of a series of CRAC channel inhibitors, detailed information can be found in Patent WO 2010122089 A1, intermediate 9.
|
-
- HY-U00292
-
|
AMPK
|
Metabolic Disease
|
AMPK activator 1 is an AMPK activator extracted from patent WO2013116491A1, compound No.1-75, has an EC50 of <0.1μM.
|
-
- HY-U00308
-
-
- HY-10013A
-
MK-0364 racemate
|
Cannabinoid Receptor
|
Neurological Disease
|
Taranabant racemate (MK-0364 racemate) is an antagonist and/or inverse agonist of the Cannabinoid-1 (CB1) receptor extracted from patent WO 2004048317 A1 .
|
-
- HY-12424A
-
|
Others
|
Cancer
|
42-(2-Tetrazolyl)rapamycin is a proagent compound of a rapamycin analog extracted from patent US 20080171763 A1, Example 1. Rapamycin is a specific mTOR inhibitor.
|
-
- HY-103695
-
|
CD73
|
Cancer
|
CD73-IN-1 is an inhibitor of CD73 which can be used in the treatment of cancer extracted from patent WO 2017153952 A1, example 80.
|
-
- HY-112219A
-
-
- HY-102998
-
-
- HY-101526
-
RA03546849
|
c-Fms
|
Inflammation/Immunology
|
GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.
|
-
- HY-130680
-
|
Syk
|
Cancer
|
Syk-IN-3, a potent spleen tyrosine kinase (Syk) inhibitor, extracted from patent WO2011075515A1, compound example 152, has an IC50 of 1 nM .
|
-
- HY-12219B
-
|
Others
|
Metabolic Disease
|
MSI-1701 is an analogue of MSI-1436 which can control weight gain and blood glucose level extracted from patent US 7410959 B1.
|
-
- HY-135516
-
SM-04554; Wnt pathway activator 1
|
Wnt
|
Cancer
|
Dalosirvat (SM-04554) is a potent Wnt activator extracted from patent WO2012024404A1, compound 1, has an EC50s of 28-29 nM .
|
-
- HY-136773A
-
ALK2-IN-4 succinate
|
TGF-β Receptor
|
Metabolic Disease
|
ALK2-IN-4 succinate is a potent ALK2 inhibitor extracted from patent WO2020086963A1, compound Formula I free base .
|
-
- HY-139084
-
|
Others
|
Others
|
XL388-C2-NH2 is a monomeric compound extracted from patent WO2019212990A1, Monomer Z .
|
-
- HY-135898
-
-
- HY-139316
-
|
IRAK
PROTACs
|
Cancer
|
PROTAC IRAK4 degrader-5 is a Cereblon-based IRAK4 degrader extracted from patent US20190192668A1, compound I-171 .
|
-
- HY-139423
-
-
- HY-139760
-
|
Bacterial
|
Infection
|
Antibacterial agent 43 is an antibacterial agent extracted from patent WO2013030735A1, example 6. Antibacterial agent 43 can be used for the research of bacterial infections .
|
-
- HY-139761
-
|
Bacterial
|
Infection
|
Antibacterial agent 44 is an antibacterial agent extracted from patent WO2013030735A1, example 7. Antibacterial agent 44 can be used for the research of bacterial infections .
|
-
- HY-139763
-
|
Bacterial
|
Infection
|
Antibacterial agent 46 is an antibacterial agent extracted from patent WO2013030735A1, example 9. Antibacterial agent 46 can be used for the research of bacterial infections .
|
-
- HY-139754
-
|
Bacterial
|
Infection
|
Antibacterial agent 37 is an antibacterial agent extracted from patent WO2015063714A1, compound B. Antibacterial agent 37 can be used for the research of bacterial infections .
|
-
- HY-139755
-
|
Bacterial
|
Infection
|
Antibacterial agent 38 is an antibacterial agent extracted from patent WO2015063714A1, compound C. Antibacterial agent 38 can be used for the research of bacterial infections .
|
-
- HY-145043
-
|
FGFR
|
Cancer
|
FGFR-IN-1 is a potent FGFR inhibitor with an IC50 of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219) .
|
-
- HY-145577
-
|
Others
|
Neurological Disease
|
Lafadofensine is the monoamines reuptake inhibitor. Lafadofensine has th sufficient effects after short-term administration (extracted from patent WO2006121218A1, compound 1) .
|
-
- HY-W001957
-
4-Acetylbutyric acid; 5-Oxohexanoic acid; NSC-5281
|
Antibiotic
|
Infection
|
Glurate (4-Acetylbutyric acid; 5-Oxohexanoic acid) can be used to construct antiviral agents (acyclic nucleoside esters) (extracted from patent WO1997030052A1) .
|
-
- HY-150403
-
-
- HY-11105
-
XL147 analogue
|
PI3K
Apoptosis
|
Cancer
|
Pilaralisib analogue (XL147 analogue) is a representative and selective PI3Kα inhibitor extracted from patent WO2012006552A1, Compound 147 in Table 1.
|
-
- HY-10497
-
|
c-Met/HGFR
VEGFR
|
Cancer
|
BMS-794833 is a VEGFR2 and Met inhibitor extracted from patent WO2009094417, compound example 1; has IC50s of 15 and 1.7 nM, respectively.
|
-
- HY-100380
-
|
Thrombopoietin Receptor
|
Cardiovascular Disease
|
TPO agonist 1 is a thrombopoietin (TPO) agonist extracted from patent WO2008134338A1, compound TPO mimetic. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopenia .
|
-
- HY-U00321
-
-
- HY-103664
-
-
- HY-U00417
-
|
Ras
|
Cancer
|
ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.
|
-
- HY-103620
-
|
ROCK
|
Inflammation/Immunology
|
ROCK2-IN-2 is a selective ROCK2 inhibitor extracted from patent US20180093978A1, Compound A-30, has an IC50 of <1 μM.
|
-
- HY-135089
-
-
- HY-111810
-
-
- HY-128726
-
|
Itk
|
Inflammation/Immunology
|
ITK inhibitor 2 is a interleukin-2-inducible T-cell kinase (ITK) inhibitor extracted from patent WO2011065402A1, compound 4, with an IC50 of 2 nM.
|
-
- HY-122615
-
|
Others
|
Cancer
|
SPOP-IN-6b is a speckle-type POZ protein (SPOP) inhibitor with an IC50 of 3.58 μM (patent CN 107141287, SPOP-B-88) .
|
-
- HY-135088
-
-
- HY-12813
-
-
- HY-138181
-
MRX-I phosphoramidic acid
|
Others
|
Others
|
Contezolid phosphoramidic acid is an intermediate in the synthesis of proagents of antibacterial oxazolidinone agent MRX-I. Contezolid phosphoramidic acid is extracted from patent WO2015127316A1, Intermediate 3, Method I .
|
-
- HY-126378
-
|
Kallikrein
|
Inflammation/Immunology
|
LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioedema, with an EC50 less than 100 nM in cell .
|
-
- HY-132850
-
BLD-2660
|
Proteasome
|
Inflammation/Immunology
|
Dazcapistat is a potent calpain inhibitor, with IC50s of <3 μM for calpain 1, calpain 2 and calpain 9, respectively (patent WO2018064119A1, compound 405) .
|
-
- HY-145107
-
-
- HY-145120
-
|
Raf
|
Cancer
|
B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancer .
|
-
- HY-145585
-
MIJ-821
|
iGluR
|
Neurological Disease
|
Onfasprodil is negative allosteric modulator of NR2B. Onfasprodil in combination with GABA receptor regulator has the potential for the research of Alzheimer's disease (extracted from patent CN111481543A) .
|
-
- HY-142518
-
|
VEGFR
|
Cancer
|
EGFR-IN-26 is a EGFR inhibitor extracted from patent WO2019162323A1 compound I-028. EGFR-IN-26 can be used for the research of cancer .
|
-
- HY-145995
-
|
Others
|
Others
|
CS12192 is a compound improving survival and weight gain. CS12192 has the potential for the research of graft-versus-host disease (GVHD) (extracted from the patent CN112773802A) .
|
-
- HY-148830
-
|
Liposome
|
Others
|
Piperazine-bis(ethyl octadeca-9,12-dienoate) is a cationic lipid extracted from patent WO2023036148A1, and can be used for the generation of Lipid nanoparticles (LNPs).
|
-
- HY-D1500
-
|
Fluorescent Dye
|
Others
|
Fluorescent NIR 885 is a cyanine near-infrared-absorbing dye. Fluorescent NIR 885 can be used as a photoprotective agent (extracted from patent WO2014006589 compound 1-35) .
|
-
- HY-15884
-
|
HIV
|
Infection
|
GSK2838232 inhibit HIV reverse transcriptase activity across a broad panel of HIV-1 isolates, extracted from patent WO/2013090664A1, compound51.
|
-
- HY-U00413
-
-
- HY-108940
-
-
- HY-125873
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 22, has an IC50 of 5 nM .
|
-
- HY-129749
-
-
- HY-125875
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 17 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 82, has an IC50 of 5 nM .
|
-
- HY-125874
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 39, has an IC50 of 97 nM .
|
-
- HY-114428
-
|
PI3K
|
Cancer
|
P110δ-IN-1 is a potent and selective inhibitor of P110δ extracted from patent WO 2014055647 A1, with an IC50 of 8.4 nM .
|
-
- HY-N3961
-
|
Others
|
Cardiovascular Disease
|
Neoglycyrol is isolated from the root of Glycyrrhiza uralensis Fisch . Neoglycyrol is a potential myocardial protection active compound screened from traditional patent medicine Tongmai Yangxin pill (TMYXP) .
|
-
- HY-125872
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 14 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 17, has an IC50 of 18 nM .
|
-
- HY-19845A
-
ACR-325 hydrochloride
|
Dopamine Receptor
|
Neurological Disease
|
Ordopidine hydrochloride is a modulator of dopamine receptor extracted from patent WO/2005/121087A1, compound example 2; exhibits an ED50 of 68 μmol/kg on increase of DOPAC in the rat striatum.
|
-
- HY-136567
-
|
Raf
|
Cancer
|
TBAP-001 (Synthesis 13), extracted from patent WO2015075483A1, is a pan-RAF kinase inhibitor, with an IC50 of 62 nM in BRAF V600E kinase assay .
|
-
- HY-136613
-
|
Bacterial
|
Infection
|
Demethyl linezolid is a impurity of linezolid. Demethyl linezolid is a useful antimicrobial agent extracted from patent WO1995007271A1, example 9, effective against a number of human and veterinary pathogens .
|
-
- HY-136774
-
|
Bcl-2 Family
|
Cancer
|
BCL6-IN-5 is a potent BCL6 inhibitor exacted from patent WO2018215801A1, example 1n, has a pIC50 of 5.82 .
|
-
- HY-110325
-
|
Sodium Channel
|
Neurological Disease
|
PF-04885614 is a potent NaV1.8 inhibitor, extracted from patent US2018328915. PF-04885614 has potential for neurological and neurodevelopmental diseases treatment .
|
-
- HY-111351
-
-
- HY-111451
-
M1774; ATR inhibitor 1
|
ATM/ATR
|
Cancer
|
Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active ATR inhibitor extracted from patent WO2015187451A1, compound I-l, with a Ki value below 1 μΜ .
|
-
- HY-U00304
-
|
Aurora Kinase
|
Cancer
|
Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a Ki value of <0.010 uM.
|
-
- HY-105686
-
-
- HY-109154
-
|
Others
|
Inflammation/Immunology
|
Obafistat is a potent aldo-keto reductase AKR1C3 inhibitor with an IC50 of 1.2 nM for human AKR1C3 (patent WO2017202817A1, example 4) .
|
-
- HY-114371
-
DNL-758; SAR-443122
|
RIP kinase
|
Inflammation/Immunology
|
Eclitasertib (DNL-758) is a potent receptor-interacting protein kinase 1 (RIPK1) inhibitor with an IC50 of <1 µΜ (From patent WO2017136727A2, example 42) .
|
-
- HY-141647
-
|
Dopamine Receptor
|
Others
|
[18F]-Labeled L-dopa precursor is a precursor for synthesis of 18F-labeled L-dopa extracted from patent WO2014095739A1, example 8 .
|
-
- HY-139957
-
-
- HY-145592
-
RO7020531; RG7854
|
Toll-like Receptor (TLR)
|
Infection
|
Ruzotolimod is the agonist of TLR7. Ruzotolimod has the potential for the research of HBV, COVID-19 or SARS-CoV-2 infection (extracted from patent WO2021130195A1) .
|
-
- HY-132977
-
|
Others
|
Others
|
BTTAA-OH is a kind of tris(triazolylmethyl)amine compound. BTTAA-OH has the potential for the research of labeling and/or imaging in living system (extracted from patent WO2012021390A1) .
|
-
- HY-113862
-
|
Fluorescent Dye
|
Others
|
PHOME is a fluorogenic substrate for sEH. sEH can hydrolyze the epoxy ring in the PHOME substrate. PHOME can be used for fluorescent epoxide hydrolase assay (extracted from patent CN113402447A) .
|
-
- HY-131515
-
-
- HY-139593S
-
-
- HY-108324R
-
|
5-HT Receptor
|
Neurological Disease
|
(Z)-Thiothixene (Standard) is the analytical standard of (Z)-Thiothixene. This product is intended for research and analytical applications. (Z)-Thiothixene is an antagonist of serotonergic receptor extracted from patent US 20150141345 A1.
|
-
- HY-112219
-
-
- HY-150402
-
-
- HY-18604
-
|
Ras
|
Cancer
|
K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1.
|
-
- HY-19758A
-
|
Sirtuin
|
Cancer
|
Sirtuin modulator 1 is a modulator of SIRTl, a homolog of SIRT3, with EC1.5 of < 1 μM, extracted from patent WO 2010071853 A1, Compound No.4.
|
-
- HY-19761
-
|
RIP kinase
|
Cancer
|
RIP2 kinase inhibitor 2 is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043437 A1, compound example 9.
|
-
- HY-B2175
-
Aluminum diacetylsalicylate
|
Others
|
Inflammation/Immunology
|
Aspirin Aluminum is a novel intermolecular compound which can inhibit gastrointestinal mucosal disorders induced by NSAIDs (non-steroidal anti-inflammatory agents) extracted from patent WO 2010064441 A1.
|
-
- HY-131132
-
SHP2-IN-6
|
SHP2
Phosphatase
|
Cancer
|
JAB-3068 (SHP2-IN-6) is a potent SHP2 inhibitor, extracted from patent WO2017211303A1, compound 7, has an IC50 of 25.8 nM .
|
-
- HY-111468
-
|
Bcl-2 Family
|
Cancer
|
Mcl1-IN-3 is an inhibitor of Mcl1 extracted from patent WO2015153959A2, compound example 57; has an IC50 and Ki of 0.67 and 0.13 μM, respectively.
|
-
- HY-111429
-
|
YAP
|
Cancer
|
YAP/TAZ inhibitor-1 is a YAP/TAZ inhibitor extracted from patent WO2017058716A1, Compound 1, has an IC50 of <0.100 μΜ in firefly luciferase assay .
|
-
- HY-111940
-
|
Raf
|
Inflammation/Immunology
|
LUT014 is a B-Raf inhibitor with an IC50 of 11.7 nM, and developed to reduce dose-limiting acneiform lesions associated EGFR Inhibitors treatment. Extracted from patent WO 2019026065A2 .
|
-
- HY-116649
-
-
- HY-13707
-
Stannsoporfin; SnMP
|
Others
|
Metabolic Disease
|
Tin(IV) mesoporphyrin IX dichloride (Stannsoporfin) is a heme oxygenase (HO) inhibitor being developed for the prevention of hyperbilirubinemia in infants at risk of developing jaundice, extracted from patent WO2011103196A1 .
|
-
- HY-135379
-
|
Drug Metabolite
|
Cardiovascular Disease
|
Atorvastatin acetonide is an impurity of Atorvastatin, and extracted from patent WO2011131605A1, Compound 4. Atorvastatin is an orally active HMG-CoA reductase inhibitor and has the ability to effectively decrease blood lipids .
|
-
- HY-136301
-
|
Others
|
Inflammation/Immunology
|
Acid secretion-IN-1 is a polycyclic compound extracted from patent WO2018024188A1, Compound Example 17.4. Acid secretion-IN-1 is synthesized and used in the IDO inhibitor synthetic experiment .
|
-
- HY-135793
-
|
Others
|
Cancer
|
Macropa-NH2 diester is a compound can be used for imaging during the investigation of cancer. Macropa-NH2 diester is compound 210 extracted from patent WO2018187631 .
|
-
- HY-139707
-
-
- HY-145073
-
|
PROTACs
Estrogen Receptor/ERR
|
Cancer
|
PROTAC ER Degrader-10 is a potent PROTAC ER degrader and can be used for cancer research. PROTAC ER Degrader-10 is extracted from patent WO2021133886, example 36.
|
-
- HY-144880
-
|
ADC Cytotoxin
EGFR
Drug Metabolite
|
Cancer
|
SC209, an ADC cytotoxin extracted from patent WO2021247798, is used in synthesis of anti-EGFR antibody-drug conjugate ADC. SC209 is a metabolite of STRO-002 .
|
-
- HY-144422
-
|
RET
|
Cancer
|
RET-IN-15 is a rearranged during transfection (RET) kinase inhibitor extracted from patent WO2021115457A1 compound 51. RET-IN-15 can be used for the research of cancer .
|
-
- HY-111348
-
Ro 44-9883
|
Others
|
Cardiovascular Disease
|
Lamifiban is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban is promising for research of acute coronary syndromes .
|
-
- HY-18769
-
IDO-IN-4
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
BMS-978587 (IDO-IN-4) is an indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, extracted from patent WO2014150677A1, Compound example 1 enantiomer 1.
|
-
- HY-100083
-
|
HIV
|
Others
|
Dolutegravir intermediate-1 is a synthetic intermediate of Dolutegravir extracted from patent WO 2016125192 A2. Dolutegravir is an integrase inhibitor developed for the treatment of human immunodeficiency virus (HIV)-1 infection.
|
-
- HY-P1355
-
|
Calcineurin
Cyclophilin
|
Inflammation/Immunology
|
Cyclosporin A-Derivative 1 is a crystalline intermediate derived from the opening of cyclosporin A extracted from patent WO 2013167703 A1. Cyclosporin A is an immunosuppressive agent which can bind to the cyclophilin and inhibit calcineurin.
|
-
- HY-128831
-
-
- HY-125997
-
|
Btk
|
Inflammation/Immunology
|
BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment .
|
-
- HY-129169
-
|
Deubiquitinase
|
Cancer
|
USP7-IN-6 is a potent ubiquitin specific protease 7 (USP7) inhibitor, extracted from patent WO2017212010A1, example 25, has an IC50 of 6.8 nM .
|
-
- HY-18770A
-
NLG-1486
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
IDO-IN-6 (NLG-1486) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, Compound 1486, has an IC50 of <1 μM.
|
-
- HY-132988
-
|
Amino Acid Derivatives
|
Others
|
Fmoc-Tyr(3-F,tBu)-OH is a cyclic peptide compound with high membrane permeability and can specifically binds to a target molecule (extracted from patent WO2018225864A1) .
|
-
- HY-144419
-
|
Adenosine Receptor
|
Cancer
|
Adenosine receptor antagonist 3 is a potent antagonist of adenosine receptor. Adenosine receptor antagonist 3 has the potential for the research of cancer disease (extracted from patent WO2019233994A1, compound 1) .
|
-
- HY-144209
-
|
CD73
|
Cancer
|
CD73-IN-6 is a CD73 inhibitor extracted from patent WO2022007677A1 compound 2. CD73-IN-6 can be used for the research of cancer .
|
-
- HY-147229
-
|
Ras
|
Cancer
|
GDC-6036-NH is from patent WO2020097537A2, and a precursor of compound 17 a/b. Compound 17 a/b is a RAS inhibitor and can be used in cancer research .
|
-
- HY-117887
-
BLU-782; IPN-60130; ALK2-IN-1
|
TGF-β Receptor
|
Cancer
|
ALK2-IN-1 is a activin receptor-like kinase-2 (ALK2) inhibitor extracted from patent WO2017181117A1, Compound 876, has an IC50 of <10 nM .
|
-
- HY-17477R
-
|
Others
|
Inflammation/Immunology
|
Guacetisal (Standard) is the analytical standard of Guacetisal. This product is intended for research and analytical applications. Guacetisal is obtained from the esterification of acetylsalicylic acid with guaiacol which has the potential for chronic bronchitis treatment extracted from patent CN 106866420 A.
|
-
- HY-18770
-
NLG-1489
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
IDO-IN-5 (NLG-1489) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, compound 1489, has an IC50 of 1-10 μM.
|
-
- HY-100342
-
|
Btk
|
Cancer
|
Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker, extracted from patent WO2014059368A1 Compound 1-5, has an IC50 of 0.755-1.02 nM for BTK.
|
-
- HY-U00424
-
Vitamin D3 derivative
|
VD/VDR
|
Metabolic Disease
|
Chol-5-en-24-al-3β-ol is a steroid compound (Vitamin D3 derivative) extracted from patent US 4354972 A, Compound IX.
|
-
- HY-107902
-
|
HBV
HCV
HIV
Influenza Virus
|
Infection
|
RIG-1 modulator 1 is an anti-viral compound which can be useful for the treatment of viral infections including influenza virus, HBV, HCV and HIV extracted from patent WO 2015172099 A1.
|
-
- HY-10792A
-
-
- HY-128876
-
-
- HY-18770C
-
NLG-1487
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
IDO-IN-8 (NLG-1487) is an indoleamine 2,3-dioxygenase (IDO) inhibitor extracted from patent WO WO2012142237A1, compound 1487, has an IC50 of 1-10 μM.
|
-
- HY-131132A
-
SHP2-IN-6 hydrochloride
|
SHP2
Phosphatase
|
Cancer
|
JAB-3068 (SHP2-IN-6) hydrochloride is a potent SHP2 inhibitor with an IC50 of 25.8 nM. JAB-3068 hydrochloride is extracted from patent WO2017211303A1, compound 7 .
|
-
- HY-128978
-
|
Phosphatase
|
Metabolic Disease
|
(E,E)-RAMB4 is a potent and selective potent protein tyrosine phosphatase-1B (PTP1B) inhibitor extracted from patent CN103626692A, example 1 .
|
-
- HY-139019
-
|
Acyltransferase
|
Inflammation/Immunology
|
ACAT-IN-2 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 187. ACAT-IN-2 inhibits NF-κB mediated transcription .
|
-
- HY-139026
-
|
Acyltransferase
|
Inflammation/Immunology
|
ACAT-IN-9 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 207. ACAT-IN-9 inhibits NF-κB mediated transcription .
|
-
- HY-141453
-
|
RIP kinase
|
Cancer
|
Desmethyl-WEHI-345 analog is a protein kinase inhibitor extracted from patent WO2012003544A1, example 12. Desmethyl-WEHI-345 analog can be used for the research of colon cancer .
|
-
- HY-141690A
-
|
PI3K
|
Cancer
|
PI3K-IN-19 hydrochloride is a phosphotidylinositol-3-kinase (PI3K) inhibitor extracted from patent WO2017153220, step 5 .
|
-
- HY-19982
-
|
Akt
|
Cancer
|
AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC50s < 500nM, respectively. (patent WO2013056015A1).
|
-
- HY-109004A
-
(S)-BTA-C585
|
RSV
|
Cancer
|
(S)-Enzaplatovir ((S)-BTA-C585) is the S-enantiomer of Enzaplatovir. (S)-Enzaplatovir shows antiviral activities with an EC50 of 56 nM for respiratory syncytial viral (RSV) (patent WO2011094823A1 compound 77) .
|
-
- HY-145450
-
|
Others
|
Cancer
|
ATR-IN-9 is a potent inhibitor of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR) extracted from patent WO2020087170A1, compound 59, has an IC50 of 10 nM .
|
-
- HY-145723
-
|
FLT3
FGFR
|
Inflammation/Immunology
Cancer
|
MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032) .
|
-
- HY-145723A
-
|
FLT3
FGFR
|
Inflammation/Immunology
Cancer
|
MAX-40279 hydrochloride is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hydrochloride has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032) .
|
-
- HY-144682
-
|
OGA
|
Neurological Disease
|
O-GlcNAcase-IN-4 is a O-GlcNAcase inhibitor extracted from patent WO2018140299A1 Formulaic Ic. O-GlcNAcase-IN-4 can be used for the research of neurodegenerative diseases and disorders, such as Alzheimer's disease .
|
-
- HY-N10356
-
|
Others
|
Neurological Disease
|
4,27-Dimethyl withaferin A is a synthetic analog of withanolide natural products. 4,27-Dimethyl withaferin A has the potential for the research of neurodegenerative diseases (extracted from patent WO2015077780A1) .
|
-
- HY-120273
-
|
Glucocorticoid Receptor
|
Metabolic Disease
Inflammation/Immunology
|
Glucocorticoids receptor agonist 3 is a potent agonist of glucocorticoids receptor. Glucocorticoids receptor agonist 3 is useful to research diseases, such as obesity, diabetes, and inflammation (extracted from patent WO2000066522A1, compound 345) .
|
-
- HY-143545
-
|
RET
|
Cancer
|
RET-IN-8 is a rearranged during transfection (RET) kinase inhibitor extracted from patent WO2021093720A1 compound I-1. RET-IN-8 can be used for the research of cancer .
|
-
- HY-144058
-
|
JAK
|
Inflammation/Immunology
|
JAK-IN-18 is a potent inhibitor of JAK. JAK-IN-18 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2018204238A1, compound 1) .
|
-
- HY-145950
-
|
DNA Methyltransferase
|
Cancer
|
2′-Deoxy-5-nitrocytidine is a DNA Methyltransferase inhibitor extracted from patent CN108498529A. 2′-Deoxy-5-nitrocytidine can be used for the research of cancer .
|
-
- HY-144195
-
-
- HY-144194
-
-
- HY-145959
-
|
iGluR
|
Neurological Disease
|
AMPA receptor antagonist-3 is an AMPA receptor antagonist extracted from patent US20070027143A1. AMPA receptor antagonist-3 can be used for the research of central nervous system disorders .
|
-
- HY-145917
-
|
Others
|
Neurological Disease
|
SARM1-IN-2 is a SARM1 inhibitor extracted from patent WO2019236890A1 example 82. SARM1-IN-2 can be used for the research of axonal degeneration .
|
-
- HY-145965
-
|
Ferroportin
|
Metabolic Disease
|
Ferroportin-IN-1 is a ferroportin inhibitor extracted from patent WO2020123850A1 compound 23. Ferroportin-IN-1 can be used for the research of diseases caused by a lack of hepcidin or iron metabolism disorders .
|
-
- HY-156576
-
|
DGK
|
Cancer
|
DGKα-IN-6 is a DGKα inhibitor with the IC50 of 1.377 nM, extracted from patent WO2022271650 (compound 143). DGKα-IN-6 has the potential for cancer study.
|
-
- HY-156577
-
|
DGK
|
Cancer
|
DGKα-IN-7 is a DGKα inhibitor with the IC50 of 6.225 nM, extracted from patent WO2022271684 (compound 100). DGKα-IN-7 has the potential for cancer study.
|
-
- HY-13984
-
|
EGFR
|
Cancer
|
Mutant EGFR inhibitor is a potent and selective mutant EGFR inhibitor extracted from patent WO 2013014448 A1; inhibits EGFR L858R, EGFR Exon 19 deletion and EGFR T790M.
|
-
- HY-102031
-
YY-20394
|
PI3K
|
Inflammation/Immunology
Cancer
|
Linperlisib (YY-20394) is a potent, orally bioavailable and selective inhibitor of PI3Kδ extracted from patent WO 2015055071 A1, compound 10; has an IC50 of 6.4 nM .
|
-
- HY-U00453
-
-
- HY-P1348
-
|
GCGR
|
Metabolic Disease
|
GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide which is a glucagon-like peptide 1 receptor (GLP-1) agonist, extracted from patent US 20160369010 A1.
|
-
- HY-129167
-
|
Epigenetic Reader Domain
|
Cancer
|
Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction extracted from patent WO2017214367, compound example 1. Menin-MLL inhibitor 4 has antitumor activity .
|
-
- HY-111996
-
|
Potassium Channel
|
Inflammation/Immunology
|
Kv3 modulator 1 is a Kv3 voltage-gated potassium channel modulator extracted from patent WO2018020263A1, Compound X. Kv3 modulator 1 has the potential for inflammatory pain treatment .
|
-
- HY-117491
-
|
Epigenetic Reader Domain
|
Cancer
|
BRD4 Inhibitor-10 is a potent BRD4-BD1 inhibitor extracted from patent WO2015022332A1, Compound II-25, has an IC50 of 8 nM .
|
-
- HY-P1355A
-
|
Calcineurin
Cyclophilin
|
Others
|
Cyclosporin A-Derivative 1 (Free base) is a crystalline intermediate derived from the opening of cyclosporin A extracted from patent WO 2013167703 A1. Cyclosporin A is an immunosuppressive agent which can bind to the cyclophilin and inhibit calcineurin.
|
-
- HY-101097
-
|
PD-1/PD-L1
|
Cancer
|
PD-1-IN-17 is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM .
|
-
- HY-112718
-
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
PROTAC BET Degrader-10 is a potent BET protein BRD4 degrader extracted from patent WO2017007612A1, example 37, connected by ligands for Cereblon and BRD4, with a DC50 of 49 nM .
|
-
- HY-79583
-
|
Glutaminase
|
Cancer
|
Glutaminase-IN-3 (compound 657) is a potent glutaminase inhibitor with an IC50 of 0.24 μM for Glutaminase 1 (GLS1). Glutaminase-IN-3 is extracted from patent WO2014089048A1, compound 657 .
|
-
- HY-139027
-
|
Acyltransferase
|
Inflammation/Immunology
|
ACAT-IN-10 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 197. ACAT-IN-10 weakly inhibits NF-κB mediated transcription .
|
-
- HY-139027A
-
|
Acyltransferase
|
Inflammation/Immunology
|
ACAT-IN-10 dihydrochloride is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 197. ACAT-IN-10 dihydrochloride weakly inhibits NF-κB mediated transcription .
|
-
- HY-139023
-
|
Acyltransferase
|
Inflammation/Immunology
|
ACAT-IN-6 is an acyl-Coenzyme A:cholesterol acyltransferase (ACAT) inhibitor extracted from patent EP1236468A1, example 200. ACAT-IN-6 potently inhibits NF-κB mediated transcription .
|
-
- HY-139453
-
|
Others
|
Cancer
|
LP-184 (compound 6), an acylfulvene analog, inhibits tumor growth. LP-184 has potent anti-cancer activity in the ovarian, colon, prostate and pancreatic cell lines. (patent WO2007019308A2).
|
-
- HY-139751
-
|
Beta-lactamase
Bacterial
|
Infection
|
β-Lactamase-IN-4 is a β-lactamase inhibitor extracted from patent WO2013149121A1, compound 708. β-Lactamase-IN-4 can be used for the research of bacterial infections .
|
-
- HY-139779
-
|
Beta-lactamase
Bacterial
|
Infection
|
β-Lactamase-IN-5 is a β-lactamase inhibitor extracted from patent WO2013149121A1, compound 720. β-Lactamase-IN-5 can be used for the research of bacterial infections .
|
-
- HY-139861
-
-
- HY-145195
-
-
- HY-145581
-
AZD4831
|
Glutathione Peroxidase
|
Cardiovascular Disease
|
Mitiperstat (AZD4831) is the potent inhibitor of myeloperoxidase (MPO). Mitiperstat is particularly useful in the research of prophylaxis of cardiovascular disorders such as heart failure and coronary artery disease related conditions (extracted from patent US20160152623A1) .
|
-
- HY-144057
-
|
JAK
|
Inflammation/Immunology
|
JAK-IN-17 is a potent inhibitor of JAK. JAK-IN-17 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2021185305A1, compound 9-1) .
|
-
- HY-143431
-
|
CDK
|
Cancer
|
Cdc7-IN-17 is a potent CDC7 inhibitor with an IC50 of <10 μM, extracted from patent WO2018217439A1. Cdc7-IN-17 can be used for cancer research .
|
-
- HY-144097
-
|
EGFR
|
Inflammation/Immunology
Cancer
|
HER2-IN-8 is a HER-2 inhibitor extracted from patent WO2021179274A1 compound 107. HER2-IN-8 can be used for the research of cancer and inflammation .
|
-
- HY-160283
-
|
PI3K
|
Cancer
|
PI3K-IN-50 is a phosphotidylinositol-3-kinase (PI3K) inhibitor extracted from patent WO2023239710A1, example 35 .
|
-
- HY-155988
-
-
- HY-164192
-
|
DNA/RNA Synthesis
|
Others
|
m7(3'AcmG)(5')ppp(5')(2'OMeA)pG ammonium, a cap analogue derived from patent WO2023159930A1, can be used for the synthesis of mRNA.
|
-
- HY-153452
-
|
PCSK9
|
Cardiovascular Disease
|
PCSK9-IN-16 is a potent PCSK9 inhibitor. PCSK9-IN-16 is extracted from patent WO2020150474, example 87, has the potential for hypercholesterolemia and other cardiovascular diseases research .
|
-
- HY-153564
-
|
ROCK
|
Inflammation/Immunology
|
ROCK-IN-6 is a potent and selectiveROCK2 inhibitor with an IC50 of 2.19 nM. ROCK-IN-6 is extracted from patent WO2021164351 A1, example 7, has the potential for glaucoma and retinal diseases research .
|
-
- HY-128829
-
|
Potassium Channel
|
Inflammation/Immunology
|
Kv3 modulator 2 (formula (I)) is a potent Kv3 channels modulator extracted from patent WO2018109484A1, compound formula (I) , has analgesic activity and is used in the prophylaxis or treatment of related disorders .
|
-
- HY-135831
-
|
Aryl Hydrocarbon Receptor
|
Cancer
|
AHR antagonist 2 is a potent aryl hydrocarbon receptor (AHR) antagonist, extracted from patent WO2019101641A1, compound example 1, with IC50s of 0.885 and 2.03 nM for human and mouse AhR .
|
-
- HY-135829
-
|
Aryl Hydrocarbon Receptor
|
Cancer
|
BAY 2416964 is a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018146010A1, example 192, has an IC50 of 341 nM. BAY 2416964 has the potential for solid tumors treatment .
|
-
- HY-21292
-
SU4949
|
VEGFR
|
Cancer
|
SU5214 is a potent VEGFR2 inhibitor extracted from patent US5834504A, SU5214, has IC50s of 14.8 µM (FLK-1) and 36.7 µM (EGFR), respectively .
|
-
- HY-101097A
-
|
PD-1/PD-L1
|
Cancer
|
PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM .
|
-
- HY-134594
-
|
E1/E2/E3 Enzyme
|
Cancer
|
SENP1-IN-1 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 29. SENP1-IN-1 is developed for tumor radiosensitivity enhancement .
|
-
- HY-134595
-
|
E1/E2/E3 Enzyme
|
Cancer
|
SENP1-IN-2 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 30. SENP1-IN-2 is developed for tumor radiosensitivity enhancement .
|
-
- HY-134596
-
|
E1/E2/E3 Enzyme
|
Cancer
|
SENP1-IN-3 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 17. SENP1-IN-3 is developed for tumor radiosensitivity enhancement .
|
-
- HY-134597
-
|
E1/E2/E3 Enzyme
|
Cancer
|
SENP1-IN-4 is a specific deSUMOylation protease 1 (SENP1) inhibitor extracted from patent CN110627860, Compound 21. SENP1-IN-4 is developed for tumor radiosensitivity enhancement .
|
-
- HY-10652
-
|
JAK
|
Inflammation/Immunology
Cancer
|
JAK-2/3-IN-1 is a potent JAK-2 and JAK-3 inhibitor extracted from patent US8163732B2, compound 46, has Kis of <250 nM for both isoforms .
|
-
- HY-112191
-
|
PI3K
|
Cancer
|
PI3K-IN-10 is a potent pan-PI3K inhibitor as a benzimidazole derivative, compound 332, extracted from patent WO2018057808A1 .
|
-
- HY-138843
-
-
- HY-139245
-
|
ADC Linker
|
Cancer
|
MC-Ala-Ala-Asn-PAB is a linker extracted from patent CN104147612A, page 14. MC-Ala-Ala-Asn-PAB can be used to synthesis the tumor microenvironment specific activated micromolecular targeted conjugate .
|
-
- HY-132980
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 19 is a potent inhibitor of KRAS G12C. KRAS G12C inhibitor 19 significantly inhibits tumor growth (extracted from patent WO2021118877A1) .
|
-
- HY-145191
-
-
- HY-145192
-
-
- HY-145193
-
-
- HY-145601
-
TT 00420
|
Aurora Kinase
VEGFR
|
Cancer
|
Tinengotinib is the modulator of one or more protein kinases such as Aurora kinase and VEGFR kinase. Tinengotinib has the potential for the research of these kinase abnormalities diseases mediated, especially cancer-related diseases (extracted from patent WO2018108079A1) .
|
-
- HY-145723B
-
|
FLT3
FGFR
|
Inflammation/Immunology
Cancer
|
MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032) .
|
-
- HY-145723C
-
|
FLT3
FGFR
|
Inflammation/Immunology
Cancer
|
MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032) .
|
-
- HY-144093
-
|
MAP4K
|
Infection
|
HPK1-IN-26 is a HPK1 and GLK inhibitor extracted from patent WO2021254118A1 compound 1. HPK1-IN-26 can be used for the research of animal pathogen infection .
|
-
- HY-160247
-
|
Drug-Linker Conjugates for ADC
|
Others
|
Boc-Lys-PEG8-N-bis(D-glucose) (compound 89-5) is a drug linker that can be used in the synthesis of antibody-drug conjugates (ADCs) extracted from patent WO2023280227A2 .
|
-
- HY-B2208R
-
|
Others
|
Others
|
Glycol salicylate (Standard) is the analytical standard of Glycol salicylate. This product is intended for research and analytical applications. Glycol salicylate is a derivative of salicylic acid and can be used to improve the aesthetic appearance of the skin, extracted from patent US 20150148320 A1.
|
-
- HY-158866
-
|
Liposome
|
Others
|
BP Lipid 401 is derived from patent WO2020219876A1 (Example 102). BP Lipid 401 features a unique piperidine head group three carbon atoms in length. This compound can be useful for the building or modification of lipid nanoparticles.
|
-
- HY-10531
-
|
EGFR
|
Cancer
|
ARRY-380 analog, an inhibitor of EGFR (ErbB1), is extracted from patent WO2015153959A2, compound 249 . ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2 .
|
-
- HY-136142
-
|
Drug Metabolite
|
Others
|
Prasugrel chloride impurity is a catp impurity of Prasugrel, exacted from patent US20130345428A1, line 0053. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .
|
-
- HY-109574
-
|
Raf
|
Cancer
|
Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research .
|
-
- HY-138247
-
EX-A4764; UUN51204
|
Beta-lactamase
Bacterial
Antibiotic
|
Infection
|
β-Lactamase-IN-2 is a beta-lactamase inhibitor, extracted from patent WO 2019075084 A1, compound 1. β-Lactamase-IN-2 has anti-microbial and anti-bacterial effects .
|
-
- HY-139139
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A inhibitor 3 is a methionine adenosyltransferase 2A (MAT2A) inhibitor extracted from patent WO2020123395A1, compound 24, has an IC50 of <200 nM. MAT2A inhibitor 3 can be used for the research of cancers .
|
-
- HY-141515
-
|
Opioid Receptor
|
Neurological Disease
|
BMS-986121 is a positive allosteric modulator (PAM) of the μ opioid receptor extracted from patent WO2014107344. BMS-986121 is built on a chemical scaffold representing a new chemotype for μ receptor PAMs .
|
-
- HY-139315
-
|
PROTACs
IRAK
|
Cancer
|
PROTAC IRAK4 degrader-4 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-127 .
|
-
- HY-139317
-
|
PROTACs
IRAK
|
Cancer
|
PROTAC IRAK4 degrader-6 is a Cereblon-based PROTAC as interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1, compound I-172 .
|
-
- HY-50856S
-
CTP-543; Ruxolitinib d8; Deuterated Ruxolitinib
|
JAK
|
Inflammation/Immunology
|
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I) .
|
-
- HY-139612
-
JDQ-443; NVP-JDQ443
|
Ras
PERK
|
Cancer
|
Opnurasib (JDQ-443) (NVP-JDQ443) is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity .
|
-
- HY-134377
-
ASP0367; MA-0211
|
PPAR
|
Metabolic Disease
|
Bocidelpar is a modulator of peroxisome proliferator-activated receptor delta (PPAR-δ). Bocidelpar improves mitochondrial biogenesis and function in Duchenne Muscular Dystrophy (DMD) muscle cells (extracted from patent WO2017062468A1, compound 2b) .
|
-
- HY-145588
-
INCB54707
|
JAK
|
Inflammation/Immunology
|
Povorcitinib (INCB54707) is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib is used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) (information extracted from patent WO2021076124A1).
|
-
- HY-142478
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 29 is a KRAS G12C inhibitor extracted from patent WO2021252339A1, compound 3. KRAS G12C inhibitor 29 can be used for the research of cancer .
|
-
- HY-142481
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 30 is a KRAS G12C inhibitor extracted from patent WO2021252339A1, compound 2. KRAS G12C inhibitor 30 can be used for the research of cancer .
|
-
- HY-142485
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 31 is a KRAS G12C inhibitor extracted from patent WO2021252339A1, compound 1. KRAS G12C inhibitor 31 can be used for the research of cancer .
|
-
- HY-142490
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 33 is a KRAS G12C inhibitor extracted from patent WO2021244603A1, compound 1. KRAS G12C inhibitor 33 can be used for the research of cancer .
|
-
- HY-148492
-
-
- HY-153754
-
|
Others
|
Metabolic Disease
|
Phosphatidylcholine transfer protein inhibitor-1 (Answer 37 in Patent) is a phosphatidylcholine transfer protein (PC-TP) inhibitor. Phosphatidylcholine transfer protein inhibitor-1 can be used for research of PC-TP related disease such as obesity .
|
-
- HY-145588A
-
INCB54707 phosphate
|
JAK
|
Inflammation/Immunology
|
Povorcitinib (INCB54707) phosphate is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib phosphate can be used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) (information extracted from patent WO2021076124A1).
|
-
- HY-U00457
-
|
IKK
|
Cancer
|
TBK1/IKKε-IN-1 is a dual TBK1 and IKKε inhibitor extracted from patent US20160376283 A1, Compound 274 in Example 60, has IC50s of <100 nM.
|
-
- HY-136535
-
hTrkA-IN-1
|
Trk Receptor
|
Inflammation/Immunology
|
Anizatrectinib (hTrkA-IN-1) is a potent and orally active inhibitor of TrkA kinase with an IC50 of 1.3 nM, compound 2 extracted from patent WO2015175788. Anizatrectinib can be used for the study of inflammatory disease, such as prostatitis, pelvic, et al .
|
-
- HY-108285
-
|
Others
|
Inflammation/Immunology
|
(Rac)-Telmesteine is a protease inhibitor and is thus a suitable enzyme stabilizer extracted from patent WO 2017220302 A1, compound II-1. (Rac)-Telmesteine can be used as an enzyme stabilizer in protease-containing detergents and cleaning agents .
|
-
- HY-125970
-
|
Prostaglandin Receptor
|
Endocrinology
|
CRTh2 antagonist 2 is selective and potent CRTH2 antagonist extracted from patent US20140148470A1, compound Example 1, has an IC50 of ≤10 nM. CRTh2 antagonist 2 can be used in research of androgenic alopecia .
|
-
- HY-138843A
-
-
- HY-132845
-
PTC857
|
α-synuclein
|
Neurological Disease
|
Utreloxastat (PTC857) is a compound used for the research of the disorders including α-synucleinopathies, tauopathies, Amyotrophic lateral sclerosis (ALS), traumatic brain injury, and ischemic-reperfusion related injuries (patent WO2020081879A2, example A1) .
|
-
- HY-139313
-
-
- HY-145034
-
-
- HY-145554
-
|
Others
|
Others
|
Bafrekalant is a diazabicyclic substituted imidazo[l,2-a]pyrimidine-derivative. Bafrekalant has the potential for the research of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring (extracted from patent WO2018228907A1).
|
-
- HY-145053
-
|
HBV
|
Infection
|
HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). From patent WO2021204258A1, compound 6 .
|
-
- HY-142511
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 34 is a KRAS G12C inhibitor extracted from patent WO2021239058A1, compound Z1. KRAS G12C inhibitor 34 can be used for the research of cancer .
|
-
- HY-144179
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A-IN-4 is a methionine adenosyltransferase 2A (MAT2A) inhibitor extracted from patent WO2020123395A1 compound 426 . MAT2A-IN-4 can be used for the research of cancer .
|
-
- HY-150617A
-
(Rac)-M4076; (Rac)-ATM Inhibitor-5
|
ATM/ATR
|
Cancer
|
(Rac)-Lartesertib ((Rac)-M4076; (Rac)-ATM Inhibitor-5) is an isoform of Lartesertib (HY-150617), which is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1) .
|
-
- HY-W016622R
-
|
Others
|
Others
|
Watermelon ketone (Standard) is the analytical standard of Watermelon ketone. This product is intended for research and analytical applications. Watermelon ketone is fragrance chemical compound with special odorant which has been widely used in the fragrance industry, extracted from patent CN 103058984 A.
|
-
- HY-153935
-
-
- HY-19764
-
|
RIP kinase
|
Cancer
|
GSK2983559 active metabolite is an active metabolite of GSK2983559. GSK2983559 active metabolite is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1.
|
-
- HY-111234
-
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
IDO-IN-11 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50s of 0.18 μM (Kinase) and 0.014 μM (Hela Cell), extracted from patent WO 2016041489 A1, compound 13.
|
-
- HY-112254
-
-
- HY-110387
-
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
IDO-IN-9 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50s of 0.011 μM (Kinase) and 0.0018 μM (Hela Cell), extracted from patent WO 2016041489 A1, compound 6.
|
-
- HY-136464
-
|
β-catenin
|
Cancer
|
β-catenin-IN-2 is a potent β-catenin inhibitor, compound H1B1, extracted from patent US20150374662A1. β-catenin-IN-2 can be used for the study of colorectal cancer .
|
-
- HY-130264
-
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
HIF-2α-IN-2 is a hypoxia-inducible factors (HIF-2α) inhibitor extracted from patent WO2015035223A1, Compound 232, has an IC50 of 16 nM in scintillation proximity assay (SPA) .
|
-
- HY-135967
-
|
DNA/RNA Synthesis
|
Cancer
|
MTH1-IN-2 is a MutT homolog 1 (MTH1) inhibitor extracted from patent WO2016135138A1, Compound (6), MTH1-IN-2 can be used for the research of cancer. Anti-tumor activity .
|
-
- HY-139292
-
|
Amino Acid Derivatives
|
Cancer
|
Fmoc-NH-PEG6-alcohol is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-NH-PEG6-alcohol is extracted from patent WO2016030791, example comp 91 .
|
-
- HY-138059
-
|
IAP
Apoptosis
|
Cancer
|
SM-433, a Smac mimetic, function as inhibitor of inhibitor of apoptosis proteins (IAPs). SM-433 exhibits strong binding affinity XIAP BIR3 protein with an IC50<1 μM (patent WO2008128171A2) .
|
-
- HY-145194
-
-
- HY-145925B
-
|
Epigenetic Reader Domain
|
Cancer
|
CFT8634 is an oral activity degrader targeting BRD9 extracted from patent WO2021178920A1 compound 174. CFT8634 can be used for the research of synovial sarcoma and SMARCB1-deleted solid tumors .
|
-
- HY-153417
-
|
Amyloid-β
|
Neurological Disease
|
Anti-amyloid agent-1 is a potent anti-amyloid compound and inhibits amyloid aggregation. Anti-amyloid agent-1, compound ex1140 from patent WO2012119035A1, provides a useful method for amyloidosis treatment research .
|
-
- HY-111772A
-
(R)-VX-445
|
CFTR
|
Inflammation/Immunology
|
(R)-Elexacaftor is an enantiomer of Elexacaftor (HY-111772). (R)-Elexacaftor is the Compound 37 from patent WO2018107100A1. (R)-Elexacaftor is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR), the EC50 for CFTR dF508 is 0.29 uM .
|
-
- HY-147563
-
|
RET
|
Cancer
|
RET-IN-17 is a potent inhibitor of RET. RET-IN-17 has the potential for the research of pain associated with IBS and other gastrointestinal disorders and for the research of cancers with constitutive RET kinase activity (extracted from patent WO2016038552A1, compound 1) .
|
-
- HY-153436
-
|
RIP kinase
|
Cancer
|
RIP1 kinase inhibitor 6 is a potent and selective RIP1 kinase inhibitor with an IC50 of < 100 nM in human R1P1 kinase assay. RIP1 kinase inhibitor 6 is extracted from patent WO2020103884, example 80 .
|
-
- HY-112597
-
REN001 free acid; HPP593 free acid; Pparδ agonist
|
PPAR
|
Metabolic Disease
|
Mavodelpar free acid is a PPARδ agonist extracted from patent US20180071304, compound example 10. Mavodelpar (free acid) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-129179
-
APG-2575; Bcl-2/Bcl-xl inhibitor 1
|
Bcl-2 Family
|
Cancer
|
Lisaftoclax (compound 6) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, extracted from patent WO2018027097A1. Lisaftoclax exhibits IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively .
|
-
- HY-100132
-
|
Histone Acetyltransferase
|
Cancer
|
P300/CBP-IN-5 is a potent p300/CBP histone acetyltransferase inhibitor extracted from patent WO2016044770A1, Example 715, has an IC50 of 18.8 nM .
|
-
- HY-112762
-
LHF-535
1 Publications Verification
|
Arenavirus
|
Infection
|
LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC50s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively .
|
-
- HY-114339
-
|
CDK
|
Cancer
|
CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor extracted from patent US20180000819A1, Compound 1, has IC50s of 2.7 and 16 nM for CDK4 and CDK6, respectively .
|
-
- HY-10549
-
|
PI3K
|
Cancer
|
PI3Kγ inhibitor 1 is a PI3Kδ and PI3Kγ inhibitor extracted from patent WO2014004470A1, Compound 168 in Table 4, has IC50s of <100 nM.
|
-
- HY-124607
-
|
GSK-3
|
Neurological Disease
|
(R)-BRD3731 is a GSK3 inhibitor extracted from patent US20160375006A1, compound example 273, has IC50s of 1.05 and 6.7 μM for GSK3β and GSK3α, respectively .
|
-
- HY-137978
-
GNS561
|
Others
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Ezurpimtrostat (compound 2-2) is a potent and orally active anti-fibrotic agent. Ezurpimtrostat can be used for the research of fibrosis, cancer, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases (extracted from patent WO2020048694 A1) .
|
-
- HY-139807
-
|
JAK
|
Inflammation/Immunology
|
JAK-IN-14 is a potent and selective JAK1 inhibitor, with an IC50 of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16) .
|
-
- HY-141873
-
|
β-catenin
|
Others
|
Wnt/β-catenin agonist 2 is a potent Wnt agonist. Wnt/β-catenin agonist 2 activates Wnt/β-catenin signaling and can be used in the research of diseases related to the signal transduction . (From patent WO2007078113A1, compound 39)
|
-
- HY-139908
-
|
SARS-CoV
|
Infection
|
MERS-CoV-IN-1 exhibits excellent inhibitory activity against coronavirus. MERS-CoV-IN-1 is useful as a pharmaceutical composition for preventing coronavirus-induced diseases (MERS-CoV and SARS) (extracted from patent WO2018174442A1, compound 1) .
|
-
- HY-145062
-
|
Phosphodiesterase (PDE)
|
Cancer
|
Enpp-1-IN-4 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). Enpp-1-IN-4 has the potential for the research of cancer diseases (extracted from patent WO2019177971A1, compound 1) .
|
-
- HY-145759
-
|
MDM-2/p53
|
Cancer
|
Mutant p53 modulator-1 is a mutant p53 modulator. Mutant p53 modulator-1 reduces the progression of cancers that contain a p53 mutation (extracted from patent WO2021231474A1, compound 231B) .
|
-
- HY-142924
-
|
ATM/ATR
|
Cancer
|
ATR-IN-8 is a potent inhibitor of ATR. ATR is a key enzyme in the homologous recombination repair pathway and belongs to the PIKK family. ATR-IN-8 has the potential for the research of cancer diseases (extracted from patent WO2021143821A1, compound 3) .
|
-
- HY-147230
-
|
Histone Methyltransferase
|
Cancer
|
EZH2-IN-13 is a potent EZH2 inhibitor, for details please refer to compound 73 in patent WO2017139404. EZH2-IN-13 can be used to study cancers or precancerous lesions associated with EZH2 activity .
|
-
- HY-143736
-
|
RAD51
|
Cancer
|
RAD51-IN-5 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-5 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 3) .
|
-
- HY-143737
-
|
RAD51
|
Cancer
|
RAD51-IN-6 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-6 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 23) .
|
-
- HY-143741
-
|
RAD51
|
Cancer
|
RAD51-IN-7 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-7 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2021164746A1, compound 71) .
|
-
- HY-112950
-
|
RET
|
Cancer
|
RET-IN-1 is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 552, has IC50s of 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively .
|
-
- HY-136256
-
DCC-3014
|
c-Fms
c-Kit
|
Cancer
|
Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC50s of <0.01 μM and 0.1-1 μM, respectively .
|
-
- HY-12812
-
|
Phosphodiesterase (PDE)
|
Neurological Disease
Cancer
|
Autotaxin modulator 1 is an autotaxin (ATX) enzyme inhibitor, extracted from patent WO 2014018881 A1, Compound Example 12b. Autotaxin modulator 1 is expected to be useful for researching demyelination due to injury or disease, as well as for researching proliferative disorders such as cancer .
|
-
- HY-132268
-
|
Calcium Channel
|
Neurological Disease
|
Cav 2.2 blocker 2 is a Cav2.2 calcium channel blocker extracted from patent WO2017046581A1, compound 1. Cav 2.2 blocker 2 can reverses hyperalgesia associated with an injury or inflammation in conjunction with the opioid .
|
-
- HY-139600
-
|
Histone Demethylase
|
Cancer
|
KDM2B-IN-3 is a histone demethylase KDM2B inhibitor extracted from patent WO2016112284A1, compound 183c. KDM2B-IN-3 can be used for the research of cancer .
|
-
- HY-139601
-
|
Histone Demethylase
|
Cancer
|
KDM2B-IN-4 is a histone demethylase KDM2B inhibitor extracted from patent WO2016112284A1, compound 182b. KDM2B-IN-4 can be used for the research of cancer .
|
-
- HY-138059A
-
|
IAP
Apoptosis
|
Cancer
|
SM-433 hydrochlorid, a Smac mimetic, function as inhibitor of inhibitor of apoptosis proteins (IAPs). SM-433 hydrochlorid exhibits strong binding affinity XIAP BIR3 protein with an IC50<1 μM (patent WO2008128171A2) .
|
-
- HY-145604
-
RG7774
|
Cannabinoid Receptor
|
Neurological Disease
|
Vicasinabin (RG7774) is the potent agonist of cannabinoid receptor 2 (CB2). Vicasinabin has the potential for the research of human diseases including chronic pain, atherosclerosis, regulation of bone mass, neuroinflammation, and other related diseases (extracted from patent US20130116236A1) .
|
-
- HY-143421
-
CMG
|
Drug Metabolite
|
Cancer
|
Curcumin monoglucuronide is known as a glucuronic acid conjugate, which is one of the in vivo metabolites of curcumin. Curcumin monoglucuronide is used for research on the metabolism of curcumin and examination of its development as a pharmaceutical. Curcumin monoglucuronide has the potential for the research of cancer disease (extracted from patent WO2022004873A1) .
|
-
- HY-158864
-
|
Liposome
|
Others
|
BP Lipid 378 is derived from patent WO2020219876A1 (Example 8). BP Lipid 378 is an ionizable amino lipid that features a unique pyrrolidine head group with a carbamate linkage to the lipid tails. This lipid may be used in the generation of lipid nanoparticles (LNPs) for mRNA delivery.
|
-
- HY-143735
-
|
RAD51
|
Cancer
|
RAD51-IN-4 is a potent inhibitor of RAD51. RAD51 is a eukaryote gene. RAD51-IN-4 has the potential for the research of conditions involving mitochondrial defects (extracted from patent WO2019014315A1, compound R12) .
|
-
- HY-147204
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE (compound S6) is a potent anticancer agent, which can be specific activated by tumor microenvironment. Mc-Alanyl-Alanyl-Asparagine-PAB-MMAE can suppress tumor growth in mice (extracted from patent CN104147612A) .
|
-
- HY-103663
-
MAK683
1 Publications Verification
|
Histone Methyltransferase
|
Cancer
|
MAK683 is an embryonic ectoderm development (EED) inhibitor extracted from patent US20160176882 A1, compound example 2. MAK683 exhibits IC50s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay .
|
-
- HY-129172A
-
-
- HY-141552
-
|
Others
|
Cardiovascular Disease
|
FC9402 is a potent and selective sulfide quinone oxidoreductase (SQOR) inhibitor extracted from patent WO 2020/146636 A1. FC9402 attenuates TAC-induced cardiomyocyte hypertrophy and left ventricle (LV) fibrosis. FC9402 can be used for cardiovascular regulation .
|
-
- HY-A0298
-
|
Histone Methyltransferase
|
Cancer
|
EZH2-IN-2 is a EZH2 inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC50 of 64 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activity .
|
-
- HY-145361
-
|
Eukaryotic Initiation Factor (eIF)
|
Cancer
|
eIF4A3-IN-7 is a potent inhibitor of eIF4A3. eIF4A3-IN-7 has the potential for researching cancer and other dysproliferative diseases (extracted from patent WO2019161345A1, Compound 8) .
|
-
- HY-143766
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-13 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-13 has the potential for the research of influenza virus infection (only influenza A) (extracted from patent WO2021180147A1, compound I-1) .
|
-
- HY-143752
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-8 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-8 inhibits replication of orthomyxoviruses (including influenza A, influenza B and influenza C) (extracted from patent CN111410661A, compound I-196) .
|
-
- HY-142697
-
|
Guanylate Cyclase
|
Cardiovascular Disease
|
SGC agonist 1 is a potent agonist of soluble guanylate cyclase (SGC). SGC agonist 1 improves solubility combined with high cell permeability. SGC agonist 1 has the potential for the research of cardiovascular disease (extracted from patent WO2016030354A1, compound 18A) .
|
-
- HY-145686
-
|
Others
|
Inflammation/Immunology
|
AV023 is a potent inhibitor of ANKRD22. AV023 promotes the expansion of gastrointestinal mucosal epithelial stem cells and indirectly activates the Wnt classical pathway, which helps the recovery of damaged gastrointestinal mucosal tissues in the body (extracted from patent CN111205231B) .
|
-
- HY-142926
-
|
Estrogen Receptor/ERR
|
Cancer
|
ER degrader 2 is a potent degrader of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. ER degrader 2 has the potential for the research of cancer diseases (extracted from patent CN112830919A, compound 1) .
|
-
- HY-103663A
-
|
Histone Methyltransferase
|
Cancer
|
MAK683 hydrochloride is an embryonic ectoderm development (EED) inhibitor extracted from patent US20160176882 A1, compound example 2. MAK683 exhibits IC50s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay .
|
-
- HY-157067
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 62 is a KRAS G12C inhibitor. KRAS G12C inhibitor 62 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021121367A1) .
|
-
- HY-143734
-
|
EGFR
|
Cancer
|
HER2-IN-6 is a potent inhibitor of HER2. HER2-IN-6 has the potential for the research of wild and/or mutant EGFR and/or HER2 kinase mediated tumor (extracted from patent WO2021164697A1, compound 11) .
|
-
- HY-147594
-
|
CD73
|
Cancer
|
CD73-IN-13 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-13 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437039A, compound 7) .
|
-
- HY-19702
-
|
Pyruvate Kinase
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
PKR activator 3 is a pyruvate kinase isoform PKR activator extracted from patent WO2014139144A1, compound 160. PKR activator 3 can be used for the research of PKR function related diseases, including cancer, diabetes, obesity, autoimmune disorders, and benign prostatic hyperplasia .
|
-
- HY-107371
-
NSC95682
|
IRE1
|
Cancer
|
6-Bromo-2-hydroxy-3-methoxybenzaldehyde (NSC95682) is an IRE-1α inhibitor with an IC50 of 0.08 μM, extracted from patent WO 2008154484 A1, IRE-lα inhibitor compound 3-5.
|
-
- HY-129172
-
-
- HY-114661
-
|
PROTAC Linkers
|
Cancer
|
m-PEG4-Tos is a derivative of silybin ethers, extracted from patent CN105037337A (compound III-b). m-PEG4-Tos is a PEG-based PROTAC linker can be used in the synthesis of Silymarin (HY-W043277) .
|
-
- HY-135090
-
|
PROTAC Linkers
|
Cancer
|
Tos-PEG8-m is a derivative of silybin ethers, extracted from patent CN105037337A (compound III-d). Tos-PEG8-m is a PEG-based PROTAC linker can be used in the synthesis of Silymarin (HY-W043277) .
|
-
- HY-W042501
-
|
PROTAC Linkers
|
Cancer
|
m-PEG5-Tos is a derivative of silybin ethers, extracted from patent CN105037337A (compound III-c). m-PEG5-Tos is a PEG-based PROTAC linker can be used in the synthesis of Silymarin (HY-W043277) .
|
-
- HY-130515
-
|
CDK
|
Cancer
|
Cdc7-IN-3 (compound I-A) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle .
|
-
- HY-12820
-
Antibiotic-202
|
Bacterial
Antibiotic
|
Infection
|
Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD) .
|
-
- HY-139076
-
|
Epigenetic Reader Domain
|
Metabolic Disease
Cancer
|
Menin-MLL inhibitor 19, a potent exo-aza spiro inhibitor of menin-mll interaction, example A17, extracted from patent WO2019120209A1. Menin-MLL inhibitor 19 can be used for the reseaech of various diseases, such as cancer, myelodysplastic syndrome (MDS) and diabetes .
|
-
- HY-141535A
-
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
IL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator extracted from patent WO 2020127685. IL-17 modulator 1 (disodium) can be used for the research of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .
|
-
- HY-139323
-
-
- HY-141799
-
|
Ligands for Target Protein for PROTAC
|
Cancer
|
Dimethyl-F-OICR-9429-COOH a ligand for WD40 repeat domain protein 5 (WDR5) extracted from patent WO2019246570A1 intermediate 19. Dimethyl-F-OICR-9429-COOH can be used in the synthesis of PROTACs .
|
-
- HY-145052
-
|
HBV
|
Infection
|
HBV-IN-9 is a potent HBsAg (HBV Surface antigen) inhibitor (IC50=10 nM) and HBV DNA production inhibitor (IC50=0.15 nM in HepG2.2.15 cells) . From patent WO2018001952A1, example 20.
|
-
- HY-143770
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-16 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-16 is a pyridone polycyclic derivative. Cap-dependent endonuclease-IN-16 has the potential for the research of influenza (extracted from patent CN112778330A, compound 15A) .
|
-
- HY-142925
-
|
Estrogen Receptor/ERR
|
Cancer
|
ER degrader 1 is a potent degrader of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. ER degrader 1 has the potential for the research of cancer diseases (extracted from patent WO2021139756A1, compound 11) .
|
-
- HY-142927
-
|
Estrogen Receptor/ERR
|
Cancer
|
ER degrader 3 is a potent degrader of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. ER degrader 3 has the potential for the research of cancer diseases (extracted from patent WO2018233591A1, compound 1) .
|
-
- HY-145193A
-
-
- HY-131515R
-
|
Others
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
Tri-Salicylic acid (Standard) is the analytical standard of Tri-Salicylic acid. This product is intended for research and analytical applications. Tri-Salicylic acid is the compound with similar properties of salicylic acid. Tri-Salicylic acid has the potential for the research of inflammation, obesity and cardiovascular diseases (extracted from patent US20170368079A1, compound III) .
|
-
- HY-158865
-
|
Liposome
|
Others
|
BP Lipid 399 is derived from patent WO2020219876A1 (Example 3).BP Lipid 399 is an ionizable amino lipid analog of LP01 featuring a novel pyrrolidine head group three carbon atoms in length. This compound can be useful for the building or modification of lipid nanoparticles.
|
-
- HY-14794A
-
(1S,2R)-Milnacipran; F2695
|
Serotonin Transporter
|
Metabolic Disease
|
Levomilnacipran (F2696; (1R,2S)-milnacipran), an enantiomer of milnacipran, is a selective serotonin and norepinephrine (5-HT/NE) reuptake inhibitor. Levomilnacipran also is a human alpha-adrenergic receptor antagonist, with an IC50 of 3.4 μM. (patent WO2013014263A1).
|
-
- HY-139331
-
|
Proteasome
|
Neurological Disease
Inflammation/Immunology
Cancer
|
20S Proteasome-IN-1 is a 26S proteasome inhibitor extracted from patent WO2006128196A2 compound 2. 20S Proteasome-IN-1 has the potential for cancer, immune-related disorders, inflammation, ischemic conditions, neurodegenerative disorders and other diseases research .
|
-
- HY-U00286
-
|
5-HT Receptor
|
Cardiovascular Disease
|
5-HT2A antagonist 1 is a 5-HT2A antagonist extracted from patent US5728835A and JP 1007727. 5-HT2A antagonist 1 may be useful in treatment of gastrointestinal disorders circulatory disorders.
|
-
- HY-115688
-
|
Others
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
TXNIP-IN-1 is TXNIP-TRX (thioredoxin-interacting protein- thioredoxin) complex inhibitor extracted from patent US20200085800A1, Compound 1. TXNIP-IN-1 can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease .
|
-
- HY-136788
-
AKST4290
|
CCR
|
Neurological Disease
Inflammation/Immunology
|
ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3 . ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism .
|
-
- HY-130516
-
|
CDK
|
Cancer
|
Cdc7-IN-4 (compound I-C) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-C. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle .
|
-
- HY-130519
-
|
CDK
|
Cancer
|
Cdc7-IN-7 (compound I-E) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-E. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle .
|
-
- HY-111623
-
|
Deubiquitinase
|
Cancer
|
USP30 inhibitor 11 is a selective and potent ubiquitin specific peptidase 30 (USP30) inhibitor with an IC50 of 0.01 µΜ, the example 83 extracted from patent WO2017009650A1. USP30 inhibitor 11 is used for the study of cancer and conditions involving mitochondrial dysfunction .
|
-
- HY-101093B
-
|
PD-1/PD-L1
|
Cancer
|
PD-1-IN-20 is the less active enantiomer of PD-1-IN-1. PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4 .
|
-
- HY-109198
-
ME-401; PWT-143
|
PI3K
|
Cancer
|
Zandelisib (ME-401) is a phosphatidylinositol 3-kinase (PI3K) inhibitor extracted from patent WO2019183226 A1, Compound Example 1. Zandelisib selectively inhibits p110δ with an IC50 of 3.5 nM. Zandelisib functions as an antineoplastic .
|
-
- HY-100754B
-
(2R,5S)-PF-06651600
|
JAK
|
Inflammation/Immunology
|
(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective JAK3 inhibitor (IC50=144.8 nM) extracted from patent US20150158864A1, example 68 .
|
-
- HY-130517
-
|
CDK
|
Cancer
|
Cdc7-IN-5 (compound I-B) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle .
|
-
- HY-14794
-
(1R,2S)-milnacipran; F2696
|
Serotonin Transporter
|
Metabolic Disease
|
Dextromilnacipran (F2696; (1R,2S)-milnacipran), an enantiomer of milnacipran, is a selective serotonin and norepinephrine (5-HT/NE) reuptake inhibitor. Dextromilnacipran also is a human alpha-adrenergic receptor antagonist, with an IC50 of 3.4 μM. (patent WO2013014263A1).
|
-
- HY-132846
-
TAS0953/HM06
|
RET
|
Others
|
Vepafestinib (TAS0953/HM06; compound 6) is a RET inhibitor (extracted from patent WO2019039439) . Vepafestinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-141885
-
|
Others
|
Metabolic Disease
|
APOL1-IN-1 is a apolipoprotein L1 (APOL1) inhibitor extracted from patent WO2020131807A1 compound 87. APOL1-IN-1 can be used for the research of focal segmental glomerulosclerosis (FSGS) and non-diabetic kidney disease (NDKD) .
|
-
- HY-145571
-
D-1553
|
Ras
|
Cancer
|
Garsorasib is a potent inhibitor of KRAS G12C with an IC50 of 10 nM. Garsorasib has the potential for the research of various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (non-small cell lung cancer) (extracted from patent WO2020233592A1, compound 2) .
|
-
- HY-138996
-
|
GCGR
|
Metabolic Disease
|
GLP-1 receptor agonist 8 is a potent agonist of GLP-1 R. GLP-1 receptor agonist 8 has the potential for the research of diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD) (extracted from patent WO2019239319A1, compound 17) .
|
-
- HY-144070A
-
|
Estrogen Receptor/ERR
|
Cancer
|
(Rac)-ErSO-DFP is a derivative of ErSO-DFP and a selective small molecule Erα biomodulator. (Rac)-ErSO-DFP againsts ERα+ breast cancer (including resistant tumors) by hyperactiving the Erα-dependent a-UPR (extracted from patent WO2022087234A1) .
|
-
- HY-158863
-
|
Liposome
|
Others
|
BP Lipid 377 is derived from patent WO2018062413A1. BP Lipid 377 is an ionizable amino lipid comprised of three linoleic acid tails and an N,N-dimethylamine head group four carbon atoms in length. This lipid may be used in the generation of lipid nanoparticles (LNPs) for mRNA and drug delivery.
|
-
- HY-W440802
-
|
Liposome
|
Others
|
BP Lipid 217 is derived from patent WO2023178065A2 (B32). BP Lipid 217 is an ethanolamine ionizable lipid with both ester bonds located adjacent to C8 relative to the amine head. The introduction of ester linkages can improve the clearance of the lipid in the liver. This compound is analgous to ALC-0315.
|
-
- HY-50162
-
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
GPR120 modulator 1 is a G protein coupled receptor 120 (GPR120) modulator extracted from patent US8394841B2, compound example F1. GPR120 modulator 1 can be used for the research of diseases associated with abnormal or deregulated GPR120, such as diabetes .
|
-
- HY-50172
-
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
GPR120 modulator 2 is a G protein coupled receptor 120 (GPR120) modulator extracted from patent US8394841B2, compound example F13. GPR120 modulator 2 can be used for the research of diseases associated with abnormal or deregulated GPR120, such as diabetes .
|
-
- HY-109585
-
|
IRAK
|
Inflammation/Immunology
Cancer
|
IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment .
|
-
- HY-126293
-
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
|
Apelin agonist 1 is an oral selective apelin agonist AM-2995, a agonist of the APJ (APLNR, angiotensin receptor like-1) receptor, may be used in the treatment of cardiovascular conditions. Apelin agonist 1 is extracted from patent WO 2018097944 (210.0), Example 210.0 .
|
-
- HY-136220
-
|
Aryl Hydrocarbon Receptor
|
Cancer
|
AHR antagonist 5, a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018195397, example 39, has an IC50 of < 0.5 µΜ. AHR antagonist 5 significantly inhibits tumor growth combined with checkpoint inhibitor anti-PD-1 .
|
-
- HY-126298
-
|
Raf
|
Cancer
|
RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAF V600E and B-RAF WT, respectively .
|
-
- HY-137246
-
|
CD73
|
Cancer
|
CD73-IN-3 is a potent CD73 inhibitor (IC50=7.3 nM in Calu6 human cell assay). CD73-IN-3, example 2 extracted from patent WO2019168744 A1, has the potential for cancer research .
|
-
- HY-103715
-
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
NLRP3 modulators 1 is the potent modulator of NLRP3. NLRP3 modulators 1 agonizes or partially agonizes NLRP3 that are useful for researching a condition, disease or disorder in which a decrease in LRP3 activity contributes to the pathology (extracted from patent WO2017184746A1, compound 107) .
|
-
- HY-145053A
-
|
HBV
|
Infection
|
(5S,8R)-HBV-IN-10 is an enantiomer of compound 6 (WO2021204258A1). Compound 6 is a hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). From patent WO2021204258A1, compound 6 .
|
-
- HY-144139
-
|
Estrogen Receptor/ERR
|
Cancer
|
Estrogen receptor antagonist 3 is a potent antagonist of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. Estrogen receptor antagonist 3 has the potential for the research of cancer diseases (extracted from patent WO2021213358A1, compound 7) .
|
-
- HY-144202
-
|
Estrogen Receptor/ERR
|
Cancer
|
Estrogen receptor antagonist 4 is a potent antagonist of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. Estrogen receptor antagonist 4 has the potential for the research of cancer diseases (extracted from patent WO2021213358A1, compound 1) .
|
-
- HY-133699
-
|
E3 Ligase Ligand-Linker Conjugates
|
Others
|
Pomalidomide-PEG4-COOH is a E3 ligase ligand-linker conjugate. Pomalidomide-PEG4-COOH contains the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology (extracted from patent WO2017184995A1) .
|
-
- HY-139612A
-
(S)-NVP-JDQ443
|
Ras
PERK
|
Cancer
|
(S)-JDQ-443 is an isomer of JDQ-443 (HY-139612). JDQ-443 is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). JDQ-443 shows antitumor activity .
|
-
- HY-145925C
-
|
Epigenetic Reader Domain
|
Cancer
|
(S,R)-CFT8634 is a selective and orally active BRD9 protein degrader. (S,R)-CFT8634 has the potential for the research of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation (extracted from patent WO2021178920A1, compound 176) .
|
-
- HY-136788A
-
AKST4290 dihydrochloride
|
CCR
|
Inflammation/Immunology
|
ALK4290 dihydrochloride (AKST4290 dihydrochlorid) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3 . ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism .
|
-
- HY-147597
-
|
CDK
|
Cancer
|
CDK7-IN-13 is a potent inhibitor of CDK7. CDK7-IN-13 is a pyrimidinyl derivative compound. CDK7-IN-13 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 1) .
|
-
- HY-147600
-
|
CDK
|
Cancer
|
CDK7-IN-15 is a potent inhibitor of CDK7. CDK7-IN-15 is a pyrimidinyl derivative compound. CDK7-IN-15 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 8) .
|
-
- HY-147602
-
|
CDK
|
Cancer
|
CDK7-IN-17 is a potent inhibitor of CDK7. CDK7-IN-17 is a pyrimidinyl derivative compound. CDK7-IN-17 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 1) .
|
-
- HY-147603
-
|
CDK
|
Cancer
|
CDK7-IN-18 is a potent inhibitor of CDK7. CDK7-IN-18 is a pyrimidinyl derivative compound. CDK7-IN-18 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 15) .
|
-
- HY-147598
-
|
CDK
|
Cancer
|
CDK7-IN-14 is a potent inhibitor of CDK7. CDK7-IN-14 is a pyrimidinyl derivative compound. CDK7-IN-14 has the potential for the research of various cancers, especially the cancer with transcriptional dysregulation (extracted from patent CN114249712A, compound 3) .
|
-
- HY-112436A
-
|
Trk Receptor
|
Neurological Disease
Cancer
|
(3S,4R)-PF-6683324 is a tropomyosin-related kinase (Trk) inhibitor extracted from patent WO2015092610A1 example 9. (3S,4R)-PF-6683324 has the potential for the research of pain and cancer .
|
-
- HY-111820
-
|
Casein Kinase
|
Inflammation/Immunology
|
CK1-IN-1 is a casein kinase 1 (CK1) inhibitor extracted from patent WO2015119579A1, compound 1c, has IC50s of 15 nM, 16 nM, 73 nM for CK1δ, and CK1ε, p38σ MAPK, respectively .
|
-
- HY-128761
-
|
Epigenetic Reader Domain
|
Cancer
|
CBP/EP300-IN-2 is an inhibitor of CBP/EP300 with IC50 values of 1.07 nM and 5.96 nM for CBP/HTRF and Myc, respectively. CBP/EP300-IN-2, example 25, is extracted from patent WO2017205538A1 .
|
-
- HY-128680
-
|
c-Fms
|
Cancer
|
c-Fms-IN-9 is a c-FMS inhibitor extracted from patent WO2014145023A1, Compound Example 7. c-Fms-IN-9 inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT with IC50s of <0.01 μM and 0.1-1 μM, respectively .
|
-
- HY-W036733
-
|
Biochemical Assay Reagents
|
Others
|
4-Hydroxy-4-methylcyclohexanone is a useful synthetic reagent extracted from patent JP2009022162A. 4-Hydroxy-4-methylcyclohexanone can be used to synthesize trans-4-amino-1-methylcyclohexanol which is intermediate of pharmaceutical synthesis .
|
-
- HY-124676A
-
|
Apoptosis
|
Cancer
|
DB2115 (tertahydrochloride) is a potent inhibitor of myeloid master regulator PU.1. DB2115 (tertahydrochloride) has the potential for researching cancers, including hematologic cancers such as leukemia, as well as other conditions associated with PU. 1 dysfunction (extracted from patent WO2017223260A1, compound DB2115) .
|
-
- HY-145122
-
|
Others
|
Metabolic Disease
|
ELOVL1-IN-1 is an ELOVL1 inhibitor extracted from patent WO2018107056A1, compound 87. ELOVL1-IN-1 can reduce very long chain fatty acid levels. ELOVL1-IN-1 can be used for the research of adrenoleukodystrophy (ALD) .
|
-
- HY-145550
-
BI894999
|
Epigenetic Reader Domain
|
Cancer
|
Amredobresib is a potent inhibitor of BET. Amredobresib inhibits the binding of bromodomains to acetylated lysines on histone H3 and H4 and thus acts as important regulators of gene transcription. Amredobresib is useful for the research of acute myeloid leukemia (AML) and cancer (extracted from patent WO2019145410A1 and WO2021175824A1) .
|
-
- HY-142931
-
|
ATM/ATR
|
Neurological Disease
Cancer
|
ATM-IN-1 is a potent inhibitor of ATM. ATM is located mainly in the nucleus and microsomes and is involved in cell cycle progression and in the cell cycle checkpoint response to DNA damage. ATM-IN-1 has the potential for the research of cancer and neurology diseases (extracted from patent WO2021139814A1, compound 3) .
|
-
- HY-143615
-
|
RET
|
Cancer
|
RET-IN-10 is a potent inhibitor of RET. RET loss of function mutations leads to Hirschsprung's disease, while its gain of function mutations is associated with a variety of human tumors. RET-IN-10 has the potential for the research of cancer diseases (extracted from patent WO2021135938A1, compound 18) .
|
-
- HY-B2121R
-
Naproxen impurity O (Standard)
|
iGluR
|
Neurological Disease
|
6-Methoxy-2-naphthoic acid (Standard) is the analytical standard of 6-Methoxy-2-naphthoic acid. This product is intended for research and analytical applications. 6-Methoxy-2-naphthoic acid is an NMDA receptor modulator extracted from patent WO 2012019106 A2.
|
-
- HY-W800737
-
|
Liposome
|
Cancer
|
BP Lipid 126 is an amino ionizable lipid (Compound 143) from patent WO2017201333A1 with ester bonds located at C8 and C7 position relative to nitrogen. The ester linkages are introduced to improve tissue clearance. The ethanolamine head can effectively enhance mRNA encapsulation. BP Lipid 126 can be used in the generation of liposomes.
|
-
- HY-147202
-
|
Epigenetic Reader Domain
|
Cancer
|
BRD4 Inhibitor-24 (compound 3U) is a potent BRD4 inhibitor, BRD4 Inhibitor-24 shows antitumor activity against MCF7 and K652 cells, with IC50 values of 33.7 and 45.9 μM, respectively (extracted from patent CN107721975A) .
|
-
- HY-12291
-
HMSL 10017-101-1
|
Raf
|
Cancer
|
HG6-64-1 is a potent and selective B-Raf inhibitor extracted from patent WO 2011090738 A2, example 9 (XI-1); has a IC50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells.
|
-
- HY-19773
-
|
Beta-lactamase
Bacterial
|
Infection
|
β-Lactamase-IN-1 is an inhibitor of β-Lactamase extracted from patent WO2016027249A1, page 77. β-Lactamase-IN-1 can be used to prepare of tricyclic nitrogen containing compound. β-Lactamase-IN-1 can be used for the research of neisseria gonorrhea infection .
|
-
- HY-128527
-
|
PROTACs
Estrogen Receptor/ERR
|
Cancer
|
PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab) .
|
-
- HY-128830
-
|
Potassium Channel
|
Inflammation/Immunology
|
Kv3 modulator 3 (Compound 4) is a selective modulator of Kv3.1 and/or Kv3.2 and/or Kv3.3 channels extracted from patent WO2017098254A1, compound 4, has analgesic activity for use in the prophylaxis o or treatment of pain .
|
-
- HY-120947
-
|
Others
|
Neurological Disease
|
AV-105 is a Florbetapir ( 18F)-radiolabeled slyrylpyridine tosylate precursor extracted from patent WO2010078370A1, example 1.5. AV-105 can synthesize 18F-radiolabeled compounds, which are used for positron emission tomography (PET) imaging of neurodegenerative diseases of the brain .
|
-
- HY-128528
-
|
PROTACs
Estrogen Receptor/ERR
|
Cancer
|
PROTAC ER Degrader-2 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab) .
|
-
- HY-137298
-
|
Aminopeptidase
|
Inflammation/Immunology
|
LTA4H-IN-1 is a potent inhibitor of leukotriene A4 hydrolase (LTA4H) extracted from patent WO2015092740A1, example 29, has an IC50 of 2 nM. LTA4H-IN-1 can be used for the research of inflammatory and autoimmune disorders .
|
-
- HY-131448
-
|
Others
|
Metabolic Disease
|
A3051 is a potent and orally active inhibtor of CXXC5-DVL extracted from patent WO2020079569, has an IC50 of 63.06 nM. A3334 can be used for the research of high fat diet (HFD)-induced and methionine-choline deficient diet (MCD)-induced phenotypes such as obesity, diabetes, and NASH .
|
-
- HY-130735
-
JF646, SE; JF646, NHS
|
Fluorescent Dye
|
Others
|
Janelia Fluor 646, SE (JF646, SE) is a red fluorescent dye can be used in cellular imaging . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-131020
-
JF525, SE; JF525, NHS
|
Fluorescent Dye
|
Others
|
Janelia Fluor 525, SE (JF525, SE) is a yellow fluorescent dye (Ex = 525 nm; Em = 549 nm) . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-138761
-
|
Prostaglandin Receptor
|
Inflammation/Immunology
Cancer
|
EP4 receptor antagonist 3 is a potent EP4 receptor antagonist, example 3,extracted from patent WO2010019796 A1. EP4 receptor antagonist 3 can be used for the reseacrh of EP4 receptor-mediated diseases, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer .
|
-
- HY-141535
-
|
Interleukin Related
|
Infection
Inflammation/Immunology
|
IL-17 modulator 1 is an orally active, highly efficacious small molecule IL-17 modulators extracted from patent WO 2020127685. IL-17 modulator 1 can be used for the research of preventing, researching or ameliorating a variety of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis .
|
-
- HY-135653A
-
(Rac)-BPN-19186
|
Epoxide Hydrolase
|
Neurological Disease
|
(Rac)-EC5026 ((Rac)-BPN-19186) is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) extracted from patent WO2019156991A1, page 39, has a Ki of 0.06 nM. (Rac)-EC5026 can be used for the research of Parkinson's disease and dementia with Lewy Bodies (DLB) .
|
-
- HY-139449
-
|
CDK
|
Cancer
|
CDK4/6-IN-5 is a potent CDK4 and CDK6 inhibitor with Kis of 0.2 and 4.4 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively . (from patent WO2019207463A1 example A93).
|
-
- HY-138832
-
APG-1252-M1
|
Bcl-2 Family
|
Cancer
|
BM-1244 (APG-1252-M1) is a potent Bcl-xL/Bcl-2 inhibitor with Kis of 134 and 450 nM for Bcl- xL and Bcl-2, respectively. BM-1244 inhibits senescent fibroblasts (SnCs) with an EC50 of 5 nM. (From patent WO2019033119A1) .
|
-
- HY-139348
-
|
Histone Demethylase
Apoptosis
|
Cancer
|
PFI-90 is a selective inhibitor of histone demethylase (KDM3B) that inhibits PAX3-FOXO1 action. PFI-90 induces apoptosis and myogenic differentiation, resulting in the cell death increased. PFI-90 has the potential for the antitumor activity. (patent WO2021101929A1).
|
-
- HY-145578
-
X842
|
Others
|
Inflammation/Immunology
|
Linaprazan glurate inhibits exogenously or endogenously stimulated gastric acid secretion. Linaprazan glurate exhibits several advantageous properties, such as fast onset, high in vivo potency and/or long duration of action. Linaprazan glurate is useful in the research of gastrointestinal inflammatory diseases and peptic ulcer diseases (extracted from patent WO2010063876A1) .
|
-
- HY-116877
-
|
COX
|
Cancer
|
C2 Ceramide (d14:1/2:0) is a composition for diagnosing diseases associated with cyclooxygenase 2 (COX2) overexpression. C2 Ceramide (d14:1/2:0) exhibits a strong binding activity to COX2 protein (extracted from patent WO2019235824A1).
|
-
- HY-145059
-
|
HBV
|
Infection
|
HBV-IN-12 is a potent hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). HBV-IN-12 shows anti-HBV DNA activity (0.001 μM<EC50 ≤0.02 μM). From patent WO2021204252A1, compound 15 .
|
-
- HY-142671
-
|
ATM/ATR
|
Cancer
|
ATR-IN-5 is a potent inhibitor of ATR. ATR is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-5 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent CN112047938A, compound D24) .
|
-
- HY-143563
-
|
NOD-like Receptor (NLR)
|
Cancer
|
NLRP3 antagonist 1 is a potent antagonist of NLRP3. NLRP3 is mainly expressed in macrophages and neutrophils and is involved in the body's intrinsic immunity against pathogenic infections and stress injury. NLRP3 antagonist 1 has the potential for the research of cancer disease (extracted from patent WO2021114691A1, compound 3) .
|
-
- HY-143713
-
|
Aurora Kinase
|
Cancer
|
Aurora A inhibitor 1 is a potent and selective inhibitor of Aurora A. Aurora A has been implicated in cancers of diverse histological origin and may possess oncogenic properties when overexpressed. Aurora A inhibitor 1 has the potential for the research of cancer diseases mediated by aurora a (extracted from patent WO2021147974A1, compound 49) .
|
-
- HY-144065
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-19 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-19 is a spirocyclic pyridone derivative. Cap-dependent endonuclease-IN-19 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN111410661A, compound 1) .
|
-
- HY-143747
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-5 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-5 inhibits influenza virus well, and/or has lower cytotoxicity, better in vivo pharmacokinetic properties and in vivo pharmacodynamic properties (extracted from patent WO2020078401A1, compound 13-1) .
|
-
- HY-142699
-
|
Somatostatin Receptor
|
Inflammation/Immunology
|
SSTR4 agonist 2 is a potent agonist of somatostatin receptor subtype 4 (SSTR4). SSTR4 pathway inhibits nociceptive and inflammatory processes. SSTR4 agonist 2 has the potential for the research of medical disorders related to SSTR4 (extracted from patent WO2014184275A1, compound 107) .
|
-
- HY-144867
-
|
HSP
|
Cancer
|
CCT245232 is a potent inhibitor of heat shock factor 1 (HSF1). HSF1 is the master regulator of the heat shock response, in which multiple genes are induced in response to temperature increase and other stresses. CCT245232 has the potential for the research of proliferative diseases, such as cancer (extracted from patent WO2015049535A1) .
|
-
- HY-144169
-
|
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
|
Inflammation/Immunology
Cancer
|
DHODH-IN-19 is a potent inhibitor of DHODH. DHODH is present in the inner membrane of human mitochondria and is an iron-containing flavin-dependent enzyme. DHODH-IN-19 inhibits tumor growth. DHODH-IN-19 has the potential for the research of cancer and inflammation disease (extracted from patent WO2021238881A1, compound 1) .
|
-
- HY-144137
-
|
Estrogen Receptor/ERR
|
Cancer
|
Estrogen receptor antagonist 1 is a selective estrogen receptor antagonist. Estrogen (E2) and estrogen alpha receptor (ERα) are important drivers of breast cancer development. Estrogen receptor antagonist 1 has the potential for the research of breast cancer diseases (extracted from patent WO2021249533A1, compound 4) .
|
-
- HY-144138
-
|
Estrogen Receptor/ERR
|
Cancer
|
Estrogen receptor antagonist 2 is a selective estrogen receptor downregulator. Estrogen (E2) and estrogen alpha receptor (ERα) are important drivers of breast cancer development. Estrogen receptor antagonist 2 has the potential for the research of breast cancer diseases (extracted from patent WO2021228210A1, compound 3) .
|
-
- HY-150232
-
|
MALT1
|
Inflammation/Immunology
Cancer
|
MALT1-IN-11 (Example 151 in reference Patent) is a MALT1 protease inhibitor (IC50 < 10 nM). MALT1-IN-11 inhibits IL10 secretion with an IC50 of 10-100 nM. MALT1-IN-11 can be used for the research of cancer, autoimmune and inflammatory disorders .
|
-
- HY-139335
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
VH 101 phenol-alkylC4-amine dihydrochloride is a von-Hippel-Lindau protein ligand (VHL), and incorporates an E3 ligase ligand plus an alkylC4 linker. VH 101 phenol-alkylC4-amine dihydrochloride can be used for PROTAC research extracted from patent WO2022051326A1.
|
-
- HY-137894A
-
PF-07104091 hydrate
|
CDK
GSK-3
|
Cancer
|
PF-07104091 hydrate is a potent and selective CDK2/cyclin E1 and GSK3β inhibitor, with Kis of 1.16 and 537.81 nM, respectively. PF-07104091 hydrate has anti-tumor activity for cyclin E1-amplified cancers. (patent WO2020157652A2).
|
-
- HY-147564
-
|
RET
|
Neurological Disease
Cancer
|
RET-IN-18 is a pyridone compound. is a potent inhibitor of RET. RET-IN-18 is a potent inhibitor of RET. RET-IN-18 has the potential for the research of diseases related to irritable bowel syndrome (IBS) and other gastrointestinal disorders, as well as cancers, and neurodegenerative diseases (extracted from patent WO2022017524A1, compound 1) .
|
-
- HY-129189
-
|
Ras
|
Cancer
|
RAS GTPase inhibitor 1 (example 51) is a RAS GTPase inhibitor with anti-tumor activity, extracted from patent WO2018212774A1. RAS GTPase inhibitor 1 (example 51) exhibits an EC50 less than 1 μM for at least one nucleotide exchange and an IC50 less than 1 μM in H727 cells .
|
-
- HY-129657
-
|
GCGR
|
Metabolic Disease
|
GLP-1 receptor agonist 4 is a glucagon-like peptide-1 receptor (GLP-1R) agonist extracted from patent WO2009111700A2, compound 87, has an EC50 of 64.5 nM. GLP-1 receptor agonist 4 can be used in the research for treatment of diabetes .
|
-
- HY-112762A
-
|
Arenavirus
|
Infection
|
(E)-LHF-535 is the E-isomer of LHF-535. LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC50s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively .
|
-
- HY-103665
-
|
STING
|
Cancer
|
STING agonist-3, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pIC50 of 7.5 and 9.5, respectively. STING agonist-3 has durable anti-tumor effect and tremendous potential to improve treatment of cancer .
|
-
- HY-114181
-
|
IRAK
Cyclic GMP-AMP Synthase
|
Inflammation/Immunology
|
IRAK4-IN-4 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor extracted from patent CN107163044A, Compound15, has an IC50 of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with an IC50 of 2.1 nM .
|
-
- HY-103665A
-
|
STING
|
Cancer
|
STING agonist-3 trihydrochloride, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pEC50 of 7.5 and 9.5, respectively. STING agonist-3 trihydrochloride has durable anti-tumor effect and tremendous potential to improve treatment of cancer .
|
-
- HY-142672
-
|
ATM/ATR
|
Cancer
|
ATR-IN-6 is a potent inhibitor of ATR. ATR is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-6 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent WO2021233376A1, compound A22) .
|
-
- HY-144047
-
|
HBV
DNA/RNA Synthesis
|
Infection
|
HBV-IN-16 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-16 is a quinoline derivative. HBV-IN-16 has the potential for the research of HBV infection (extracted from patent WO2019121357A1, compound 1) .
|
-
- HY-144045
-
|
HBV
DNA/RNA Synthesis
|
Infection
|
HBV-IN-14 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-14 is a pyridinopyrimidinones compound. HBV-IN-14 has the potential for the research of HBV infection (extracted from patent WO2021190502A1, compound 5) .
|
-
- HY-143768
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-14 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-14 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-14 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113620948A, compound 1-c) .
|
-
- HY-143769
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-15 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-15 inhibits the replication of influenza virus. Cap-dependent endonuclease-IN-15 has the potential for the research of viral infections caused by influenza viruses (extracted from patent CN113226327A, compound c-1) .
|
-
- HY-144066
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-21 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-21 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-21 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8B or 8A) .
|
-
- HY-144067
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-23 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-23 inhibits the replication of influenza virus. ap-dependent endonuclease-IN-23 has the potential for the research of influenza virus infection (influenza A) (extracted from patent WO2021233302A1, compound 8A or 8B) .
|
-
- HY-144068
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-25 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-25 is a macrocyclic pyridotriazine derivative. Cap-dependent endonuclease-IN-25 has the potential for the research of viral infections caused by viruses belonging to the Orthomyxoviridae family (extracted from patent WO2020075080A1, compound 4) .
|
-
- HY-144875
-
|
CDK
|
Cancer
|
CTX-712 is a potent inhibitor of cdc2-like kinase (CLK). CTX-712 inhibits CLK kinase activity, and thus inhibits cancer survival and cancer cell growth. CTX-712 has the potential for the research of cancer disease (extracted from patent JPWO2017188374A1, compound 286) .
|
-
- HY-145761
-
|
iGluR
|
Neurological Disease
|
AMPA-IN-1 is a potent inhibitor of AMPA receptor. AMPA receptors are receptors that are widely expressed in the brain, and play a central role in the regulation of fast excitatory synaptic transmission and synaptic plasticity. AMPA-IN-1 has the potential for the research of various central diseases including epilepsy (extracted from patent WO2017082288A1, compound 14) .
|
-
- HY-142917
-
|
Others
|
Metabolic Disease
|
THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021143706A1, compound 72) .
|
-
- HY-143613
-
|
Others
|
Metabolic Disease
|
THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3) .
|
-
- HY-143614
-
|
Others
|
Metabolic Disease
|
THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021129827A1, compound 6) .
|
-
- HY-144204
-
|
Estrogen Receptor/ERR
|
Endocrinology
Cancer
|
Estrogen receptor antagonist 5 is a potent antagonist of Estrogen receptor. The estrogen receptor is a ligand-activated transcriptional regulatory protein that mediates induction of a variety of biological effects through its interaction with endogenous estrogens. Estrogen receptor antagonist 5 has the potential for the research of metastatic disease (extracted from patent WO2017174757A1, compound 165) .
|
-
- HY-144206
-
|
Estrogen Receptor/ERR
|
Endocrinology
|
Estrogen receptor antagonist 6 is a potent antagonist of Estrogen receptor. The estrogen receptor is a ligand-activated transcriptional regulatory protein that mediates induction of a variety of biological effects through its interaction with endogenous estrogens. Estrogen receptor antagonist 6 has the potential for the research of metastatic disease (extracted from patent WO2017174757A1, compound 166) .
|
-
- HY-144096
-
|
Histone Methyltransferase
|
Cancer
|
EZH2-IN-11 is a potent inhibitor of E2HZ. The oncogenic activities of EZH2 have been shown by a number of studies in various different cancer types. EZH2-IN-11 has the potential for the research of cancer diseases (extracted from patent WO2019204490A1, compound 17) .
|
-
- HY-146519
-
|
Trk Receptor
|
Cancer
|
TRK-IN-14 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-14 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-47) .
|
-
- HY-146522
-
|
Trk Receptor
|
Cancer
|
TRK-IN-16 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-16 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-21) .
|
-
- HY-146518
-
|
Trk Receptor
|
Cancer
|
TRK-IN-13 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-13 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-24) .
|
-
- HY-146521
-
|
Trk Receptor
|
Cancer
|
TRK-IN-15 is a potent inhibitor of TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-15 has the potential for the research of TRK-related diseases (extracted from patent WO2012034091A1, compound X-55) .
|
-
- HY-144046
-
|
HBV
DNA/RNA Synthesis
|
Infection
|
HBV-IN-15 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-15 is a flavone derivative. HBV-IN-16 has the potential for the research of HBV infection (extracted from patent WO2020052774A1, compound 2) .
|
-
- HY-147585
-
|
Complement System
|
Inflammation/Immunology
|
C5aR-IN-1 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-1 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 47) .
|
-
- HY-147586
-
|
Complement System
|
Inflammation/Immunology
|
C5aR-IN-2 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-2 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 49) .
|
-
- HY-147587
-
|
Complement System
|
Inflammation/Immunology
|
C5aR-IN-3 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-3 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 89) .
|
-
- HY-153425
-
|
PROTACs
|
Cancer
|
PROTAC SMARCA2 degrader-2 is a potent and selective SMARCA2/4 PROTAC degrader with an IC50 of <0.1 μΜ in HeLa HiBiT assay. PROTAC SMARCA2 degrader-2 is extracted from patent WO2023287787A1 and has the potential for SMARCA4-related or deficient cancer research .
|
-
- HY-16462
-
|
CDK
|
Cancer
|
CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.
|
-
- HY-19322C
-
(1S,3R,5R)-LGH447 dihydrochloride
|
Pim
|
Cancer
|
(1S,3R,5R)-PIM447 (dihydrochloride) an PIM inhibitor extracted from patent US 20100056576 A1, compound example 72, has IC50 values of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3.
|
-
- HY-112098
-
|
PROTACs
Estrogen Receptor/ERR
|
Cancer
|
PROTAC ERα Degrader-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Degrader-1 extracts from patent WO2017201449A1, compound P1. PROTAC ERα Degrader-1 is an estrogen receptor-alpha (ERα) degrader.
|
-
- HY-U00318
-
|
JAK
|
Inflammation/Immunology
|
JAK-IN-11 is a potent and selective JAK inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment . JAK-IN-11 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-112294
-
|
Tie
VEGFR
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and/or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 is used for the study of diseases associated with inappropriate angiogenesis .
|
-
- HY-136584
-
|
Others
|
Cardiovascular Disease
Metabolic Disease
|
2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid is a ketone compound extracted from patent WO2002030860A2, compound example II-9. 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid can be used for the research of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders .
|
-
- HY-136866
-
|
γ-secretase
|
Neurological Disease
|
Aβ42-IN-2 is a γ-secretase modulator extracted from patent WO2016070107, compound example 36. Aβ42-IN-2 has an IC50 of 6.5 nM for Αβ42. Aβ42-IN-2 can be used for the research of Alzheimer's disease .
|
-
- HY-138061
-
|
Flavivirus
Dengue virus
DNA/RNA Synthesis
|
Infection
|
DENV-IN-2 is a potent dengue viral replication inhibitor extracted from patent WO2018215315A1, compound 6AB, has an EC50 of 0.016 nM. DENV-IN-2 shows high potent activity against all four serotypes of the Dengue virus with EC50s ranging from 0.013 to 0.029 nM .
|
-
- HY-138281
-
|
Complement System
|
Inflammation/Immunology
|
Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases .
|
-
- HY-130736
-
JF549, SE; JF549, NHS
|
Fluorescent Dye
|
Others
|
Janelia Fluor® 549, SE (JF549, SE) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-131022
-
JF549 TFA
|
Fluorescent Dye
|
Others
|
Janelia Fluor® 549 TFA (JF549 TFA) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-131024
-
JF549, Tetrazine
|
Fluorescent Dye
|
Others
|
Janelia Fluor® 549, Tetrazine (JF549, Tetrazine) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-139504
-
CC-99677
|
MAPKAPK2 (MK2)
|
Inflammation/Immunology
|
Gamcemetinib (CC-99677) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM). Gamcemetinib is extracted from patent WO2020236636, compound 1 .
|
-
- HY-145424
-
|
CDK
|
Others
|
CDK7-IN-10 is a CDK7 inhibitor with an IC50 of less than 100 nM, extracted from patent WO2021016388A1, compound I-1. CDK7-IN-10 is useful in inhibiting the activity of a kinase. CDK7-IN-10 has the potential of inhibiting cell growth and inducing cell apoptosis .
|
-
- HY-145359
-
|
Eukaryotic Initiation Factor (eIF)
|
Cancer
|
eIF4A3-IN-5 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), such as eIF4AI and eIF4AII. eIF4A3-IN-5 has the potential for the research of eIF4A dependent diseases, including the research of cancer (extracted from patent US20170145026A1) .
|
-
- HY-145360
-
|
Eukaryotic Initiation Factor (eIF)
|
Cancer
|
eIF4A3-IN-6 is a potent inhibitor of eukaryotic initiation factor 4A (eIF4A), such as eIF4AI and eIF4AII. eIF4A3-IN-6 has the potential for the research of eIF4A dependent diseases, including the research of cancer (extracted from patent US20170145026A1) .
|
-
- HY-145309
-
|
Eukaryotic Initiation Factor (eIF)
|
Cancer
|
eIF4E-IN-3 is a potent inhibitor of eukaryotic initiation factor 4e (eIF4e). eIF4E-IN-3 has the potential for researching eIF4e dependent diseases, including the research of cancer (extracted from patent WO2021003157A1, compound 485) .
|
-
- HY-143714
-
|
Cathepsin
|
Inflammation/Immunology
|
Cathepsin K inhibitor 2 is a potent inhibitor of cathepsin K. Cathepsin K, Cat K is a cysteine protease expressed under the control of CTSK gene and closely related to osteoporosis, whose main function is to hydrolyze collagen. Cathepsin K inhibitor 2 has the potential for the research of osteoarthfitis (extracted from patent WO2021147882A1, compound 78) .
|
-
- HY-142806
-
|
ROR
|
Inflammation/Immunology
|
RORγt inverse agonist 26 is a potent reverse agonist of RORγt. RORγt inverse agonist 26 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 26 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 1) .
|
-
- HY-142703
-
|
ROR
|
Inflammation/Immunology
|
RORγt inverse agonist 28 is a potent reverse agonist of RORγt. RORγt inverse agonist 28 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 28 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 6) .
|
-
- HY-143583
-
|
Others
|
Neurological Disease
Cancer
|
ATX inhibitor 10 is a potent inhibitor of ATX. ATX inhibitor 10 is s nitrogen-containing heterocyclic compound. ATX plays a role in causing pathological conditions including fibrosis, arthritis, neurodegeneration, neuropathic pain, and cancer. ATX inhibitor 10 has the potential for the research of ATX related diseases (extracted from patent WO2021115375A1, compound 35) .
|
-
- HY-146530
-
|
Others
|
Neurological Disease
Cancer
|
c-ABL-IN-4 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-4 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 54) .
|
-
- HY-146528
-
|
Others
|
Neurological Disease
Cancer
|
c-ABL-IN-3 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-3 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 50) .
|
-
- HY-144062
-
|
SARS-CoV
|
Infection
|
INSCoV-614(1B) is a potent inhibitor of M pro (3CL pro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-614(1B) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .
|
-
- HY-101265
-
S1p receptor agonist 1
|
LPL Receptor
|
Inflammation/Immunology
|
Icanbelimod (S1p receptor agonist 1) is a potent and orally active S1P receptor agonist, exhibits an activity of inducing S1P1 internalization (EC50=9.83 nM). Icanbelimod has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis). Icanbelimod is extracted from patent WO2015039587A1, Compound 2.
|
-
- HY-19323A
-
(S)-AZD6738
|
ATM/ATR
|
Cancer
|
(S)-Ceralasertib ((S)-AZD6738) is extracted from patent WO2011154737A1, Compound II, exhibits an IC50 of 2.578 nM .
(S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics.
(S)-Ceralasertib is developed improving aqueous solubility and eliminates CYP3A4 time-dependent inhibition .
|
-
- HY-131029
-
JF646, Maleimide
|
Fluorescent Dye
|
Others
|
Janelia Fluor® 646, Maleimide (JF646, Maleimide) is a red fluorescent dye that contains a maleimide group. JF646, Maleimide can be used in cellular imaging . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-135830
-
|
Aryl Hydrocarbon Receptor
|
Cancer
|
AHR antagonist 4 is a 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compound and a potent aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018146010A1, example 293, has an IC50 of 82.2 nM. AHR antagonist 4 has anti-cancer effects .
|
-
- HY-132161
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a Camptothecin-linker compound extracted from patent WO2019195665A1, example 4-1. MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT is a agent-linker conjugate for antibody-drug conjugate (ADC) .
|
-
- HY-131023
-
JF549, Maleimide TFA
|
Fluorescent Dye
|
Others
|
Janelia Fluor® 549, Maleimide TFA (JF549, Maleimide TFA) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-141798
-
|
Ligands for Target Protein for PROTAC
|
Cancer
|
OICR-9429-N-C2-NH2 is a ligand for Wd40 repeat domain protein 5 (WDR5) extracted from patent WO2019246570A1, intermediate 2. OICR-9429-N-C2-NH2 can be used in the synthesis of PROTACs .
|
-
- HY-139791
-
XEN1101
|
Potassium Channel
|
Cancer
|
KCNQ2/3 activator-1 is an activator of Kv7.2/Kv7.3 (KCNQ2/3) potassium channel. KCNQ2/3 activator-1 has the potential in relieving pain (the main problem from medical treatment) (extracted from patent WO2021113757A1, compound A) .
|
-
- HY-145412
-
|
GCGR
|
Metabolic Disease
|
GLP-1 receptor agonist 7 is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 7 has the potential for the research of GLP-1-associated diseases, disorders, and conditions including diabetes mellitus (extracted from patent WO2021219019A1, compound 130b) .
|
-
- HY-144048
-
|
EGFR
|
Cancer
|
EGFR-IN-31 is a potent inhibitor of EGFR. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-31 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185298A1, compound 2) .
|
-
- HY-144049
-
|
EGFR
|
Cancer
|
EGFR-IN-32 is a potent inhibitor of EGFR. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-32 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185297A1, compound 2) .
|
-
- HY-145709
-
|
Androgen Receptor
|
Cancer
|
Ar-V7-IN-1 is a potent inhibitor of Ar-V7. AR-V7 is a hormone-independent splice variant of the androgen receptor. Ar-V7-IN-1 has the potential for the research of various indications, in particular cancers such as prostate cancer (extracted from patent WO2018114781A1, compound 43) .
|
-
- HY-143592
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 39 is a potent inhibitor of KRAS G12C. KRas is a highly attractable target of the pharmaceutical industry for cancer research. KRAS G12C inhibitor 39 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2019099524A1, compound 494) .
|
-
- HY-143589
-
JAB-21822; KRAS G12C inhibitor 36
|
Ras
|
Cancer
|
Glecirasib (KRAS G12C inhibitor 36) is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. Glecirasib has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021121367A1, compound 1-2) .
|
-
- HY-143874
-
|
EGFR
|
Cancer
|
HER2-IN-7 is a potent inhibitor of HER2. Deregulation of ErbB family signalling modulates proliferation, invasion, metastasis, angiogenesis, and tumour cell survival. HER2-IN-7 has the potential for the research of diseases associated ErbBs (especially HER2), including cancer (extracted from patent WO2019214634A1, compound 23) .
|
-
- HY-144061
-
|
SARS-CoV
|
Infection
|
INSCoV-601I(1) is a potent inhibitor of M pro (3CL pro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-601I(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .
|
-
- HY-144063
-
|
SARS-CoV
|
Infection
|
INSCoV-600K(1) is a potent inhibitor of M pro (3CL pro). Proteases (PL pro and 3CL pro) are involved with transcription and replication of the virus. INSCoV-600K(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .
|
-
- HY-156569
-
|
DGK
|
Inflammation/Immunology
Cancer
|
DGKα-IN-2 (example 48) is a DGKα inhibitor with the IC50 of 0.9 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.
|
-
- HY-156570
-
|
DGK
|
Inflammation/Immunology
Cancer
|
DGKα-IN-3 (example 25) is a DGKα inhibitor with the IC50 of 283 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.
|
-
- HY-156571
-
|
DGK
|
Cancer
|
DGKα-IN-4 (example 432) is a DGKα inhibitor with the IC50 of 0.1 nM, extracted from patent WO2021105117. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-3 has the potential for cancer and immunology study.
|
-
- HY-145552A
-
QR-01019K
|
Angiotensin Receptor
|
Metabolic Disease
|
Azilsartan mepixetil potassium (QR-01019K) is the antagonist of angiotensin II receptor. Azilsartan mepixetil potassium has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil potassium has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .
|
-
- HY-W800749
-
|
Liposome
|
Cancer
|
BP Lipid 223 is an pentanolamine lipid (Compound 7) from patent WO2017075531A with both ester bonds located adjacent to C6 relative to the amine head. The introduction of ester linkages can improve the clearance of the lipid in the liver. This compound is analgous to ALC-0315. The lipid can be used to prepare mRNA nanocarriers with good balance of delivery efficiency and pharmakokinetics as well as rapid lipid clearance profile.
|
-
- HY-147584
-
|
Btk
|
Inflammation/Immunology
Cancer
|
BTK-IN-14 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1) .
|
-
- HY-153913
-
|
MMP
|
Inflammation/Immunology
|
MMP-9-IN-7 is a potent MMP9 inhibitor with an IC50 of 0.52 μM in proMMP9/MMP3 P126 activation assay. MMP-9-IN-7 is extracted from patent WO2012162468 (example 59), and can be used for MMP9/MMP13 mediated syndrome research .
|
-
- HY-135593
-
|
Others
|
Endocrinology
|
LY88074 analog 1 is a benzothiophene compound with nitrogen-containing non-basic side chains, Compound 26, extracted from patent EP0747380A1. LY88074 analog 1 is an agent for alleviating the symptoms of post-menopausal symptoms, such as osteoporosis, cardiovascular related pathological conditions, and estrogen-dependent cancer. LY88074 analog 1 can be used alone or in combination with estrogen or progestin .
|
-
- HY-W019939
-
|
ADC Linker
|
Cancer
|
Hydroxy-PEG10-Boc is extacted from patent CN108707228 (example 0024) . Hydroxy-PEG10-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG10-Boc can be conjugated to Paclitaxel (HY-B0015) or docetaxel (HY-B0011) .
|
-
- HY-W074648
-
|
Bacterial
|
Infection
|
Antibacterial agent 18 is a multi-arm AIE molecule extracted from patent CN110123801A, compound 23. Antibacterial agent 18 can be used for resisting Gram-positive and Gram-negative bacteria. Antibacterial agent 18 can be conjugated in the cell wall of rigid arm configuration insertion bacterium, and block cell wall turns sugar and turns peptide process, to inhibit or kill bacterium .
|
-
- HY-145312
-
|
ATM/ATR
|
Cancer
|
ATR-IN-4 is a potent ATR (Ataxia telangiectasia mutated gene Rad 3-associated kinase) inhibitor. ATR-IN-4 inhibits growth of human prostate cancer cells DU145 and human lung cancer cells NCI-H460 with IC50s of 130.9 nM and 41 .33 nM, respectively. (Patent CN112142744A, compound 13) .
|
-
- HY-145390
-
|
Keap1-Nrf2
|
Inflammation/Immunology
|
Nrf2 activator-1 is a potent activator of NF-E2 related factor 2 (Nrf2). Nrf2 activator-1 has the potential for the research of COPD and other respiratory diseases, including asthma, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis (extracted from patent WO2018109647A1) .
|
-
- HY-142452
-
|
Raf
|
Cancer
|
Pan-RAF kinase inhibitor 1 is a potent inhibitor of Pan-RAF kinase. Pan-RAF kinase inhibitor 1 regulates MAPK signaling by inhibiting RAF kinase, thereby exerting an effect on the proliferation of RAS-mutant tumor cells. Pan-RAF kinase inhibitor 1 has the potential for the research of cancer diseases (extracted from patent WO2021110141A1, compound 16B) .
|
-
- HY-143750
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-7 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-7 Inhibits the synthesis of viral mRNA and eventually inhibits virus proliferation. Cap-dependent endonuclease-IN-7 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2020177715A1, compound 5)
|
-
- HY-142441
-
|
Others
|
Endocrinology
|
THR-β Agonist 1 is a potent and selective agonist of THRβ. Thyroid hormone receptor mediates the physiological activity of thyroid hormones which plays a key role in normal growth and development of the body and in maintaining metabolic balance. THR-β Agonist 1 has the potential for the research of thyroid hormone receptor-related diseases (extracted from patent WO2021104288A1, compound 2) .
|
-
- HY-144874
-
|
PARP
|
Neurological Disease
Cancer
|
AZ3391 is a potent inhibitor of PARP. AZ3391 is a quinoxaline derivative. PARP family of enzymes play an important role in a number of cellular processes, such as replication, recombination, chromatin remodeling, and DNA damage repair. AZ3391 has the potential for the research of diseases and conditions occurring in tissues in the central nervous system, such as the brain and spinal cord (extracted from patent WO2021260092A1, compound 23) .
|
-
- HY-143432A
-
|
CDK
|
Cancer
|
(S)-Cdc7-IN-18 is a potent inhibitor of CDC7. Overexpression of huCdc7 promotes overactivation of MCM2, an important marker of tumor cells, and thus promotes aberrant proliferation of tumor cells. (S)-Cdc7-IN-18 has the potential for the research of cancer diseases (extracted from patent WO2020239107A1, compound 1-1) .
|
-
- HY-143588
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 35 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 35 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent CN112920183A, compound 3) .
|
-
- HY-142938
-
|
ROR
|
Inflammation/Immunology
|
RORγt agonist 3 is a potent agonist of RORγt. RORγt agonist 3 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 3 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136326A1, compound 23) .
|
-
- HY-142937
-
|
ROR
|
Inflammation/Immunology
|
RORγt agonist 2 is a potent agonist of RORγt. RORγt agonist 2 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 2 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136339A1, compound 17) .
|
-
- HY-147581
-
|
Btk
|
Inflammation/Immunology
Cancer
|
BTK-IN-11 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-11 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022063101A1, compound Z2) .
|
-
- HY-143377
-
|
CDK
|
Cancer
|
Cdc7-IN-8 is a potent inhibitor of Cdc7. Cdc7 is a serine/threonine kinase which activates MCM promotion by phosphorylating the microchromosome maintenance protein (MCM protein), an important element of the DNA replication initiator. Cdc7-IN-8 has the potential for the research of cancer diseases (extracted from patent WO2021032170A1, compound 1-1/1-2) .
|
-
- HY-19763
-
PI3Kα inhibitor 1
|
PI3K
|
Cancer
|
BEBT-908 (PI3Kα inhibitor 1) is a selective PI3Kα inhibitor extracted from patent US/20120088764A1, Compound 243, has an IC50<0.1 μM, PI3Kα inhibitor 1 also inhibits HDAC (0.1 μM≤IC50≤1 μM) .
|
-
- HY-101490
-
|
Phosphodiesterase (PDE)
|
Neurological Disease
|
PDE1-IN-2 is a PDE1 inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC50 values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectvely. PDE1-IN-2 is developed for the research of neurodegenerative disorders and psychiatric disorders .
|
-
- HY-129966
-
|
PROTACs
IRAK
|
Cancer
|
PROTAC IRAK4 degrader-1 is a Cereblon-based PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1 Compound I-210, makes <20%, >20-50%, and >50% IRAK4 degradation at 0.01, 0.1, and 1 μM in OCI-LY-10 cells, respectively .
|
-
- HY-110247
-
|
TNF Receptor
NF-κB
|
Cardiovascular Disease
Inflammation/Immunology
|
TRAF-STOP inhibitor 6877002, is a selective inhibitor of CD40-TRAF6 interaction, compound VII, shows inhibition of NF-κB activation in RAW cells, extracted from patent WO2014033122A1 . TRAF-STOP 6877002 prevents the progression of established atherosclerosis in mice, reduces leukocyte recruitment and reduces macrophage activation; reduces macrophage proliferation in atherosclerotic plaques .
|
-
- HY-134622
-
|
CDK
GSK-3
|
Neurological Disease
Cancer
|
GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of cdk5, cdk2, and GSK-3 extracted from patent WO2002010141A1, example 9a. GSK-3/CDK5/CDK2-IN-1 can be used for the research of cancer, and neurodegenerative diseases .
|
-
- HY-44809
-
|
HIF/HIF Prolyl-Hydroxylase
|
Cardiovascular Disease
Inflammation/Immunology
|
Izilendustat is a potent inhibitor of prolyl hydroxylase which can stabilize hypoxia inducible factor- 1 alpha (HIF- lα) and hypoxia inducible factor-2 (HIF-2). Izilendustat has the potential for researching diseases that relate to the body’s inmmune response like colitis and other inflammatory bowel diseases (extracted from patent WO2011057115A1 and WO2011057121A1) .
|
-
- HY-145552
-
QR-01019
|
Angiotensin Receptor
|
Cardiovascular Disease
|
Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A) .
|
-
- HY-144059
-
|
Akt
|
Cancer
|
AKT-IN-9 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-9 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 1) .
|
-
- HY-144060
-
|
Akt
|
Cancer
|
AKT-IN-10 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-10 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 4) .
|
-
- HY-142698
-
|
Guanylate Cyclase
|
Cardiovascular Disease
|
SGC agonist 2 is a potent agonist of soluble guanylate cyclase (SGC). Soluble guanylate cyclase is a key signal transduction enzyme in the NO-sGC-cGMP signaling pathway. SGC agonist 2 has the potential for the research of cardiovascular disease (heart failure, pulmonary hypertension, angina, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis) (extracted from patent WO2021219088A1, compound 031) .
|
-
- HY-143582
-
|
Others
|
Cancer
|
ATX inhibitor 9 is a potent inhibitor of ATX. ATX inhibitor 9 is a thickened heteroaryl derivatives compound. Autotaxin (ATX), also known as ENPP2, is a secreted enzyme that is highly expressed mainly in cancer cells, bronchial epithelial cells and alveolar macrophages in the lung. ATX inhibitor 9 has the potential for the research of cancer or fibrous degenerative disease (extracted from patent WO2021078227A1, compound 3) .
|
-
- HY-143596
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 41 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 41 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021129824A1, compound 121) .
|
-
- HY-143604
-
|
Ras
|
Cancer
|
KRAS G12D inhibitor 11 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 11 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 52) .
|
-
- HY-143594
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 40 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 40 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021129824A1, compound 70) .
|
-
- HY-143606
-
|
Ras
|
Cancer
|
KRAS G12D inhibitor 12 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 12 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 134) .
|
-
- HY-143602
-
|
Ras
|
Cancer
|
KRAS G12D inhibitor 9 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 9 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 20) .
|
-
- HY-143603
-
|
Ras
|
Cancer
|
KRAS G12D inhibitor 10 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 10 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 34) .
|
-
- HY-143607
-
|
Ras
|
Cancer
|
KRAS G12D inhibitor 13 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 13 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 142) .
|
-
- HY-143590
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 37 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 37 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2018143315A1, compound 65) .
|
-
- HY-143591
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 38 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 38 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021129820A1, compound 171) .
|
-
- HY-143598
-
|
Ras
|
Cancer
|
KRAS G12C inhibitor 42 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 42 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2020146613A1, compound 10) .
|
-
- HY-143599
-
|
Ras
|
Cancer
|
KRAS G12D inhibitor 8 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 8 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021107160A1, compound 2) .
|
-
- HY-144035
-
|
GCGR
|
Cancer
|
GLP-1R agonist 4 is a potent agonist of GLP-1R. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 has the potential for the research of diabetes (extracted from patent WO2019239319A1, compound 96) .
|
-
- HY-123090
-
|
11β-HSD
|
Metabolic Disease
|
11β-HSD1-IN-12 is a 11β-HSD1 inhibitor (Example 21 in reference patent). 11β-HSD1 regenerates active glucocorticoids from inactive forms and is important in regulating intracellular glucocorticoid concentration. 11β-HSD1-IN-12 can be used in the research of obesity and metabolic syndrome .
|
-
- HY-147588
-
|
CD73
|
Cancer
|
CD73-IN-7 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-7 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 13) .
|
-
- HY-147589
-
|
CD73
|
Cancer
|
CD73-IN-8 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-8 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022052886A1, compound 57) .
|
-
- HY-147590
-
|
CD73
|
Inflammation/Immunology
|
CD73-IN-9 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-9 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 2) .
|
-
- HY-147592
-
|
CD73
|
Inflammation/Immunology
Cancer
|
CD73-IN-11 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-11 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 24) .
|
-
- HY-147591
-
|
CD73
|
Inflammation/Immunology
Cancer
|
CD73-IN-10 is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-10 be used for preparing a medicament for tumor-related diseases (extracted from patent WO2022068929A1, compound 4) .
|
-
- HY-135594
-
|
Estrogen Receptor/ERR
|
Metabolic Disease
|
4'-Raloxifene-β-D-glucopyranoside, a metabolite of Raloxifene, is a benzothiophene glucuronidated at the 4' postion. 4'-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 4'-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 4'-Raloxifene-β-D-glucopyranoside, example 5, is extracted from patent US5567820A .
|
-
- HY-135595
-
|
Estrogen Receptor/ERR
Drug Metabolite
|
Metabolic Disease
|
6-Raloxifene-β-D-glucopyranoside, a derivative of Raloxifene, is a benzothiophene glucuronidated at the 6' postion. 6-Raloxifene-β-D-glucopyranoside is a selective and orally active estrogen receptor antagonist. 6-Raloxifene-β-D-glucopyranoside can be used for inhibiting bone loss and resorption, and lowering lipid levels. 6'-Raloxifene-β-D-glucopyranoside, compound Ia, is extracted from patent US5567820A .
|
-
- HY-138295
-
|
Ras
|
Cancer
|
KRAS inhibitor-10 (compound 11) selectively and effectively inhibit RAS proteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used for cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1 .
|
-
- HY-132142
-
|
DNA/RNA Synthesis
|
Others
|
5-Propargylamino-dCTP is a nucleoside molecule extracted from patent US9035035B2, compound dCTP-PA. 5-Propargylamino-dCTP can conjugate to molecular markers for use in nucleic acid labeling or sequence analysis . 5-Propargylamino-dCTP is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-131026
-
JF635, SE; JF635, NHS
|
Fluorescent Dye
|
Others
|
Janelia Fluor® 635, SE (JF635, SE) is a red fluorogenic fluorescent dye containing an NHS ester that can be conjugated with primary amine groups. JF635, SE can be used for live cell imaging . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-144036
-
|
DNA-PK
|
Cancer
|
DNA-PK-IN-3 is a potent inhibitor of DNA-PK. DNA-PK-IN-3 synergistically enhances the effect of radiotherapy and chemotherapy and effectively inhibits tumor growth. DNA-PK-IN-3 also effectively reduces the damage to normal cells and reducing side effects. DNA-PK-IN-3 has the potential for the research of cancer disease (extracted from patent WO2021213460A1, compound 4) .
|
-
- HY-144037
-
|
DNA-PK
|
Cancer
|
DNA-PK-IN-4 is a potent inhibitor of DNA-PK. DNA-PK-IN-4 is a imidazolinone derivative compound. DNA-PK-IN-4 inhibits DNA-PKcs activity, thus greatly reducing tumor DNA repair and inducing cells to enter the apoptotic program. DNA-PK-IN-4 has the potential for the research of cancer disease (extracted from patent WO2021209055A1, compound 27) .
|
-
- HY-144175
-
|
CDK
|
Cancer
|
CDK7-IN-12 is a potent inhibitor of CDK7. CDK7-IN-12 plays a key role in transcriptional regulation and cell cycle regulation. CDK7-IN-12 effectively inhibit malignant tumor proliferation in vitro and in vivo. CDK7-IN-12 has the potential for the research of cancer disease (extracted from patent WO2021249417A1, compound 43) .
|
-
- HY-126003
-
|
Aldehyde Dehydrogenase (ALDH)
|
Cancer
|
ALDH1A1-IN-2 is a potent inhibitor of aldehyde dehydrogenase 1a1 (aldh1a1). Aldehyde dehydrogenases (ALDH) constitute a family of enzymes that play a critical role in oxidizing various cytotoxic xenogenic and biogenic aldehydes. ALDH1A1-IN-2 has the potential for the research of cancer, inflammation, or obesity (extracted from patent WO2019089626A1, compound 295) .
|
-
- HY-142943
-
|
DNA-PK
|
Cancer
|
DNA-PK-IN-1 is a potent inhibitor of DNA-PK. DNA-dependent protein kinase (DNA-PK) is a DNA-PK enzyme complex composed of Ku70/Ku80 heterodimer and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). DNA-PK-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021136463A1, compound 1) .
|
-
- HY-142944
-
|
DNA-PK
|
Cancer
|
DNA-PK-IN-2 is a potent inhibitor of DNA-PK. DNA-dependent protein kinase (DNA-PK) is a DNA-PK enzyme complex composed of Ku70/Ku80 heterodimer and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). DNA-PK-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2021136462A1, compound 1) .
|
-
- HY-143862
-
|
PPAR
|
Metabolic Disease
|
Pparδ agonist 7 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 7 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2019105234A1, compound TM4) .
|
-
- HY-143868
-
|
MAP4K
|
Cancer
|
HPK1-IN-27 is a potent inhibitor of HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1-IN-27 has the potential for the research of cancer diseases (extracted from patent WO2019016071A1, compound 38) .
|
-
- HY-143871
-
|
MAP4K
|
Cancer
|
HPK1-IN-30 is a potent inhibitor of HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1-IN-30 has the potential for the research of cancer diseases (extracted from patent WO2021175271A1, compound 3) .
|
-
- HY-143863
-
|
PPAR
|
Metabolic Disease
|
Pparδ agonist 8 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 8 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2021169769A1, compound TM2) .
|
-
- HY-125996
-
|
FXR
|
Inflammation/Immunology
|
NR1H4 activator 1 is a potent and selective Famesoid X Receptor (FXR) agonist, extracted from patent WO2018152171A1, example 4. NR1H4 activator 1 shows strong FXR agonistic potency with a EC50 value of 1 nM in a Human FXR (NR1H4) Assay. NR1H4 activator 1 has the potential for treatment of gastrointestinal disease .
|
-
- HY-138139A
-
T785 hydrochloride
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
AXC-715 (T785) hydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1 . AXC-715, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .
|
-
- HY-145394
-
|
CDK
|
Cancer
|
CDK7-IN-6 is a potent and selective cyclin-dependent kinase (CDK7) inhibitor (IC50≤100 nM), extracted from patent WO2019197549 A1, compound 210. CDK7-IN-6 is > 200-fold selective for CDK7 over CDK1, CDK2, and CDK5. CDK7-IN-6 can be used for the research of cancer .
|
-
- HY-138139B
-
T785 trihydrochloride
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1 . AXC-715 trihydrochloride, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .
|
-
- HY-145026
-
|
ERK
|
Inflammation/Immunology
Cancer
|
ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1) .
|
-
- HY-145036
-
|
MAP4K
|
Inflammation/Immunology
Cancer
|
HPK1-IN-10 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-10 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 103) .
|
-
- HY-145037
-
|
MAP4K
|
Inflammation/Immunology
Cancer
|
HPK1-IN-11 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-11 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 2) .
|
-
- HY-145038
-
|
MAP4K
|
Inflammation/Immunology
Cancer
|
HPK1-IN-12 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-12 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 85) .
|
-
- HY-145039
-
|
MAP4K
|
Inflammation/Immunology
Cancer
|
HPK1-IN-13 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-13 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 64) .
|
-
- HY-145040
-
|
MAP4K
|
Inflammation/Immunology
Cancer
|
HPK1-IN-14 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-14 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 79) .
|
-
- HY-145064
-
|
Phosphodiesterase (PDE)
|
Infection
Cancer
|
Enpp-1-IN-6 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-6 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
|
-
- HY-145065
-
|
Phosphodiesterase (PDE)
|
Infection
Cancer
|
Enpp-1-IN-7 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-7 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
|
-
- HY-145069
-
|
Phosphodiesterase (PDE)
|
Cancer
|
Enpp-1-IN-8 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-8 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
|
-
- HY-145070
-
|
Phosphodiesterase (PDE)
|
Infection
Cancer
|
Enpp-1-IN-9 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-9 has the potential for the research of cancer and infectious diseases (extracted from patent WO2021203772A1, compound 51) .
|
-
- HY-145027
-
|
ERK
|
Cancer
|
ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1) .
|
-
- HY-145035
-
|
MAP4K
|
Inflammation/Immunology
Cancer
|
HPK1-IN-9 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-9 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 112) .
|
-
- HY-143587
-
|
CDK
|
Cancer
|
CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1) .
|
-
- HY-W181102
-
|
Calcineurin
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
NFAT Inhibitor-2 is a potent inhibitor of calcineurin NFAT signalling. Calcineurin is a serine/threonine protein phosphatase regulated by Ca2+ and calmodulin. NFAT Inhibitor-2 has the potential for the research of inflammatory disease, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a disease occurring with uncontrolled cell proliferation and/or differentiation, an angiogenesis-related disease, an allergy, anaphylaxis and alopecia (extracted from patent WO2016207212A1, compound 17) .
|
-
- HY-145071
-
|
PROTACs
Estrogen Receptor/ERR
|
Cancer
|
PROTAC ERα Y537S degrader-1 comprises a ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Y537S degrader-1 extracts from patent WO2021143822, example 12. PROTAC ERα Y537S degrader-1 is an estrogen receptor-alpha (ERα) Y537S degrader .
|
-
- HY-144200
-
|
CCR
|
Neurological Disease
Cancer
|
CCR8 antagonist 2 is a potent antagonist of CCR8. CCR8 (C-C Motif Chemokine Receptor 8) is predominantly expressed on Treg cells and Th2 cells, but not on Th1 cells. CCR8 antagonist 2 inhibits CCR8 activity, which may be used in the research of diseases mediated by CCR8, such as cancer, and/or neuropathic pain (extracted from patent WO2022000443A1, compound 220) .
|
-
- HY-147593
-
|
CD73
|
Cancer
|
CD73-IN-12 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-12 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437038A, compound 9) . CD73-IN-12 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-147615
-
|
c-Fms
|
Cancer
|
CSF1R-IN-12 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-12 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 1) .
|
-
- HY-147619
-
|
FGFR
|
Cancer
|
FGFR-IN-4 is a potent inhibitor of FGFR. Fibroblast growth factor receptor (FGFR) is a tyrosine kinase receptor that binds to fibroblast growth factor ligands. FGFR-IN-4 has the potential for the research of cancer diseases (extracted from patent WO2022033532A1, compound 20) . FGFR-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-147616
-
|
c-Fms
|
Cancer
|
CSF1R-IN-13 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-13 has the potential for the research of cancer diseases (extracted from patent WO2019134661A1, compound 32) .
|
-
- HY-147620
-
|
FGFR
|
Cancer
|
FGFR-IN-5 is a potent inhibitor of FGFR. Fibroblast growth factor receptor (FGFR) is a tyrosine kinase receptor that binds to fibroblast growth factor ligands. FGFR-IN-5 has the potential for the research of cancer diseases (extracted from patent WO2022042612A1, compound 3) . FGFR-IN-5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-42488
-
|
ADC Linker
PROTAC Linkers
|
Cancer
|
Hydroxy-PEG2-(CH2)2-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG2-(CH2)2-Boc is extracted from patent WO2004008101A2 (compound 196) . Hydroxy-PEG2-(CH2)2-Boc is also a PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-W039178
-
|
ADC Linker
PROTAC Linkers
|
Cancer
|
Hydroxy-PEG4-(CH2)2-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG4-(CH2)2-Boc is extracted from patent WO2004008101A2 (compound 191). Hydroxy-PEG4-(CH2)2-Boc is also a PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-W067061
-
|
ADC Linker
PROTAC Linkers
|
Cancer
|
Hydroxy-PEG2-(CH2)2-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG2-(CH2)2-Boc is extracted from patent WO2004008101A2 (compound 196) . Hydroxy-PEG2-(CH2)2-Boc is also a PROTAC linker that can be used in the synthesis of PROTACs.
|
-
- HY-131028
-
JF646 TFA
|
Fluorescent Dye
|
Others
|
Janelia Fluor® 646 TFA (JF646 TFA), a red fluorogenic fluorescent dye, can be used in the synthesis of Janelia Fluor 646 HaloTag and SNAP-Tag ligands. JF646 TFA is used in live cell imaging experiments . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-138658
-
JF526, SE; JF526, NHS
|
Fluorescent Dye
|
Others
|
Janelia Fluor 526, SE (JF526,SE) is a fluorogenic yellow fluorescent dye that contains NHS ester group. JF526 is a versatile scaffold for fluorogenic ligands, including labels for genetically encoded self-labeling protein tags and stains for endogenous structures . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-139643
-
|
CXCR
|
Inflammation/Immunology
Cancer
|
CXCR7 antagonist-1 is a CXCR7 antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. CXCR7 antagonist-1 is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases (extracted from patent WO2014085490A1, compound 1.128) .
|
-
- HY-145240
-
|
Eukaryotic Initiation Factor (eIF)
|
Infection
Cancer
|
eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y) .
|
-
- HY-143208
-
|
DNA/RNA Synthesis
|
Cancer
|
HOE 33187-O-CONH-PEG4-phenol-thiophenone-NHPh-COOEt has inhibitory activity against pre-miR-21 RNA. HOE 33187-O-CONH-PEG4-phenol-thiophenone-NHPh-COOEt has the potential for the research of neoplastic disease such as cancer and especially cancers expressing miR-21 (extracted from patent WO2021087084A1, compound 25) .
|
-
- HY-145025
-
|
ERK
|
Inflammation/Immunology
Cancer
|
ERK1/2 inhibitor 3 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 3 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021218912A1, compound 1) .
|
-
- HY-145028
-
|
ERK
|
Inflammation/Immunology
Cancer
|
ERK1/2 inhibitor 6 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 6 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021063335A1, compound 1) .
|
-
- HY-145041
-
|
MAP4K
|
Inflammation/Immunology
Cancer
|
HPK1-IN-15 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-15 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2018049200A1, compound 50) .
|
-
- HY-145042
-
|
MAP4K
|
Inflammation/Immunology
Cancer
|
HPK1-IN-16 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-16 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2019051199A1, compound 39) .
|
-
- HY-145044
-
|
MAP4K
|
Inflammation/Immunology
Cancer
|
HPK1-IN-17 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-17 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2019238067A1, compound 73) .
|
-
- HY-145045
-
|
MAP4K
|
Inflammation/Immunology
Cancer
|
HPK1-IN-18 is a potent and selective inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-18 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer (extracted from patent WO2019238067A1, compound 1) .
|
-
- HY-145048
-
|
Ras
|
Cancer
|
SOS1-IN-5 is a potent inhibitor of SOS1. SOS1-IN-5 is a pyrimidobicyclic derivative. SOS1-IN-5 blocks the activation of KRAS by interfering with RAS-SOS1 interaction, and achieves the purpose of broad-spectrum inhibition of KRAS activity. SOS1-IN-5 has the potential for the research of cancer diseases (extracted from patent WO2021203768A1, compound 4) .
|
-
- HY-143744
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-3 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-3 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-3 has the potential for the research of influenza A and influenza B infection (extracted from patent WO2019141179A1, compound VI-1) .
|
-
- HY-143743
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-2 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-2 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-2 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent WO2019052565A1, compound 28) .
|
-
- HY-143755
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-9 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-9 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo agent kinetic properties and in vivo pharmacodynamic properties. Cap-dependent endonuclease-IN-9 has strong inhibitory effect on RNA polymerase activity of A virus (extracted from patent CN112521386A, compound VI-1) .
|
-
- HY-143546
-
|
RET
|
Cancer
|
RET-IN-9 is a potent inhibitor of RET. RET kinase is a single-pass transmembrane receptor tyrosine kinase that plays an important role in the development of the kidney and enteric nervous system, and the maintenance of homeostasis in the nervous, endocrine, hematopoietic, and male reproductive systems. RET-IN-9 has the potential for the research of RET-related disease including non-small cell lung cancer and medullary thyroid cancer (extracted from patent WO2021115457A1, compound 29) .
|
-
- HY-142700
-
|
Somatostatin Receptor
|
Neurological Disease
|
SSTR4 agonist 3 is a potent agonist of SSTR4. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, memory and learning regions, and Alzheimer's disease pathology. SSTR4 agonists are potent in rodent models of pain associated with acute and chronic associated anti-peripheral nociceptive and anti-inflammatory activity. SSTR4 agonist 3 has the potential for the research of pain (extracted from patent WO2021233427A1, compound 14) .
|
-
- HY-142701
-
|
Somatostatin Receptor
|
Neurological Disease
|
SSTR4 agonist 4 is a potent agonist of SSTR4. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, memory and learning regions, and Alzheimer's disease pathology. SSTR4 agonists are potent in rodent models of pain associated with acute and chronic associated anti-peripheral nociceptive and anti-inflammatory activity. SSTR4 agonist 4 has the potential for the research of pain (extracted from patent WO2021233428A1, compound 14) .
|
-
- HY-144039
-
|
DNA-PK
|
Cancer
|
DNA-PK-IN-6 is a potent inhibitor of DNA-PK. DNA-PK-IN-6 inhibits DNA-PKcs activity, thus greatly reducing tumor DNA repair and inducing cells to enter the apoptotic program. DNA-PK-IN-6 enhances the sensitivity of tumor tissues to radiotherapy, overcomes the problem of agent resistance, and enhances the inhibitory effect on a variety of solid tumors and hematological tumors (extracted from patent WO2021197159A1, compound 6) .
|
-
- HY-144038
-
|
DNA-PK
|
Cancer
|
DNA-PK-IN-5 is a potent inhibitor of DNA-PK. DNA-PK-IN-5 inhibits DNA-PKcs activity, thus greatly reducing tumor DNA repair and inducing cells to enter the apoptotic program. DNA-PK-IN-5 enhances the sensitivity of tumor tissues to radiotherapy, overcomes the problem of agent resistance, and enhances the inhibitory effect on a variety of solid tumors and hematological tumors (extracted from patent WO2021204111A1, compound 2) .
|
-
- HY-142932
-
|
Btk
|
Neurological Disease
Inflammation/Immunology
Cancer
|
BTK-IN-6 is a potent inhibitor of Bruton's Tyrosine Kinase (BTK). BTK is a member of the Tec family of tyrosine kinases and plays an important role in the regulation of early B-cell development and mature B-cell activation and survival. BTK-IN-6 has the potential for the research of immune disorders, cancer, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, and neurological disorders (extracted from patent WO2021136219A1, compound 8) .
|
-
- HY-143869
-
|
MAP4K
|
Cancer
|
HPK1-IN-28 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-28 enhances the body's anti-tumor immunity. HPK1-IN-28 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 1) .
|
-
- HY-143870
-
|
MAP4K
|
Cancer
|
HPK1-IN-29 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-29 enhances the body's anti-tumor immunity. HPK1-IN-29 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 38) .
|
-
- HY-144181
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A-IN-5 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-5 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-5 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 1) .
|
-
- HY-144184
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A-IN-6 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-6 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-6 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 18) .
|
-
- HY-144185
-
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
MAT2A-IN-7 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-7 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-7 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 24) .
|
-
- HY-143864
-
|
LPL Receptor
|
Inflammation/Immunology
|
S1PR1 agonist 1 is a potent agonist of S1PR1. Sphingosine-1-phosphate (S1P) is a cell membrane-derived lysophospholipid signalling molecule that exerts its physiological functions mainly by stimulating some members of the G protein-coupled receptor family. S1PR1 agonist 1 has the potential for the research of autoimmune diseases (extracted from patent WO2021175223A1, compound 22) .
|
-
- HY-143865
-
|
LPL Receptor
|
Inflammation/Immunology
|
S1PR1 agonist 2 is a potent agonist of S1PR1. Sphingosine-1-phosphate (S1P) is a cell membrane-derived lysophospholipid signalling molecule that exerts its physiological functions mainly by stimulating some members of the G protein-coupled receptor family. S1PR1 agonist 2 has the potential for the research of autoimmune diseases (extracted from patent WO2021175225A1, compound 1) .
|
-
- HY-143717
-
|
JAK
Btk
|
Inflammation/Immunology
|
JAK3/BTK-IN-2 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-2 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 004)
|
-
- HY-143720
-
|
JAK
Btk
|
Inflammation/Immunology
|
JAK3/BTK-IN-5 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-5 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 35)
|
-
- HY-143716
-
|
JAK
Btk
|
Inflammation/Immunology
|
JAK3/BTK-IN-1 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-1 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 002) .
|
-
- HY-143718
-
|
JAK
Btk
|
Inflammation/Immunology
|
JAK3/BTK-IN-3 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-3 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 009)
|
-
- HY-143719
-
|
JAK
Btk
|
Inflammation/Immunology
|
JAK3/BTK-IN-4 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-4 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147953A1, compound 003)
|
-
- HY-142930
-
|
Somatostatin Receptor
|
Cancer
|
MAT2A-IN-3 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-3 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-3 has the potential for the research of cancer diseases (extracted from patent WO2019191470A1, compound 265) .
|
-
- HY-142929
-
|
Somatostatin Receptor
|
Cancer
|
MAT2A-IN-2 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-2 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2020243376A1, compound 172) .
|
-
- HY-142928
-
|
Somatostatin Receptor
|
Cancer
|
MAT2A-IN-1 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-1 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021139775A1, compound 64) .
|
-
- HY-139643A
-
|
CXCR
|
Inflammation/Immunology
Cancer
|
CXCR7 antagonist-1 hydrochloride is a CXCR7 antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. CXCR7 antagonist-1 hydrochloride is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases (extracted from patent WO2014085490A1, compound 1.128) .
|
-
- HY-W440787
-
|
Liposome
|
Others
|
BP Lipid 142 is derived from patent WO2018170306A1 (Example 102). BP Lipid 142 is an ionizable amine lipid analogous to SM-102. The propanolamine head improves encapsulation of mRNA. The lipid has both esters at C6 and C8 position relative to the amine nitrogen. Ester linkages in the lipid tails are introduced into the structure to improve tissue clearance. The primary ester located at C6 is attached with a long (11-carbon) lipid tail. The lipid can be used for mRNA-based therapies.
|
-
- HY-147595
-
|
Ras
|
Cancer
|
KRAS G12D inhibitor 15 is a potent inhibitor of KRAS G12D. KRAS G12D inhibitor 15 has the potential for the research of various diseases or disorders, such as cancer or cancer metastasis (extracted from patent WO2022042630A1, compound 243) . KRAS G12D inhibitor 15 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-153567
-
|
Others
|
Inflammation/Immunology
|
Immune cell migration-IN-2 is a potent immune cell migration inhibitor with an EC50 of 13.5 nM in a T-cell adhesion assay. Immune cell migration-IN-2 is extracted from patent WO2019001171, example 11, can be used for dry-eye and other retinal diseases research . Immune cell migration-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-156519
-
|
NF-κB
|
Inflammation/Immunology
|
ALPK1-IN-3 is an inhibitor of ALPK1 extracted from patent WO2022063153A1 compound T007. ALPK1-IN-3 inhibits kidney proinflammatory gene expression and improves the survival rate of the animals in sepsis induced acute kidney injury animal model . ALPK1-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-B1218
-
Sulfaphenazole
Maximum Cited Publications
10 Publications Verification
|
Cytochrome P450
Antibiotic
Bacterial
Necroptosis
Apoptosis
|
Infection
Cardiovascular Disease
|
Sulfaphenazole is a selective inhibitor of human cytochrome P450 (CYP) 2C9 enzyme. Sulfaphenazole is a cytoprotective agent against light-induced death of photoreceptors. Sulfaphenazole inhibits light-induced necrosis and mitochondrial stress-initiated apoptosis. Sulfaphenazole is an off patent sulfonamide antibiotic and demonstrates bactericidal activity through enhanced M1 macrophage activity. Sulfaphenazole can significantly reduce infarct size and restore post-ischemic coronary flow following ischemia and reperfusion .
|
-
- HY-131030
-
JF669, SE; JF669, NHS
|
Fluorescent Dye
|
Others
|
Janelia Fluor 669, SE (JF669, SE), a red fluorescent dye, can be directly reacted with the available thiol-containing HaloTag ligand under mild conditions (DIEA, DMF) to afford a JF669HaloTag ligand in a single step (Ex = 669 nm; Em = 682 nm) . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-132842
-
DZD9008
|
EGFR
Btk
|
Cancer
|
Sunvozertinib (DZD9008) is a potent ErbBs (EGFR, Her2, especially mutant forms) and BTK inhibitor. Sunvozertinib shows IC50s of 20.4, 20.4, 1.1, 7.5, and 80.4 nM for EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively (patent WO2019149164A1, example 52) .
|
-
- HY-145063
-
|
Phosphodiesterase (PDE)
|
Infection
Inflammation/Immunology
Cancer
|
Enpp-1-IN-5 is a potent inhibitor of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1). The ENPP 1 has broad specificity and can cleave a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds nucleotides and nucleotide sugars. Enpp-1-IN-5 has the potential for the research of cancer and infectious diseases (extracted from patent WO2019046778A1/WO2021203772A1, compound 1) .
|
-
- HY-143757
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-10 is a potent inhibitor of cap-dependent endonuclease (CEN). Not only can Cap-dependent endonuclease-IN-10 inhibit influenza virus well, but also has lower cytotoxicity, better in vivo pharmacokinetic and in vivo pharmacodynamic properties, and better hepatic microsomal stability. Cap-dependent endonuclease-IN-10 has the potential for the research of viral infections (including influenza A, influenza B and influenza C) (extracted from patent WO2021129799A1, compound 1-1) .
|
-
- HY-144056
-
|
EGFR
|
Cancer
|
EGFR-IN-39 is a potent inhibitor of EGFR. EGFR-IN-39 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-39 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 2) .
|
-
- HY-144055
-
|
EGFR
|
Cancer
|
EGFR-IN-38 is a potent inhibitor of EGFR. EGFR-IN-38 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-38 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 4) .
|
-
- HY-144054
-
|
EGFR
|
Cancer
|
EGFR-IN-37 is a potent inhibitor of EGFR. EGFR-IN-37 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-37 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 7) .
|
-
- HY-144052
-
|
EGFR
|
Cancer
|
EGFR-IN-35 is a potent inhibitor of EGFR. EGFR-IN-35 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-35 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 11) .
|
-
- HY-144051
-
|
EGFR
|
Cancer
|
EGFR-IN-34 is a potent inhibitor of EGFR. EGFR-IN-34 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-34 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 12) .
|
-
- HY-144050
-
|
EGFR
|
Cancer
|
EGFR-IN-33 is a potent inhibitor of EGFR. EGFR-IN-33 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 13) .
|
-
- HY-144034
-
|
GCGR
|
Metabolic Disease
|
GLP-1R agonist 3 is a potent agonist of GLP-1R. GLP-1R agonist 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 3 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 1) .
|
-
- HY-144033
-
|
GCGR
|
Metabolic Disease
|
GLP-1R agonist 1 is a potent agonist of GLP-1R. GLP-1R agonist 1 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 1 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 4) .
|
-
- HY-146524
-
|
Trk Receptor
|
Cancer
|
TRK-IN-18 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-18 has the potential for the research of cancer diseases (extracted from patent WO2021148805A1, compound 7) .
|
-
- HY-146523
-
|
Trk Receptor
|
Cancer
|
TRK-IN-17 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-17 has the potential for the research of cancer diseases (extracted from patent WO2021148807A1, compound 3) .
|
-
- HY-19767A
-
|
Integrin
|
Cardiovascular Disease
|
GSK 3008348 hydrochloride is a small molecule integrin αvβ6 antagonist, extracted from patent WO/2014154725A1, example 1. The affinity (pIC50) for the human - a 6 protein in the Fluorescence Polarisation Assay for GSK 3008348 (hydrochloride) is 8.1, whereas its affinity in the cell Adhesion Assays was for: ανβ6 (pIC50 = 8.4); ανβ3 (pIC50 = 6); ανβ5 (pIC50 = 6.9); ανβ8 (pIC50 = 7.7).
|
-
- HY-136857
-
|
Epigenetic Reader Domain
|
Cancer
|
BRD4 degrader-3 is a potent bromodomain BRD4 degrader extracted from patent WO2020055976A1, example 1a, has IC50s of 15.5 and 12.3 nM for BRD4-BD1 and BRD4-BD2, respectively . PROTAC BRD4 Degrader-7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-133487
-
VH032-C8-NH2 dihydrochloride
|
E3 Ligase Ligand-Linker Conjugates
|
Inflammation/Immunology
Cancer
|
(S,R,S)-AHPC-C8-NH2 dihydrochloride (VH032-C8-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1 .
|
-
- HY-133487B
-
VH032-C8-NH2
|
E3 Ligase Ligand-Linker Conjugates
|
Inflammation/Immunology
Cancer
|
(S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1 .
|
-
- HY-136006A
-
VH032-C6-NH2 hydrochloride
|
E3 Ligase Ligand-Linker Conjugates
|
Inflammation/Immunology
Cancer
|
(S,R,S)-AHPC-C6-NH2 hydrochloride (VH032-C6-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C6-NH2 hydrochloride is XF038-161A, example 6, extracted from patent WO2019173516A1 .
|
-
- HY-136006
-
VH032-C6-NH2 dihydrochloride
|
E3 Ligase Ligand-Linker Conjugates
|
Inflammation/Immunology
Cancer
|
(S,R,S)-AHPC-C6-NH2 dihydrochloride (VH032-C6-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C6-NH2 dihydrochloride is XF038-161A, example 6, extracted from patent WO2019173516A1 .
|
-
- HY-46531
-
|
Ligands for E3 Ligase
|
Inflammation/Immunology
Cancer
|
Thalidomide-5-NH2-CH2-COOH (compound 114) is a potent and selective inhibitor of tropomyosin receptor kinase (trk). Thalidomide-5-NH2-CH2-COOH is a ligand of E3 ligase. Thalidomide-5-NH2-CH2-COOH has the potential for researching one or more diseases (extracted from patent WO2021170109A1) .
|
-
- HY-142669
-
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
Lp-PLA2-IN-4 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-4 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 38) .
|
-
- HY-142670
-
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
Lp-PLA2-IN-5 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-5 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 32) .
|
-
- HY-142677
-
|
PI3K
|
Inflammation/Immunology
Cancer
|
PI3K-IN-27 is a potent inhibitor of PI3K. PI3K belongs to a large family of lipid signaling kinase that plays key role in cellular process including cell growth, differentiation, migration and apoptosis. PI3K-IN-27 has the potential for the research of hyper-proliferative diseases like cancer and inflammation, or immune and autoimmune diseases (extracted from patent WO2021233227A1, compound 1) .
|
-
- HY-144043
-
|
TGF-β Receptor
|
Cancer
|
ALK5-IN-8 is a potent inhibitor of TGFβRI (ALK5). ALK5-IN-8 Inhibits the phosphorylation of ALK5 on its downstream signaling proteins (Smad2 or Smad3) by blocking the binding of TGFβRI to ligands, thereby affecting or blocking TGF-β signaling. ALK5-IN-8 has the potential for the research of various ALK5-mediated related diseases (extracted from patent WO2021190425A1, compound 1) .
|
-
- HY-142949
-
|
TGF-β Receptor
|
Inflammation/Immunology
Cancer
|
ALK5-IN-7 is a potent inhibitor of ALK5. Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation and apoptosis through complex receptor signaling pathways on the cell surface in an autocrine, paracrine and endocrine manner. ALK5-IN-7 has the potential for the research of TGF-β-related diseases and conditions, including but not limited to tumors, fibrotic diseases, inflammatory diseases, autoimmune diseases, etc (extracted from patent WO2021129621A1, compound 4) .
|
-
- HY-142950
-
|
TGF-β Receptor
|
Inflammation/Immunology
Cancer
|
ALK5-IN-6 is a potent inhibitor of ALK5. Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation and apoptosis through complex receptor signaling pathways on the cell surface in an autocrine, paracrine and endocrine manner. ALK5-IN-6 has the potential for the research of TGF-β-related diseases and conditions, including but not limited to tumors, fibrotic diseases, inflammatory diseases, autoimmune diseases, etc (extracted from patent WO2021129621A1, compound 1) .
|
-
- HY-146527
-
|
Bcr-Abl
|
Neurological Disease
Cancer
|
c-ABL-IN-2 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-2 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2020260871A1, compound 25) . c-ABL-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-150206
-
|
NOD-like Receptor (NLR)
|
Neurological Disease
Inflammation/Immunology
|
NLRP3-IN-13 (Compound C77 in reference patent) is a selective and potent NLRP3 inhibitor (IC50: 2.1 μM). NLRP3-IN-13 inhibits NLRP3 andNLRC4 inflammasomes, and inhibits NLRP3-mediated IL-1β production. NLRP3-IN-13 also inhibits NLRP3 ATPase activity. NLRP3-IN-13 can be used in the research of neuroinflammatory disorders .
|
-
- HY-B1218R
-
|
Cytochrome P450
Antibiotic
Bacterial
Necroptosis
Apoptosis
|
Infection
Cardiovascular Disease
|
Sulfaphenazole (Standard) is the analytical standard of Sulfaphenazole. This product is intended for research and analytical applications. Sulfaphenazole is a selective inhibitor of human cytochrome P450 (CYP) 2C9 enzyme. Sulfaphenazole is a cytoprotective agent against light-induced death of photoreceptors. Sulfaphenazole inhibits light-induced necrosis and mitochondrial stress-initiated apoptosis. Sulfaphenazole is an off patent sulfonamide antibiotic and demonstrates bactericidal activity through enhanced M1 macrophage activity. Sulfaphenazole can significantly reduce infarct size and restore post-ischemic coronary flow following ischemia and reperfusion .
|
-
- HY-147617
-
|
c-Fms
|
Cancer
|
CSF1R-IN-14 is an isoindolinone derivative compound. CSF1R-IN-14 is a potent inhibitor of CSF1R. Colony stimulating factor 1 (CSF-1, also known as macrophage colony stimulating factor, M-CSF) is an important growth factor that controls bone marrow progenitor cells, monocytes, macrophages, and giants. CSF1R-IN-14 has the potential for the research of cancer diseases (extracted from patent WO2019134662A1, compound 1) .
|
-
- HY-125990
-
|
Sodium Channel
|
Cardiovascular Disease
Metabolic Disease
|
SLC13A5-IN-1 is a selective sodium-citrate co-transporter (SLC13A5) inhibitor. SLC13A5-IN-1 completely blocks the uptake of 14C-citrate with an IC50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5 .
|
-
- HY-131025
-
JF585, SE; JF585, NHS
|
Fluorescent Dye
|
Others
|
Janelia Fluor 585, SE (JF585, SE) is an orange fluorescent dye containing an NHS ester that can be conjugated with primary amine groups. Janelia Fluor 585, SE can be used immediately for structured illumination (SIM) and stimulated emission depletion (STED) imaging and could be converted to photoactivatable derivative for single-molecule localization microscopy (SMLM) experiments . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-138659
-
JF646, Tetrazine
|
Fluorescent Dye
|
Others
|
Janelia Fluor 646, Tetrazine (JF646, Tetrazine) a red fluorescent dye that contains a tetrazine group. JF646, Tetrazine can be used in cellular imaging . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute. Janelia Fluor? 646, Tetrazine is a click chemistry reagent, it contains a Tetrazine group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing TCO groups.
|
-
- HY-145429
-
|
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
Cancer
|
IL-17A modulator-2 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 27. IL-17A modulator-2 inhibits the biological action of IL-17A with a pIC50 of 8.3. IL-17A modulator-2 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders .
|
-
- HY-145430
-
|
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
Cancer
|
IL-17A modulator-1 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 9. IL-17A modulator-1 inhibits the biological action of IL-17A with a pIC50 of 8.2. IL-17A modulator-1 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders .
|
-
- HY-145262
-
|
Eukaryotic Initiation Factor (eIF)
|
Cancer
|
eIF4E-IN-2 is a potent inhibitor of eukaryotic initiation factor 4e (eIF4e). eIF4E-IN-2 has the potential for researching eIF4e dependent diseases, including the research of cancer (extracted from patent WO2021003157A1, compound 1188) . eIF4E-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-142779
-
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-11 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2014114249A1, compound E145) .
|
-
- HY-144040
-
|
c-Fms
|
Cancer
|
CSF1R-IN-4 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-4 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-4 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 104) .
|
-
- HY-144041
-
|
c-Fms
|
Cancer
|
CSF1R-IN-5 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-5 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-5 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 11) .
|
-
- HY-144042
-
|
c-Fms
|
Cancer
|
CSF1R-IN-6 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-6 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-6 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 5) .
|
-
- HY-143423A
-
|
MALT1
|
Inflammation/Immunology
Cancer
|
(S)-MALT1-IN-5 is a potent inhibitor of MALT1 protease. (S)-MALT1-IN-5 inhibits the activity of MALT1 is expected to be able to correct the enhancement of MALT1 activity due to abnormality of T cell receptor signal or B cell receptor signal, and cancer or inflammatory disease caused by MALT1 activity is expected. (S)-MALT1-IN-5 has the potential for the research of MALT1-related diseases (extracted from patent WO2020111087A1, compound 1) .
|
-
- HY-144094
-
|
Histone Methyltransferase
|
Cancer
|
EZH2-IN-9 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-9 has the potential for the research of cancer diseases (extracted from patent WO2021180235A1, compound 17) .
|
-
- HY-143616
-
|
Histone Methyltransferase
|
Cancer
|
EZH2-IN-7 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-7 has the potential for the research of cancer diseases (extracted from patent WO2021129629A1, compound 259) .
|
-
- HY-12946A
-
|
Glucocorticoid Receptor
Cytochrome P450
HCV Protease
|
Infection
Inflammation/Immunology
|
BI 653048 phosphate is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC50 value of 55 nM . BI 653048 phosphate inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC50>30 μM) . BI 653048 phosphate is extracted from patent WO2005028501A1 (Compound 103), is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus .
|
-
- HY-12946
-
|
Glucocorticoid Receptor
Cytochrome P450
HCV Protease
|
Infection
Inflammation/Immunology
|
BI 653048 is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC50 value of 55 nM . BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC50>30 μM) . BI 653048 is extracted from patent WO2005028501A1 (Compound 103), is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus .
|
-
- HY-133536
-
PA-JF549-NHS
|
Fluorescent Dye
|
Others
|
PA Janelia Fluor 549, SE (PA-JF549-NHS) is a bright photoactivatable fluorophore of JF549,SE (JF549,NHS). JF549,SE (JF549,NHS) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-132138
-
|
DNA/RNA Synthesis
|
Others
|
5-Propargylamino-3'-azidomethyl-dCTP is a nucleoside molecule extracted from patent WO2004018497A2, compound 17. 5-Propargylamino-3'-azidomethyl-dCTP can be used in DNA synthesis and DNA sequencing . 5-Propargylamino-3'-azidomethyl-dCTP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-131021
-
JF549, Azide
|
Fluorescent Dye
|
Others
|
Janelia Fluor? 549, Azide (JF549, Azide) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm . Janelia Fluor? products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
|
-
- HY-134903
-
|
mTOR
|
Cancer
|
(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC50s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2) .
|
-
- HY-44809A
-
|
HIF/HIF Prolyl-Hydroxylase
|
Inflammation/Immunology
Cancer
|
Izilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase which stabilizes hypoxia inducible factor- 1 alpha (HIF- lα), as well as hypoxia inducible factor-2 (HIF-2). Izilendustat (hydrochloride) has the potential for the research of HIF- lα related diseases including Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, anemia, colitis, and other inflammatory bowel diseases (extracted from patent WO2011057115A1/WO2011057112A1/WO2011057121A1) .
|
-
- HY-142778
-
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-10 has the potential for the research of neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis (extracted from patent WO2022001881A1, compound 4) .
|
-
- HY-128860
-
|
EGFR
|
Cancer
|
Mutated EGFR-IN-2 (compound 91) is a mutant-selective EGFR inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC50=<1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity .
|
-
- HY-138660
-
HM-JF526 NHS
|
Fluorescent Dye
|
Others
|
HM Janelia Fluor® 526, SE (HM-JF526 NHS) is a derivative of hydroxymethyl JF526 (HM-JF526). SMLM (single-molecule localization microscopy) imaging in standard phosphate-buffered saline (pH 7.4) revealed that the HM-JF526 label showed spontaneous blinking behavior throughout the imaging session and did not require short-wavelength activation light . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-145177
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate. Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc can be used for the synthesis of PROTAC BET degrader . (From patent WO2017180417A1 compound s7).
|
-
- HY-142444
-
|
VAP-1
|
Metabolic Disease
|
SSAO/VAP-1 inhibitor 1 is a potent inhibitor of SSAO/VAP-1. SSAO/VAP-1 promotes the transfer of Glucose transport 4 (GLUT 4) from adipocytes to the cell membrane, thereby regulating glucose transport. In endothelial cells, SSAO/VAP-1 can mediate the adhesion and exudation of leukocytes and endothelial cells, and participate in inflammatory responses. SSAO/VAP-1 inhibitor 1 has the potential for the research of inflammation and/or inflammation-related disease or diabetes and/or diabetes-related disease (extracted from patent WO2021102774A1, compound E3) .
|
-
- HY-132137
-
|
DNA/RNA Synthesis
|
Others
|
5-Propargylamino-3'-azidomethyl-dUTP is a nucleoside molecule extracted from patent WO2004018497A2, compound 5. 5-Propargylamino-3'-azidomethyl-dUTP can be used in DNA synthesis and DNA sequencing . 5-Propargylamino-3'-azidomethyl-dUTP is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
|
-
- HY-131027
-
JF646, Azide
|
Fluorescent Dye
|
Others
|
Janelia Fluor 646, Azide (JF646, Azide) is a red fluorogenic fluorescent dye containing a click chemistry group Azide. Janelia Fluor 646, Azide can be used for live-cell imaging experiments . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute. Janelia Fluor? 646, Azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-103048
-
|
PD-1/PD-L1
|
Cancer
|
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases .
|
-
- HY-103048A
-
|
PD-1/PD-L1
|
Cancer
|
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .
|
-
- HY-133535
-
PA-JF646-NHS
|
Fluorescent Dye
|
Others
|
PA Janelia Fluor® 646, SE (PA-JF646-NHS), a photoactivatable fluorescent dye, is an NHS ester for coupling to primary amine groups. PA-JF646-NHS is non-fluorescent until activated at 365 nm. NHS ester can be converted to relevant substrate for use in self-labeling tag systems, e.g.HaloTag ® and SNAP-tag ®. PA-JF646-NHS is used for single molecule tracking and super resolution microscopy in live cells, specifically live cell sptPALM and fixed cell PALM. (λExcitation/emission~650/664 nm). Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
-
-
HY-L141
-
|
2,664 compounds
|
Drug repurposing (also called drug repositioning, reprofiling, or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, for example, lower risk of failure, less investment, and shorter development timelines. But drug repositioning projects are also subject to several risks, including regulatory and intellectual property issues. So the off-patent drugs are optimal for repositioning because of their immediate availability for clinical studies, with high feasibility and relatively low risk.
MCE carefully prepared a unique collection of 2,664 off-patent drugs, which is a good choice for drug repurposing.
|
Cat. No. |
Product Name |
Type |
-
- HY-113862
-
|
Dyes
|
PHOME is a fluorogenic substrate for sEH. sEH can hydrolyze the epoxy ring in the PHOME substrate. PHOME can be used for fluorescent epoxide hydrolase assay (extracted from patent CN113402447A) .
|
-
- HY-130735
-
JF646, SE; JF646, NHS
|
Fluorescent Dyes/Probes
|
Janelia Fluor 646, SE (JF646, SE) is a red fluorescent dye can be used in cellular imaging . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-131020
-
JF525, SE; JF525, NHS
|
Fluorescent Dyes/Probes
|
Janelia Fluor 525, SE (JF525, SE) is a yellow fluorescent dye (Ex = 525 nm; Em = 549 nm) . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-131022
-
JF549 TFA
|
Fluorescent Dyes/Probes
|
Janelia Fluor® 549 TFA (JF549 TFA) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-131029
-
JF646, Maleimide
|
Fluorescent Dyes/Probes
|
Janelia Fluor® 646, Maleimide (JF646, Maleimide) is a red fluorescent dye that contains a maleimide group. JF646, Maleimide can be used in cellular imaging . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-D1500
-
|
Fluorescent Dyes/Probes
|
Fluorescent NIR 885 is a cyanine near-infrared-absorbing dye. Fluorescent NIR 885 can be used as a photoprotective agent (extracted from patent WO2014006589 compound 1-35) .
|
-
- HY-130736
-
JF549, SE; JF549, NHS
|
Fluorescent Dyes/Probes
|
Janelia Fluor® 549, SE (JF549, SE) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-131024
-
JF549, Tetrazine
|
Fluorescent Dyes/Probes
|
Janelia Fluor® 549, Tetrazine (JF549, Tetrazine) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-131023
-
JF549, Maleimide TFA
|
Fluorescent Dyes/Probes
|
Janelia Fluor® 549, Maleimide TFA (JF549, Maleimide TFA) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-131026
-
JF635, SE; JF635, NHS
|
Dyes
|
Janelia Fluor® 635, SE (JF635, SE) is a red fluorogenic fluorescent dye containing an NHS ester that can be conjugated with primary amine groups. JF635, SE can be used for live cell imaging . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-131028
-
JF646 TFA
|
Fluorescent Dyes/Probes
|
Janelia Fluor® 646 TFA (JF646 TFA), a red fluorogenic fluorescent dye, can be used in the synthesis of Janelia Fluor 646 HaloTag and SNAP-Tag ligands. JF646 TFA is used in live cell imaging experiments . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-138658
-
JF526, SE; JF526, NHS
|
Fluorescent Dyes/Probes
|
Janelia Fluor 526, SE (JF526,SE) is a fluorogenic yellow fluorescent dye that contains NHS ester group. JF526 is a versatile scaffold for fluorogenic ligands, including labels for genetically encoded self-labeling protein tags and stains for endogenous structures . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-131030
-
JF669, SE; JF669, NHS
|
Fluorescent Dyes/Probes
|
Janelia Fluor 669, SE (JF669, SE), a red fluorescent dye, can be directly reacted with the available thiol-containing HaloTag ligand under mild conditions (DIEA, DMF) to afford a JF669HaloTag ligand in a single step (Ex = 669 nm; Em = 682 nm) . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-131025
-
JF585, SE; JF585, NHS
|
Fluorescent Dyes/Probes
|
Janelia Fluor 585, SE (JF585, SE) is an orange fluorescent dye containing an NHS ester that can be conjugated with primary amine groups. Janelia Fluor 585, SE can be used immediately for structured illumination (SIM) and stimulated emission depletion (STED) imaging and could be converted to photoactivatable derivative for single-molecule localization microscopy (SMLM) experiments . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-138659
-
JF646, Tetrazine
|
Fluorescent Dyes/Probes
|
Janelia Fluor 646, Tetrazine (JF646, Tetrazine) a red fluorescent dye that contains a tetrazine group. JF646, Tetrazine can be used in cellular imaging . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute. Janelia Fluor? 646, Tetrazine is a click chemistry reagent, it contains a Tetrazine group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing TCO groups.
|
-
- HY-133536
-
PA-JF549-NHS
|
Dyes
|
PA Janelia Fluor 549, SE (PA-JF549-NHS) is a bright photoactivatable fluorophore of JF549,SE (JF549,NHS). JF549,SE (JF549,NHS) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-131021
-
JF549, Azide
|
Fluorescent Dyes/Probes
|
Janelia Fluor? 549, Azide (JF549, Azide) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm . Janelia Fluor? products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
|
-
- HY-131027
-
JF646, Azide
|
Fluorescent Dyes/Probes
|
Janelia Fluor 646, Azide (JF646, Azide) is a red fluorogenic fluorescent dye containing a click chemistry group Azide. Janelia Fluor 646, Azide can be used for live-cell imaging experiments . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute. Janelia Fluor? 646, Azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-133535
-
PA-JF646-NHS
|
Dyes
|
PA Janelia Fluor® 646, SE (PA-JF646-NHS), a photoactivatable fluorescent dye, is an NHS ester for coupling to primary amine groups. PA-JF646-NHS is non-fluorescent until activated at 365 nm. NHS ester can be converted to relevant substrate for use in self-labeling tag systems, e.g.HaloTag ® and SNAP-tag ®. PA-JF646-NHS is used for single molecule tracking and super resolution microscopy in live cells, specifically live cell sptPALM and fixed cell PALM. (λExcitation/emission~650/664 nm). Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
Cat. No. |
Product Name |
Type |
-
- HY-W110929
-
Acid blue 1
|
Biochemical Assay Reagents
|
Patent Blue V (Acid blue 1) is a novel biological dye that can be used as an intraocular dye for retinectomy. Retinectomy refers to the removal of the translucent inner limiting membrane (ILM). The application of appropriate dyes in vitreoretinal surgery can achieve the purpose of complete removal. Patent Blue V can be used to stain retinal premembranous structures. Spectral analysis shows that Patent Blue V has strong absorption below 450 nm and above 600 nm, showing a blue-green color. Patent Blue V is also used as a marker in lymphangiography for resection of neoplastic lymph nodes .
|
-
- HY-153186
-
|
Drug Delivery
|
LNP Lipid-3 is an ionizable lipid extracted from patent WO2021113777A, and can be used for the generation of Lipid nanoparticles (LNPs).
|
-
- HY-46760
-
|
Drug Delivery
|
CCD Lipid01 is a cationic lipid useful in the delivery of biologically active agents to cells and tissues (extracted from patent WO2015095340 A1) .
|
-
- HY-139298
-
Di((Z)-Non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate
|
Drug Delivery
|
L319 is an ionizable cationic lipidoid and can be used for synthetic liposomes, from the patent WO-2011153493-A2, compound 1 .
|
-
- HY-W036733
-
|
Biochemical Assay Reagents
|
4-Hydroxy-4-methylcyclohexanone is a useful synthetic reagent extracted from patent JP2009022162A. 4-Hydroxy-4-methylcyclohexanone can be used to synthesize trans-4-amino-1-methylcyclohexanol which is intermediate of pharmaceutical synthesis .
|
-
- HY-132142
-
|
Gene Sequencing and Synthesis
|
5-Propargylamino-dCTP is a nucleoside molecule extracted from patent US9035035B2, compound dCTP-PA. 5-Propargylamino-dCTP can conjugate to molecular markers for use in nucleic acid labeling or sequence analysis . 5-Propargylamino-dCTP is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-W110929R
-
|
Biochemical Assay Reagents
|
Patent Blue V (Standard) is the analytical standard of Patent Blue V. This product is intended for research and analytical applications. Patent Blue V (Acid blue 1) is a novel biological dye that can be used as an intraocular dye for retinectomy. Retinectomy refers to the removal of the translucent inner limiting membrane (ILM). The application of appropriate dyes in vitreoretinal surgery can achieve the purpose of complete removal. Patent Blue V can be used to stain retinal premembranous structures. Spectral analysis shows that Patent Blue V has strong absorption below 450 nm and above 600 nm, showing a blue-green color. Patent Blue V is also used as a marker in lymphangiography for resection of neoplastic lymph nodes .
|
-
- HY-148830
-
|
Drug Delivery
|
Piperazine-bis(ethyl octadeca-9,12-dienoate) is a cationic lipid extracted from patent WO2023036148A1, and can be used for the generation of Lipid nanoparticles (LNPs).
|
-
- HY-132138
-
|
Gene Sequencing and Synthesis
|
5-Propargylamino-3'-azidomethyl-dCTP is a nucleoside molecule extracted from patent WO2004018497A2, compound 17. 5-Propargylamino-3'-azidomethyl-dCTP can be used in DNA synthesis and DNA sequencing . 5-Propargylamino-3'-azidomethyl-dCTP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-132137
-
|
Gene Sequencing and Synthesis
|
5-Propargylamino-3'-azidomethyl-dUTP is a nucleoside molecule extracted from patent WO2004018497A2, compound 5. 5-Propargylamino-3'-azidomethyl-dUTP can be used in DNA synthesis and DNA sequencing . 5-Propargylamino-3'-azidomethyl-dUTP is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1445
-
-
- HY-P1447
-
|
Peptides
|
Metabolic Disease
|
Exendin-3/4 (64-86) is a polypeptide from patent CN 106029087 A. The incretin receptor ligands are derived from multiple skin toxicity Shan exosomes -3 skin of SDGTFTSDLSKQM Di EAVRLFIEWLKNGGPSSGAPPPS.
|
-
- HY-P3377
-
|
Peptides
|
Inflammation/Immunology
|
Rimtoregtide is a polypeptide compound which significantly reduces the increase in the levels of amylase and lipase in the blood caused by acute pancreatitis. Rimtoregtide has the potential for the research of pancreatitis and acute pancreatitis (extracted from patent WO2018205233A1).
|
-
- HY-P1348
-
|
GCGR
|
Metabolic Disease
|
GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide which is a glucagon-like peptide 1 receptor (GLP-1) agonist, extracted from patent US 20160369010 A1.
|
-
- HY-P1355A
-
|
Calcineurin
Cyclophilin
|
Others
|
Cyclosporin A-Derivative 1 (Free base) is a crystalline intermediate derived from the opening of cyclosporin A extracted from patent WO 2013167703 A1. Cyclosporin A is an immunosuppressive agent which can bind to the cyclophilin and inhibit calcineurin.
|
-
- HY-160429
-
|
Peptides
|
Others
|
PSAR18-COOH is a derivative of PSAR extracted from patent WO2009064913A1. PSAR is a highly hydrophilic, biodegradable, non-immunogenic and water-soluble polymer that has been employed in several delivery systems for drugs or diagnostics.
|
-
- HY-103048A
-
|
PD-1/PD-L1
|
Cancer
|
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .
|
-
- HY-P1355
-
|
Calcineurin
Cyclophilin
|
Inflammation/Immunology
|
Cyclosporin A-Derivative 1 is a crystalline intermediate derived from the opening of cyclosporin A extracted from patent WO 2013167703 A1. Cyclosporin A is an immunosuppressive agent which can bind to the cyclophilin and inhibit calcineurin.
|
-
- HY-P3129
-
|
Peptides
|
Inflammation/Immunology
Cancer
|
KRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D peptide, 25 mer can be used to prepare KRAS vaccine .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-50856S
-
|
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I) .
|
-
-
- HY-79369S
-
|
Succinic anhydride-d4 is the deuterium labeled Succinic anhydride. Succinic anhydride is a cyclic anhydride and a nonclaevable ADC linker extracted from patent WO2009064913A1. Succinic anhydride can react with compound 4 of the patent to link the proagent to an amine or hydroxy 1 group of a targeting polypeptide[1].
|
-
-
- HY-79369S1
-
|
Succinic anhydride- 13C2 is the 13C labeled Succinic anhydride[1]. Succinic anhydride is a cyclic anhydride and a nonclaevable ADC linker extracted from patent WO2009064913A1. Succinic anhydride can react with compound 4 of the patent to link the proagent to an amine or hydroxy 1 group of a targeting polypeptide[2].
|
-
-
- HY-139593S
-
|
Polθ-IN-1-d3 (example 1) is a deuterated Polθ inhibitor used for cancer study (extracted from patent WO2021028670) .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-U00318
-
|
|
Alkynes
|
JAK-IN-11 is a potent and selective JAK inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment . JAK-IN-11 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-156519
-
|
|
Alkynes
|
ALPK1-IN-3 is an inhibitor of ALPK1 extracted from patent WO2022063153A1 compound T007. ALPK1-IN-3 inhibits kidney proinflammatory gene expression and improves the survival rate of the animals in sepsis induced acute kidney injury animal model . ALPK1-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-138659
-
JF646, Tetrazine
|
|
Labeling and Fluorescence Imaging
Tetrazine
|
Janelia Fluor 646, Tetrazine (JF646, Tetrazine) a red fluorescent dye that contains a tetrazine group. JF646, Tetrazine can be used in cellular imaging . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute. Janelia Fluor? 646, Tetrazine is a click chemistry reagent, it contains a Tetrazine group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing TCO groups.
|
-
- HY-131021
-
JF549, Azide
|
|
Azide
Labeling and Fluorescence Imaging
|
Janelia Fluor? 549, Azide (JF549, Azide) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm . Janelia Fluor? products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
|
-
- HY-131027
-
JF646, Azide
|
|
Labeling and Fluorescence Imaging
Azide
|
Janelia Fluor 646, Azide (JF646, Azide) is a red fluorogenic fluorescent dye containing a click chemistry group Azide. Janelia Fluor 646, Azide can be used for live-cell imaging experiments . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute. Janelia Fluor? 646, Azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-131024
-
JF549, Tetrazine
|
|
Tetrazine
Labeling and Fluorescence Imaging
|
Janelia Fluor® 549, Tetrazine (JF549, Tetrazine) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm . Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
|
-
- HY-147595
-
|
|
Alkynes
|
KRAS G12D inhibitor 15 is a potent inhibitor of KRAS G12D. KRAS G12D inhibitor 15 has the potential for the research of various diseases or disorders, such as cancer or cancer metastasis (extracted from patent WO2022042630A1, compound 243) . KRAS G12D inhibitor 15 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-132138
-
|
|
Azide
|
5-Propargylamino-3'-azidomethyl-dCTP is a nucleoside molecule extracted from patent WO2004018497A2, compound 17. 5-Propargylamino-3'-azidomethyl-dCTP can be used in DNA synthesis and DNA sequencing . 5-Propargylamino-3'-azidomethyl-dCTP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-132137
-
|
|
Azide
|
5-Propargylamino-3'-azidomethyl-dUTP is a nucleoside molecule extracted from patent WO2004018497A2, compound 5. 5-Propargylamino-3'-azidomethyl-dUTP can be used in DNA synthesis and DNA sequencing . 5-Propargylamino-3'-azidomethyl-dUTP is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
|
Cat. No. |
Product Name |
|
Classification |
-
- HY-153186
-
|
|
Cationic Lipids
|
LNP Lipid-3 is an ionizable lipid extracted from patent WO2021113777A, and can be used for the generation of Lipid nanoparticles (LNPs).
|
-
- HY-46760
-
|
|
Cationic Lipids
|
CCD Lipid01 is a cationic lipid useful in the delivery of biologically active agents to cells and tissues (extracted from patent WO2015095340 A1) .
|
-
- HY-139298
-
Di((Z)-Non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate
|
|
Cationic Lipids
|
L319 is an ionizable cationic lipidoid and can be used for synthetic liposomes, from the patent WO-2011153493-A2, compound 1 .
|
-
- HY-160705
-
|
|
Cationic Lipids
|
PNI 132, an ionizable lipid derived from the patent WO2020252589A, is useful in the formulation of lipid nanoparticles.
|
-
- HY-148830
-
|
|
Cationic Lipids
|
Piperazine-bis(ethyl octadeca-9,12-dienoate) is a cationic lipid extracted from patent WO2023036148A1, and can be used for the generation of Lipid nanoparticles (LNPs).
|
-
- HY-164192
-
|
|
Cap Analogs
|
m7(3'AcmG)(5')ppp(5')(2'OMeA)pG ammonium, a cap analogue derived from patent WO2023159930A1, can be used for the synthesis of mRNA.
|
-
- HY-158866
-
|
|
Cationic Lipids
|
BP Lipid 401 is derived from patent WO2020219876A1 (Example 102). BP Lipid 401 features a unique piperidine head group three carbon atoms in length. This compound can be useful for the building or modification of lipid nanoparticles.
|
-
- HY-158864
-
|
|
Cationic Lipids
|
BP Lipid 378 is derived from patent WO2020219876A1 (Example 8). BP Lipid 378 is an ionizable amino lipid that features a unique pyrrolidine head group with a carbamate linkage to the lipid tails. This lipid may be used in the generation of lipid nanoparticles (LNPs) for mRNA delivery.
|
-
- HY-158865
-
|
|
Cationic Lipids
|
BP Lipid 399 is derived from patent WO2020219876A1 (Example 3).BP Lipid 399 is an ionizable amino lipid analog of LP01 featuring a novel pyrrolidine head group three carbon atoms in length. This compound can be useful for the building or modification of lipid nanoparticles.
|
-
- HY-158863
-
|
|
Cationic Lipids
|
BP Lipid 377 is derived from patent WO2018062413A1. BP Lipid 377 is an ionizable amino lipid comprised of three linoleic acid tails and an N,N-dimethylamine head group four carbon atoms in length. This lipid may be used in the generation of lipid nanoparticles (LNPs) for mRNA and drug delivery.
|
-
- HY-W440802
-
|
|
Cationic Lipids
|
BP Lipid 217 is derived from patent WO2023178065A2 (B32). BP Lipid 217 is an ethanolamine ionizable lipid with both ester bonds located adjacent to C8 relative to the amine head. The introduction of ester linkages can improve the clearance of the lipid in the liver. This compound is analgous to ALC-0315.
|
-
- HY-W800737
-
|
|
Cationic Lipids
|
BP Lipid 126 is an amino ionizable lipid (Compound 143) from patent WO2017201333A1 with ester bonds located at C8 and C7 position relative to nitrogen. The ester linkages are introduced to improve tissue clearance. The ethanolamine head can effectively enhance mRNA encapsulation. BP Lipid 126 can be used in the generation of liposomes.
|
-
- HY-W800749
-
|
|
Cationic Lipids
|
BP Lipid 223 is an pentanolamine lipid (Compound 7) from patent WO2017075531A with both ester bonds located adjacent to C6 relative to the amine head. The introduction of ester linkages can improve the clearance of the lipid in the liver. This compound is analgous to ALC-0315. The lipid can be used to prepare mRNA nanocarriers with good balance of delivery efficiency and pharmakokinetics as well as rapid lipid clearance profile.
|
-
- HY-132142
-
|
|
Nucleotides and their Analogs
|
5-Propargylamino-dCTP is a nucleoside molecule extracted from patent US9035035B2, compound dCTP-PA. 5-Propargylamino-dCTP can conjugate to molecular markers for use in nucleic acid labeling or sequence analysis . 5-Propargylamino-dCTP is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-W440787
-
|
|
Cationic Lipids
|
BP Lipid 142 is derived from patent WO2018170306A1 (Example 102). BP Lipid 142 is an ionizable amine lipid analogous to SM-102. The propanolamine head improves encapsulation of mRNA. The lipid has both esters at C6 and C8 position relative to the amine nitrogen. Ester linkages in the lipid tails are introduced into the structure to improve tissue clearance. The primary ester located at C6 is attached with a long (11-carbon) lipid tail. The lipid can be used for mRNA-based therapies.
|
-
- HY-132138
-
|
|
Nucleotides and their Analogs
|
5-Propargylamino-3'-azidomethyl-dCTP is a nucleoside molecule extracted from patent WO2004018497A2, compound 17. 5-Propargylamino-3'-azidomethyl-dCTP can be used in DNA synthesis and DNA sequencing . 5-Propargylamino-3'-azidomethyl-dCTP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
|
-
- HY-132137
-
|
|
Nucleotides and their Analogs
|
5-Propargylamino-3'-azidomethyl-dUTP is a nucleoside molecule extracted from patent WO2004018497A2, compound 5. 5-Propargylamino-3'-azidomethyl-dUTP can be used in DNA synthesis and DNA sequencing . 5-Propargylamino-3'-azidomethyl-dUTP is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: